Human Malformations and Related Anomalies
OXFORD MONOGRAPHS ON MEDICAL GENETICS GENERAL EDITORS
Arno G. Motulsky Mar...
56 downloads
1526 Views
84MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Human Malformations and Related Anomalies
OXFORD MONOGRAPHS ON MEDICAL GENETICS GENERAL EDITORS
Arno G. Motulsky Martin Bobrow Peter S. Harper Charles Scriver Charles J. Epstein Judith G. Hall 16. C. R. Scriver and B. Child: Garrod’s inborn factors in disease 18. M. Baraitser: The genetics of neurological disorders 21. D. Warburton, J. Byrne, and N. Canki: Chromosome anomalies and prenatal development: an atlas 22. J. J. Nora, K. Berg, and A. H. Nora: Cardiovascullar disease: gentics, epidemiology, and prevention 24. A. E. H. Emery: Duchenne muscular dystrophy, second edition 25. E. G. D. Tuddenham and D. N. Cooper: The molecular genetics of haemostasis and its inherited disorders 26. A. Boue´: Foetalmedicine 30. A. S. Teebi and T. I. Farag: Genetic disorders among Arab populations 31. M. M. Cohen, Jr.: The child with multiple birth defects 32. W. W. Weber: Pharmacogenetics 33. V. P. Sybert: Genetic skin disorders 34. M. Baraitser: Genetics of neurological disorders, third edition 35. H. Ostrer: Non-mendelian genetics in humans 36. E. Traboulsi: Genetic diseases of the eye 37. G. L. Semenza: Transcription factors and human disease 38. L. Pinsky, R. P. Erickson, and R. N. Schimke: Genetic disorders of human sexual development 39. R. E. Stevenson, C. E. Schwartz, and R. J. Schroer: X-linked mental retardation 40. M. J. Khoury, W. Burke, and E. Thomson: Genetics and public health in the 21st century 41. J. Weil: Psychosocial genetic counseling 42. R. J. Gorlin, M. M. Cohen, Jr., and R. C. M. Hennekam: Syndromes of the head and neck, fourth edition 43. M. M. Cohen, Jr., G. Neri, and R. Weksberg: Overgrowth syndromes 44. R. A. King, J. I. Rotter, and A. G. Motulsky: The genetic basis of common diseases, second edition 45. G. P. Bates, P. S. Harper, and L. Jones: Huntington’s disease, third edition 46. R. J. M. Gardner and G. R. Sutherland: Chromosome abnormalities and genetic counselling, third edition 47. I. J. Holt: Genetics of mitochondrial disease 48. F. Flinter, E. Maher, and A. Saggar-Malik: The genetics of renal disease 49. C. J. Epstein, R. P. Erickson, and A. Wynshaw-Boris: Inborn errors of development: the molecular basis of clinical disorders of morphogenesis 50. H. V. Toriello, W. Reardon, and R. J. Gorlin: Hereditary hearing loss and its syndromes, second edition 51. P. S. Harper: Landmarks in medical genetics 52. R. E. Stevenson and J. G. Hall: Human malformations and related anomalies, second edition
Human Malformations and Related Anomalies EDITED BY
Roger E. Stevenson
Judith G. Hall
Greenwood Genetic Center
University of British Columbia
Greenwood, South Carolina
Vancouver, British Columbia
ASSOCIATE EDITORS:
Kathleen K. Sulik
Edith Gilbert-Barness
University of North Carolina
Tampa General Hospital
School of Medicine
Tampa, Florida
Chapel Hill, North Carolina
ASSISTANT EDITOR:
Karen Kiernan Buchanan Greenwood Genetic Center Greenwood, South Carolina
1 2006
Second Edition
1 Oxford University Press, Inc., publishes works that further Oxford University’s objective of excellence in research, scholarship, and education. Oxford New York Auckland Cape Town Dar es Salaam Hong Kong Karachi Kuala Lumpur Madrid Melbourne Mexico City Nairobi New Delhi Shanghai Taipei Toronto With offices in Argentina Austria Brazil Chile Czech Republic France Greece Guatemala Hungary Italy Japan Poland Portugal Singapore South Korea Switzerland Thailand Turkey Ukraine Vietnam
Copyright # 2006 by Oxford University Press, Inc. Published by Oxford University Press, Inc. 198 Madison Avenue, New York, New York 10016 www.oup.com Oxford is a registered trademark of Oxford University Press. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Oxford University Press. Library of Congress Cataloging-in-Publication Data Human malformations and related anomalies / editors, Roger E. Stevenson . . . [et al.].—2nd ed. p. ; cm.—(Oxford monographs on medical genetics ; no. 52) Includes bibliographical references and index. ISBN-13: 978-0-19-516568-5 ISBN-10: 0-19-516568-3 1. Abnormalities, Human. I. Stevenson, Roger E., 1940–. II. Series. [DNLM: 1. Abnormalities. 2. Genetics, Medical. QS 675 H918 2005] QM691.H88 2005 616'.043—dc22 2004061661
The science of medicine is a rapidly changing field. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy do occur. The authors and publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is accurate and complete, and in accordance with the standards accepted at the time of publication. However, in light of the possibility of human error or changes in the practice of medicine, neither the authors, nor the publisher, nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete. Readers are encouraged to confirm the information contained herein with other reliable sources, and are strongly advised to check the product information sheet provided by the pharmaceutical company for each drug they plan to administer.
9
8
7
6
5
4
3
2
1
Printed in the United States of America on acid-free paper
Preface
O
ver a decade has separated the first and second editions of Human Malformations and Related Anomalies. This interval has been eventful from many standpoints. A major birth defects prevention strategy—periconceptional folic acid utilization—has proved effective in large-scale studies in several countries. New understandings of the genetic basis for malformations and malformation syndromes have emerged and made possible prenatal and postnatal laboratory diagnostic technologies. While molecular advances may be considered the most spectacular, significant advances in the biochemical and cytogenetic bases for malformations have also been impressive. The interval has brought us to the threshold of recognition of potential roles that epigenetic mechanisms, genomic changes, and disruption of molecular pathways exert on human development. During this interval, birth defects have maintained their position as the leading cause of infant mortality and a major contributor to childhood morbidity. The number and scope of birth defects surveillance programs have expanded, and collaboration among the programs is providing a picture of the epidemiology of birth defects worldwide. Increased understanding of the developmental biology of malformations and related anomalies has come primarily from the various branches of genetics. Recognition that inborn errors of cholesterol synthesis are associated with embryodysgenesis is but one of a number of contributions from biochemical genetics. The long biochemical pathway from mevalonic acid to cholesterol can be interrupted at virtually every step by enzyme errors, which leads to an astonishing array of birth defects. Smith-Lemli-Opitz syndrome (caused by a deficiency of 7-dehydrocholesterol reductase), congenital hemidysplasia and ichthyosiform erythroderma and limb defects (deficiency of sterol D8 D7 isomerase), and the Conradi-Hunermann type of chondrodysplasia punctata (deficiency of sterol D8 D7 isomerase) are the most common of the inborn errors of cholesterol metabolism. These biochemical deficiencies and others in the cholesterol pathway were all delineated during the past decade. Application of emerging laboratory technologies has permitted many malformations and malformation syndromes to be explained at the molecular level. Recognition that mutations in the sonic hedgehog gene (SHH) cause holoprosencephaly is typical. The discovery process involved a series of accomplishments.
First came putative localization of a holoprosencephaly gene on 7q36 based on chromosomal rearrangements found in some patients with holoprosencephaly. This localization permitted construction of a yeast artificial chromosome (YAC) contig across the 7q36 locus and definition of a critical region containing the holoprosencephaly gene. Testing of genes within and adjacent to the critical region identified SHH to be the causative gene. Less common, but of equal importance, has been the subsequent identification of other genes on other chromosomes that can also cause holoprosencephaly. This approach to positional cloning of genes that are associated with malformations has been repeatedly successful. Witness the identification of the mutations in several FGF receptors in association with craniosynostosis, mutations in FGFR3 in achondroplasia and related chondrodysplasias, mutations in the NIPBL gene in Cornelia de Lange syndrome, and mutations in the FGD1 gene in Aarskog syndrome, among others. The assignment of genes or gene loci has been most successful perhaps in relation to malformations and malformation syndromes involving the brain and skeleton. Mutations in five genes are associated with the craniosynostoses, mutations in 47 genes are associated with skeletal dysplasias, and mutations in 14 genes are associated with various malformations of the brain. Mutational analysis of many of these genes is currently available in clinical laboratories. Identification of the genes associated with cardiac, respiratory, gastrointestinal, and renal malformations has been less successful. Knowledge that microdeletion syndromes occur throughout the genome, and technologies to detect these microdeletions, have been major contributions from cytogenetics. These advances have permitted better delineation of the structural and neurobehavioral manifestations of many common syndromes such as velocardiofacial/DiGeorge, Williams, Smith-Magenis, Miller-Dieker, and other syndromes. Deletions and duplications in the chromosomal subtelomeric regions have become recognized as important causes of severe mental retardation. These subtelomeric alterations are in some cases accompanied by malformations. In 1993, the only laboratory diagnostic technology relevant to malformations was cytogenetics. And, while cytogenetics has maintained an important and expanding role in the study of malformations, biochemical genetics and molecular genetics have
vi
Preface
become more equal contributors. Numerous are the malformations caused by perturbations of well known (e.g., disorders of cholesterol synthesis) and newly delineated (e.g., congenital disorders of glycosylation) metabolic pathways. In similar fashion, molecular studies are now essential components of the armamentarium of diagnostic and management teams. As the second edition of Human Malformations and Related Anomalies goes to press, the influences of epigenetic phenomena on human development are just being explored. The apparent increased risk for Angelman syndrome, Beckwith-Wiedemann syndrome, Prader-Willi syndrome, Russell-Silver syndrome, and bladder/cloacal exstrophy in infants conceived by assisted reproductive technologies (ARTs) raises suspicion that adverse epigenetic influences may be responsible. To be sure, imprinting defects may underlie alterations in growth and childhood development, but the role as a cause of specific malformations is not clear. Fortunately, no new environmental disasters of the magnitude of prenatal rubella infection or thalidomide exposure have occurred in recent years. Initial concern that transplacental HIV infection might produce maldevelopment has not been realized. Still, on a lesser scale, the recognition of teratogenicity of misoprostol (a prostaglandin inhibitor), fluconazole (an antifungal agent), parvovirus (B19), and early chorionic villus sampling reminds us that hazards to the unborn infant lurk in the environment. Clearly, the most effective birth defects prevention strategy of the past decade has been the use of folic acid during the periconceptional period to prevent neural tube defects. Although the protective effect of folic acid against NTDs was reported by Richard Smithells as early as 1981, it took randomized case-control studies by Great Britain’s Medical Research Council and by Andrew Czeizel in Hungary to convince medical and scientific communities of its efficacy. Increased folic acid concentration in the periconceptional period is now widely advocated for prevention of neural tube defects, and the recommendation has been advanced by decisions in several countries to fortify cereal grain flours. Evidence that folic acid also has a protective effect against other birth defects has been reported, although the magnitude of the protective effect appears to be less than for NTDs. To date, no compelling explanation for the mechanism by which folic acid conveys its protective effect against birth defects has been found. Equally obvious are the disappointments of the past decade. Additional prevention partners to take their places with folic acid have not been identified. Nor has an educational or other strategy been implemented to make significant progress in preventing pervasive teratogen exposures such as alcohol and other drug use during pregnancy. A litany of genes associated with malformations in lower animals has not been relevant to the same malformations in humans. For example, over 60 gene mutations that led to neural tube defects in mice have been identified, and in not a single instance has the homologous gene in humans been found to harbor mutations that cause human neural tube defects. Neither have examples of the much touted concept of gene—environment interactions as the basis for birth defects been found. And most disappointing, as mentioned before, has been the persistence of malformations as the leading cause of infant mortality. As we anticipated during the writing of Edition 1, the application of emerging technologies of molecular biology and developmental genetics would significantly advance the understanding
of normal and abnormal embryonic and fetal development during the ensuing decade. These research advances, continuing observations by clinicians, more comprehensive and accurate epidemiology, and new diagnostic and prevention capabilities related to birth defects called for a substantially revised edition. Human Malformations and Related Anomalies is intended to provide a body of information on individual anomalies and to connect the anomalies to malformation syndromes, primarily through the use of differential diagnostic tables. A central goal is to consider each significant human anomaly from the perspective of the clinician and in the context of the current understanding of embryonic and fetal development. What is the nature of the anatomical defect? What related anomalies and syndromes must be considered? What are the appropriate treatment and prevention strategies? Edition 2 of Human Malformations and Related Anomalies is presented in a single volume. A portion of the information in Volume 1 of Edition 1 has been condensed into an introductory chapter. Thereafter follow 34 chapters that provide detailed accounts of anomalies arranged by anatomical systems, as in Edition 1. The format of these chapters has been revised somewhat to more consistently reflect the relevant embryology, epidemiology, molecular insights, and animal studies. The occurrence of each anomaly in various associations and syndromes is documented. The natural history, approaches to treatment, and prevention strategies are given in the final subsection of each entry. Acknowledgments
Edition 2 of Human Malformations and Related Anomalies has had the benefit of the editorial touches of associate and assistant editors. Kathy Sulik took responsibility for giving a consistent and contemporary view of the human embryology relevant to each section. Enid Gilbert-Barness edited the entries from a pathology perspective. Karen Buchanan attended to the myriad details necessary to facilitate communications between the authors and editors, organize the contents, and adhere to the schedule. To these colleagues and to each of the 42 contributing authors, we are indebted. Rachel Collins, Librarian at the William A. Klauber and Betty Jane Klauber Genetics Library, has provided searches, citation verification, and reprints. Patti Broome assisted in preparation and organization of the final manuscript copy. Preparation of Edition 2 of Human Malformations and Related Anomalies has given us the pleasure of working again with Jeffrey House and Edith Barry at Oxford University Press. They have been helpful, encouraging, and accessible throughout the process. Similar support has come from our clinical and laboratory colleagues at the Greenwood Genetic Center and the University of British Columbia. Appreciation is expressed to the host of clinicians and researchers worldwide who, through their observations and laboratory findings, have contributed new knowledge and insights sufficient to warrant production of the current edition. Participants in the David W. Smith Workshop on Malformations and Morphogenesis have been continual sources of information and insight. Their innumerable contributions to this edition are gratefully acknowledged. R. E. S. J. G. H.
Contents
Contributors
3. Systemic Vasculature
xiii
121
Lynne M. Bird and Kenneth Lyons Jones
Part I—Overview 1. Human Malformations and Related Anomalies
3
Roger E. Stevenson
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8
Nomenclature 6 Classification and Coding 13 Genetic Causes of Malformations 14 Gene Mutations and Malformations 22 Environmental Causes of Malformations 33 Human Anomalies with Unknown Causes 58 Detection, Diagnosis, Evaluation, Management 58 Discussions with the Family 71
Part II—Cardiorespiratory Organs
3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13 3.14 3.15
Interrupted Aortic Arch 121 Right Aortic Arch 123 Cervical Aortic Arch 125 Double Aortic Arch 125 Double-Lumen Aortic Arch 126 Incidental Anomalies of the Aortic Arch 127 Innominate Artery Variants 128 Subclavian Artery Variants 129 Patent Ductus Arteriosus 130 Coarctation of the Aorta 133 Persistent Left Superior Vena Cava 136 Inferior Vena Cava Variants 137 Miscellaneous Venous Variants 138 Deep Vein Abnormalities 139 Vascular Malformations 140
4. Lymphatic System
145
Judith E. Allanson
2. Heart
85
Angela E. Lin, John Belmont, and Sadia Malik
2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14
Heterotaxy 93 Single Ventricle 96 Conotruncal Defects 97 Atrioventricular Septal Defects 101 Right Ventricular Outflow Tract Obstructive Defects 103 Left Ventricular Outflow Tract Obstructive Defects 106 Atrial Septal Defects 112 Ventricular Septal Defects 113 Anomalies of the Pulmonary Veins 115 Abnormal Systemic Venous Connections 117 Anomalies of the Ductus Arteriosus 118 Aortopulmonary Window (Aortopulmonary Septal Defect) 119 Anomalies of the Coronary Arteries 119 Anomalies of the Pericardium 120
4.1 4.2 4.3 4.4 4.5
Primary Lymphatic Anomalies 146 Pulmonary Lymphangiectasia 161 Fetal Cystic Hygroma 163 Lymphangioma 169 Lymphangioleiomyomatosis 180
5. Spleen
183
Arthur S. Aylsworth
5.1 5.2 5.3
Polyasplenia 185 Positional Alterations of the Spleen 195 Accessory Spleens, Structural Variation, and Fusion to Other Organs 196
6. Lower Respiratory Organs
201
Laurie H. Seaver
6.1 6.2 6.3 6.4 6.5
Bifid Epiglottis 201 Laryngeal Atresia, Webs, and Stenosis Laryngotracheoesophageal Cleft 205 Tracheal Agenesis 206 Tracheal Stenosis 207
202
viii
Contents
6.6 6.7 6.8 6.9 6.10 6.11 6.12
Congenital Tracheal Cartilaginous Sleeve 209 Tracheoesophageal Fistula 209 Pulmonary Agenesis/Aplasia 209 Congenital Cystic Adenomatoid Malformation 211 Congenital Lobar Emphysema 213 Primary Pulmonary Hypoplasia 213 Congenital Diaphragmatic Hernia 214
9.11 Congenital Cataracts 316 9.12 Persistent Hyperplastic Primary Vitreous or Persistence of the Fetal Vasculature 318 9.13 Optic Nerve Hypoplasia 320 9.14 Morning Glory Disc Anomaly 322 9.15 Optic Pit 324 10. Ear
327
John C. Carey
Part III—Craniofacial Structures External Ear 7. Skull
221
John M. Graham, Jr.
7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9 7.10 7.11 7.12 7.13 7.14 7.15 7.16 7.17 7.18 7.19 7.20 7.21 7.22
Craniosynostosis 221 Kleeblattscha¨del 235 Wide Cranial Sutures 237 Anomalies of Fontanels 238 Cranial Dermal Sinus 242 Parietal Foramina (Includes Cranium Bifidum) 243 Wormian Bones 245 Scalp Vertex Aplasia 246 Thin Cranial Bones 248 Undermineralization of the Skull 248 Craniotabes 249 Thick Cranial Bones 251 Sclerosis and Hyperostosis of the Skull 254 Vertex Birth Molding 254 Breech Head (Bathrocephaly) 257 Other Cranial Deformations Due to Abnormal Fetal Presentation 258 Anomalies of the Sella Turcica 259 Anomalies of Foramen Magnum 260 Anomalies of the Other Basal Foramina and Canals 261 Basilar Impression 261 Cephalhematoma and Caput Succedaneum 262 Miscellaneous Anomalies of the Skull 264
8. Facial Bones
267
Karen Gripp and Luis Fernando Escobar
8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 9. Eye
Premature Metopic Sutural Synostosis 268 Orbital Hypotelorism 270 Orbital Hypertelorism 273 Midline Facial Skeletal Clefting 278 Absence and Hypoplasia of the Zygoma 280 Midface Retrusion and Hypoplasia 283 Agnathia 287 Micrognathia 288 Congenital Asymmetry of the Facial Skeleton 292 297 Anophthalmia 299 Microphthalmia and Typical Uveal Coloboma Cyclopia and Synophthalmia 302 Cryptophthalmos 303 Blepharophimosis 305 Other Anomalies of the Eyelids 306 Congenital Corneal Anomalies 309 Anterior Segment Dysgenesis 311 Peters Anomaly 313 Hypoplasia of the Iris (Aniridia) 314
10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 10.9 10.10 10.11 10.12 10.13 10.14 10.15 10.16 10.17 10.18 10.19 10.20 10.21
Microtia/Anotia 331 Small Ear 335 External Auditory Canal Stenosis and Atresia Without Microtia 336 Cryptotia 338 Large Ear (Macrotia) 338 Polyotia 339 Duplication of the External Auditory Meatus 340 Synotia/Otocephaly 340 Low-set Ears 342 Posteriorly Rotated Ears 344 Lop/Cup Ear Anomaly 344 Protruding Ear 346 Stahl Ear 348 Mozart Ear 349 Darwinian Tubercle 350 Prominent Crus of the Helix 350 Lobular Defects 350 Auricular Tags 351 Auricular Pits 353 Ear Lob Creases/Pits 355 Deformation of the Auricle 356
Middle Ear
356
John C. Carey and Albert H. Park
10.22 Hypoplasia/Aplasia/Malformation of the Malleus 358 10.23 Fusion Defects of the Malleus 359 10.24 Hypoplasia/Aplasia/Malformation of the Incus 361 10.25 Fusion Defects of the Incus 362 10.26 Hypoplasia/Aplasia/Malformation of the Stapes 362 10.27 Congenital Fixation of the Stapes 363 10.28 Absence of the Oval Window 364 10.29 Congenital Cholesteatoma 364 10.30 Persistence of the Stapedial Artery 365 10.31 Highly Placed Jugular Bulb 365 Inner Ear 366 Daryl A. Scott and John C. Carey
Elias I. Traboulsi
9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 9.9 9.10
329
John C. Carey, Albert H. Park, and Harlan R. Muntz
10.32 Vestibular Dysplasias 366 10.33 Prelingual Hearing Loss 369 300
11. Nose
373
M. Michael Cohen, Jr.
11.1 11.2 11.3 11.4 11.5 11.6
Arhinia 374 Unilateral Arhinia, Heminasal Aplasia Small Nose 375 Nostril Coloboma 376 Bifid Nose 376 Nostril Atresia 377
374
Contents
11.7 11.8 11.9 11.10 11.11 11.12 11.13 11.14 11.15 11.16 11.17 12. Lips
Choanal Atresia 377 Polyrrhinia 378 Proboscis 378 Noses of Distinction 381 Deviation of the Nasal Septum 386 Turbinate Deformity 386 Arrhinencephaly 386 Hemangioma of the Nose 386 Dermoid Cyst of the Nose 388 Glioma of the Nose 388 Encephalocele Involving the Nose 388 391
Marilyn Jones
12.1 12.2 12.3
Median Cleft Lip 393 Cleft Lip With or Without Cleft Palate (CL/P) 394 Cleft Palate 400
13. Tongue
ix
14.6 14.7 14.8 14.9 14.10
13.6 13.7 13.8 13.9 13.10 13.11 13.12 13.13
13.14 13.15 13.16 13.17 13.18 13.19 13.20 13.21 13.22 14.
Teeth
425
Rena N. D’Souza, Hitesh Kapadia, and Alexandre R. Vieira
14.1 14.2 14.3 14.4 14.5
Tooth Agenesis 431 Supernumerary Teeth 444 Microdontia 446 Macrodontia 451 Abnormalities of Tooth Shape 452
469
15. Brain
Alasdair G. W. Hunter
15.1 15.2 15.3 15.4 15.5
405
Aglossia, Hypoglossia, Microglossia 406 Absence of Lingual Frenulum 406 Macroglossia 407 Bifid Tongue 408 Fissured Tongue, Scrotal Tongue, Lingua Plicata 408 Glossopalatine Ankylosis (Ankyloglossum Superius) 409 Ankyloglossia: Tongue-tie, Partial Ankyloglossia, Total and Lateral Ankyloglossia 410 Median Rhomboid Glossitis 411 Double Tongue 412 Lingual Thyroid 413 Choristoma of Tongue: Enterogenous Cyst of Tongue 414 Choristoma of Tongue: Epidermoid Cyst of Tongue 416 Choristoma of Tongue: Cyst Lined with Respiratory Epithelium or Nonciliated Columnar Epithelium 416 Choristoma of Tongue: Brain Tissue in Tongue 416 Choristoma of Tongue: Chondroma and Osteoma 417 Congenital Dermoid Cyst 418 Hamartoma: Lymphangioma of the Tongue 419 Hamartoma of the Tongue: Hemangioma 420 Hamartoma of the Tongue: Mixed Type (Mesenchymoma) 420 Congenital Teratoma 421 Abnormal Tongue Movements and Excessive Mobility of the Tongue 421 Pigmented Fungiform Papillae and Other Lingual Pigmentations 423
463
Part IV—Neuromuscular Systems
Robert J. Gorlin
13.1 13.2 13.3 13.4 13.5
Dental Malocclusion 456 Enamel Dysplasia 458 Dentin Dysplasia 461 Cementum Dysplasia 463 Abnormalities of Tooth Eruption
15.6 15.7 15.8 15.9 15.10 15.11 15.12 15.13 15.14
Microcephaly 470 Megalencephaly 511 Aprosencephaly/Atelencephaly 525 Holoprosencephaly 528 Malformations of Cortical Development: Disorders of Neuronal and Glial Formation, Migration, and Maturation; Lissencephaly, Pachygyria, Polymicrogyria, Heterotopias, Ectopias, and Cortical Dysplasias 546 Agenesis of the Corpus Callosum 581 Cavum, Cysts, and Absence of the Septum Pellucidum and Cavum Vergae 604 Hydrocephalus 610 Colpocephaly 636 Hydranencephaly 639 Porencephaly 645 Cerebellar Anomalies 654 Cystic Malformations 677 Chiari Malformations 700
16. Brain and Spinal Cord
715
Alasdair G. W. Hunter
16.1
Disorders of Neural Tube Closure
17. Spinal Cord
715
757
Alasdair G. W. Hunter
17.1 17.2 17.3 17.4 17.5 17.6 17.7 17.8
Primary Tethered Cord 757 Neurenteric Malformations 762 Intraspinal (Nonneurenteric) Cysts 764 Syringomyelia 768 Split Cord Malformation (Diastematomyelia) and Diplomyelia 773 Myelocystocele 776 Anterior and Lateral Meningoceles 778 Tailgut Cyst 782
18. Muscle
783
Judith G. Hall
18.1 18.2 18.3 18.4 18.5 18.6 18.7 18.8 18.9
Generalized Abnormalities of Muscle Mass: Increased Muscle Mass 786 Generalized Abnormalities of Muscle Mass: Decreased Muscle Mass 788 Localized Abnormalities of Muscle 790 Aglossia 791 Facial Muscle Deficiency 791 Asymmetric Crying Facies 791 Deficiency of Eye Muscles 792 Deficiency of Esophageal Muscles 792 Defects of Pectoralis Muscles and Other Muscles of the Shoulder Girdle 793
x
Contents
18.10 18.11 18.12 18.13 18.14 18.15 18.16 18.17 18.18
Poland Anomaly 794 Poland-Mo¨bius Syndrome 795 Poland-Like Gluteal-Lower Leg Anomaly 796 Prune Belly Syndrome 797 Isolated Deficiency of Abdominal Muscles 799 Diaphragmatic Defects 799 Variations with Accessory Muscle Tissue 800 Muscle Atavisms 800 Muscle Abnormalities Associated with Chromosomal Disorders 801
21. Hands and Feet
935
David B. Everman
21.1 21.2 21.3 21.4
The The The The
Polydactylies 937 Syndactylies 954 Brachydactylies 968 Oligodactylies 984
22. Skeletal Dysplasias
997
Ju¨rgen Spranger
Part VI—Gastrointestinal and Related Structures Part V—Skeletal System 23. Ventral Wall of the Trunk 19. Pectoral Girdle, Spine, Ribs, and Pelvic Girdle
805
Louanne Hudgins and Keith Vaux
19.1 19.2 19.3 19.4 19.5 19.6 19.7 19.8 19.9 19.10 19.11 19.12 19.13 19.14 19.15 19.16 19.17 19.18 19.19 19.20 19.21 19.22 20. Limbs
Clavicular Hypoplasia/Aplasia 806 Clavicular Pseudarthrosis 807 Altered Shape and Other Abnormalities of the Clavicle 807 Sprengel Anomaly 807 Glenoid Hypoplasia 809 Anomalies of the Sternum 810 Pectus Excavatum/Pectus Carinatum 811 Rib Anomalies 812 Cervical Rib 813 Occipitalization of the Atlas 813 Aplasia/Hypoplasia of the Odontoid Process of the Axis 818 Segmentation/Formation Defects of the Vertebrae 819 Klippel-Feil Anomaly 821 Altered Vertebral Body Contour 823 Sagittal Clefts of the Vertebrae 825 Coronal Clefts of the Vertebrae 826 Spondylolysis and Spondylolisthesis 827 Sacral Agenesis 829 Anomalies of the Pelvic Bones 830 Developmental Dysplasia of the Hip 830 Coxa Vara 833 Coxa Valga 833 835
23.1 23.2 23.3
23.4 23.5 23.6 23.7 23.8
Sternal Defects 1025 Ectopia Cordis, Including Cantrell Pentalogy The Umbilicus: Congenital Anomalies and Variations in Configuration and Placement 1028 Umbilical Hernia 1031 Omphalocele 1034 Gastroschisis 1038 Exstrophy of the Bladder 1042 Exstrophy of the Cloaca 1046
Breasts
1049
23.9 23.10 23.11 23.12 23.13 23.14 23.15
Amastia and Hypomastia 1051 Enlarged Breasts 1053 Symmastia 1055 Supernumerary Breasts and Nipples Widely Spaced Nipples 1058 Gynecomastia 1059 Premature Thelarche 1063
24. Upper Gastrointestinal System
Pharynx 24.1
1065
24.2
1067
Fistulas, Sinuses, and Cysts: Branchial Clefts and Pouches 1069 Congenital Pharyngeal Diverticula 1071
Esophagus 24.3
Judith G. Hall
1055
H. Eugene Hoyme
20.1 20.2 20.3 20.4 20.5 20.6 20.7 20.8 20.9 20.10 20.11 20.12 20.13 20.14
1027
Ellen Boyd and Roger E. Stevenson
Roger E. Stevenson
Limb Deficiencies 839 Synostosis 856 Constriction Rings 871 Duplications, Excessive Partitions, and Accessory Bones 876 Bowing of Long Bones 882 Short Stature 894 Tall Stature 900 Limb Overgrowth 902 Increased Bone Density 910 Decreased Bone Density 914 Osteolysis 916 Anomalies of the Patella 919 Hypermobile Joints 922 Arthrogryposis (Multiple Congenital Contractures) 925
1023
Cynthia Curry, Ellen Boyd, and Roger E. Stevenson
1071
Esophageal Stenosis, Atresia, and Tracheoesophageal Fistula 1073 24.4 Esophageal Webs and Rings 1076 24.5 Tubular Esophageal Duplications 1077 24.6 Enterogenous Cysts 1077 24.7 Esophageal Diverticula 1078 24.8 Heterotopic Gastric Mucosa in the Esophagus 1079 24.9 Congenital Short Esophagus 1079 24.10 Achalasia 1079 24.11 Chalasia 1080 Stomach 24.12 24.13 24.14 24.15
1081
Infantile Hypertrophic Pyloric Stenosis 1082 Microgastria 1084 Atresia and Stenosis of the Stomach 1084 True Diverticula of the Stomach 1085
Contents
24.16 24.17 24.18 24.19
Duplication of the Stomach 1086 Defects of Gastric Musculature 1086 Malposition of the Stomach 1087 Mucosal Heterotopia 1088
Duodenum
1089
24.20 24.21 24.22 24.23 24.24 24.25
Malrotation of the Duodenum 1090 Duodenal Stenosis and Atresia 1090 Duodenal Duplications 1092 Duodenal Diverticula 1093 Congenital Aganglionic Duodenum 1094 Extrinsic Vascular Obstruction of the Duodenum 1095 24.26 Congenital Paraduodenal Hernia through a Peritoneal Defect 1095
xi
28.6 28.7 28.8 28.9 28.10 28.11 28.12 28.13 28.14 28.15 28.16 28.17
Renal Dysplasia 1205 Familial Nephronophthisis/Medullary Cystic Disease 1215 Medullary Sponge Kidney 1217 Renal Cystic Disease Secondary to Obstruction Supernumerary Kidney 1222 Renal Ectopia 1223 Horseshoe Kidney 1228 Anomalies of the Bladder and Ureters 1232 Urachal Anomalies 1234 Urethral Agenesis or Atresia 1237 Posterior Urethral Valves and Urethral Stenosis 1241 Urethral Duplication 1247
29. Male Genital System 25. Small and Large Intestines
1097
Intestinal Agenesis 1099 Intestinal Atresia/Stenosis 1099 Duplications and Cysts 1103 Megacolon 1105 Malrotation 1109 Meckel Diverticulum 1111 Polyps 1111 Vascular Anomalies 1114
26. Rectum and Anus
1115
Cathy A. Stevens
26.1 26.2
Atresia of the Rectus and Anus Rectal Duplication 1122
27. Liver, Gallbladder, and Pancreas
1116
1123
Ian D. Krantz and Arthur S. Aylsworth
27.1 27.2 27.3
Anomalies of Liver Shape and Lobation 1127 Liver Dysplasia/Ductal Plate Malformations 1131 Intrahepatic Biliary Duct Atresia and Hypoplasia 1136 27.4 Agenesis of the Gallbladder 1139 27.5 Extrahepatic Biliary Atresia 1142 27.6 Cysts of the Biliary System 1145 27.7 Structural Variation and Miscellaneous Anomalies of the Gallbladder and Extrahepatic Ducts 1147 27.8 Pancreatic Agenesis 1150 27.9 Structural Variation and Anomalies of the Pancreas 1150 27.10 Pancreatic Cysts and Dysplasias 1154 27.11 Pancreatic Ectopia and Heterotopia 1157 Part VII—Urogenital System Organs 28. Urinary Tract
1161
Jane A. Evans
28.1 28.2 28.3 28.4 28.5
1251
Rick A. Martin
Eberhard Passarge and Roger E. Stevenson
25.1 25.2 25.3 25.4 25.5 25.6 25.7 25.8
1219
Renal Agenesis 1184 Renal Hypoplasia 1190 Cystic Diseases 1194 Autosomal Recessive (Infantile) Polycystic Kidney Disease 1197 Autosomal Dominant Polycystic Kidney Disease 1200
29.1 29.2 29.3 29.4 29.5 29.6 29.7 29.8 29.9 29.10 29.11 29.12 29.13 29.14 29.15 29.16 29.17 29.18
Micropenis 1255 Hypospadias 1258 Epispadias 1261 Hidden or Concealed Penis 1262 Megalourethra 1263 Diphallia 1264 Aphallia 1265 Penoscrotal Transposition 1265 Ectopic/Accessory Scrotum 1267 Cryptorchidism 1267 Microorchia/Anorchia/Agonadism 1268 Polyorchidism (Supernumerary Testes) 1271 Ectopic Testis 1272 Male Pseudohermaphroditism and 46,XY Sex Reversal 1272 Wolffian Duct Malformations 1276 Persistent Mu¨llerian Ducts 1276 Splenogonadal Fusion 1277 Inguinal Hernia 1277
30. Female Genital System
1279
Leah W. Burke
30.1 Ovarian Dysgenesis 1281 30.2 Mixed Gonadal Dysgenesis 1284 30.3 Hermaphroditism 1286 30.4 Ambiguous Genitalia 1287 30.5 Mu¨llerian Aplasia 1291 Isolated Anomalies of the Mu¨llerian Structures 1294 30.6 Absence of the Fallopian Tube 1294 30.7 Incomplete Mu¨llerian Fusion 1294 30.8 Cervical Atresia 1297 30.9 Vaginal Atresia 1298 30.10 Transverse Vaginal Septum 1299 30.11 Longitudinal Vaginal Septum 1300 30.12 Agenesis of the Clitoris 1300 30.13 Isolated Hypertrophy of the Clitoris/Clitoromegaly 1301 30.14 Duplication or Bifidism of the Clitoris/Female Epispadias 1302 30.15 Labial Fusion 1303 30.16 Imperforate Hymen 1303 30.17 Absence/Hypoplasia of External Genitalia 1303 30.18 Hyperplasia, Duplication, and Inversion of External Genitalia 1304
xii
Contents
Part VIII—Other Systems and Structures 31. Cutaneous Structures
1307
Julie S. Prendiville
31.1
Skin Cysts, Sinuses, Dimples, Tags, Tails, and Clefts 1309 31.2 Aplasia Cutis Congenita 1311 31.3 Mosaicism and the Lines of Blaschko 1312 31.4 Cutaneous Hamartomas 1315 31.5 Disorders of Keratinization 1319 31.6 Epidermolysis Bullosa 1319 31.7 Developmental Disorders of Connective Tissue 1321 31.8 Vascular Malformations 1322 31.9 Pigmentation Anomalies 1329 31.10 Malformations of the Epidermal Appendages 32. Endocrine Organs
1333
35. Umbilical Cord
1339
32.3 32.4 32.5 32.6 32.7 32.8 32.9
Congenital Adrenal Hyperplasia 1346 Anterior Pituitary, Hypothalamus, and Disorders of Short Stature 1349 Parathyroid Gland: Calcium Sensing Receptor Defects 1353 Parathyroid Gland: Albright Hereditary Osteodystrophy 1353 Posterior Pituitary and Water Metabolism 1354 Thyroid and Thyroid Biosynthetic Defects 1354 Endocrine Tumor Syndromes 1355 Mendelian Disorders with Endocrine Abnormalities 1356 Chromosomal Disorders with Endocrine Features 1357
33. Asymmetry and Hypertrophy
1359
Omar Abdul-Rahman and H. Eugene Hoyme
33.1 33.2
Laterality Sequences 1361 Kartagener Syndrome 1363
Patterns of Asymmetric Growth 33.3 33.4 33.5 34. Twins
1413
Will Blackburn and Nelson Reede Cooley, Jr.
Amy Potter and John A. Phillips III
32.1 32.2
Incidence of Twinning 1382 Causes of Twinning 1383 Sex Ratio 1383 Growth 1384 Spontaneous Abortions 1385 Vanishing Twin 1385 Fetus Papyraceus 1388 Perinatal Morbidity and Mortality 1389 Vascular Anastomoses in Twin Placentas 1390 Twin–Twin Transfusion Syndrome 1391 Acardia 1394 Conjoined Twins 1396 Structural Defects 1401 Mirror Image Twinning 1404 Discordance 1404 Caution for Complex Disorders 1404
1365
Hemihyperplasia (Hemihypertrophy) 1366 Hemihypoplasia and Hemiatrophy 1369 Generalized Overgrowth 1372 1377
Mary C. Phelan and Judith G. Hall
Zygosity and Placentation 1377 Polar Body Twinning 1380 Animal Models of Twinning 1380 Determination of Zygosity 1381
35.1 35.2 35.3 35.4 35.5 35.6 35.7 35.8 35.9 35.10 35.11 35.12 35.13 35.14 35.15 35.16 35.17 35.18 35.19 35.20 35.21
Umbilical Cord Calcifications 1417 Umbilical Cord Amnion (Inclusion) Cysts 1418 Umbilical Cord Cysts and Remnant Anomalies of Allantoic Duct Origin 1419 Umbilical Cord Cysts and Remnants of Vitelline (Omphalomesenteric Duct) Origin 1421 Umbilical Cord Pseudocyst (Cystic Mucoid Degeneration) 1424 Umbilical Cord Disruption (Linear) 1425 Umbilical Cord Dimensional Abnormalities 1426 Umbilical Cord-to-Cord Entanglements 1434 Umbilical Cord Hematoma 1436 Umbilical Cord Hernia 1437 Anomalies of Umbilical Cord Insertion 1439 Umbilical Cord Knots 1441 Umbilical Cord Loops (‘‘Encirclement’’) 1443 Umbilical and Umbilical Cord Polyp 1445 Abnormalities of Umbilical Cord (Abdominal Wall) Position 1448 Antenatal Separation of the Umbilical Cord 1449 Abnormalities of Postnatal Umbilical Cord Separation 1450 Umbilical Cord Torsion (Twist) Abnormalities 1451 Umbilical Cord Helical Ulceration 1453 Umbilical Cord Neoplasms 1454 Vascular Anomalies of the Umbilical Cord 1457
Index to Tables of Malformations and Associated Syndromes 1473 Subject Index
1477
Contributors
Omar Abdul-Rahman, M.D. Division of Medical Genetics Department of Pediatrics Stanford University School of Medicine Stanford, California Judith E. Allanson, M.D. Children’s Hospital of Eastern Ontario University of Ottawa Ottawa, Ontario, Canada Arthus S. Aylsworth, M.D. Department of Pediatrics University of North Carolina Chapel Hill, North Carolina John Belmont, M.D., Ph.D. Department of Molecular and Human Genetics Baylor College of Medicine Houston, Texas Lynne M. Bird, M.D. Department of Dysmorphology and Genetics Children’s Hospital San Diego, California
M. Michael Cohen, Jr., D.M.D., Ph.D. Oral and Maxillofacial Sciences Dalhousie University Halifax, Nova Scotia, Canada Cynthia Curry, M.D. Genetic Medicine Central California Fresno, California Department of Pediatrics University of California, San Francisco San Francisco, California Rena N. D’Souza, D.D.S., Ph.D. Department of Orthodontics, Dental Branch University of Texas Health Science Center Houston, Texas Luis Fernando Escobar, M.D. Medical Genetics and Developmental Pediatrics St. Vincent Hospital of Indianapolis Indianapolis, Indiana
Will Blackburn, M.D. Fairhope, Alabama
Jane A. Evans, Ph.D. Department of Biochemistry and Medical Genetics University of Manitoba Winnipeg, Manitoba, Canada
Ellen Boyd, M.D. Fullerton Genetics Center Asheville, North Carolina
David B. Everman, M.D. Greenwood Genetic Center Greenwood, South Carolina
Leah W. Burke, M.D. Division of Clinical Genetics University of Vermont College of Medicine Burlington, Vermont
Robert J. Gorlin, D.D.S., D.Sc. University of Minnesota School of Dentistry Minneapolis, Minnesota
John C. Carey, M.D. Division of Medical Genetics University of Utah Salt Lake City, Utah
John M. Graham, Jr., M.D., Sc.D. Medical Genetics Institute Steven Spielberg Pediatric Research Center David Geffen School of Medicine at UCLA Cedars Sinai Medical Center Los Angeles, California
xiii
xiv
Karen Gripp, M.D. DuPont Hospital for Children Wilmington, Delaware Judith G. Hall, M.D. Departments of Medical Genetics and Pediatrics UBC and Children’s and Women’s Health Centre of British Columbia Vancouver, British Columbia, Canada H. Eugene Hoyme, M.D. Division of Medical Genetics, Department of Pediatrics Stanford University School of Medicine Stanford, California Louanne Hudgins, M.D. Division of Medical Genetics, Department of Pediatrics Stanford University School of Medicine Stanford, California Alasdair G.W. Hunter, M.D. Children’s Hospital of Eastern Ontario Ottawa, Ontario, Canada Kenneth Lyons Jones, M.D. Division of Dysmorphology/Teratology University of California San Diego, California Marilyn Jones, M.D. Children’s Hospital San Diego, California Hitesh Kapadia, D.D.S. Department of Orthodontics University of Texas Health Science Center Houston, Texas Ian D. Krantz, M.D. Division of Human Genetics and Molecular Biology The Children’s Hospital of Philadelphia The University of Pennsylvania School of Medicine Philadelphia, Pennsylvania Angela E. Lin, M.D. Genetics and Teratology Unit Massachusetts General Hospital Boston, Massachusetts Sadia Malik, M.D. Department of Cardiology Arkansas Children’s Hospital Little Rock, Arkansas
Contributors
Eberhard Passarge, M.D. Institit fu¨r Humangenetik Universita¨tklinikum Essen, Germany Mary C. Phelan, Ph.D. T.C. Thompson Children’s Hospital Chattanooga, Tennessee John A. Phillips III, M.D. Division of Medical Genetics Department of Pediatrics Vanderbilt University School of Medicine Nashville, Tennessee Amy Potter, M.D. Division of Endocrinology and Metabolism Department of Medicine Vanderbilt University School of Medicine Nashville, Tennessee Julie S. Prendiville, M.B. British Columbia’s Children’s Hospital University of British Columbia Vancouver, British Columbia, Canada Daryl A. Scott, M.D., Ph.D. Department of Molecular and Human Genetics Baylor College of Medicine Houston, Texas Laurie H. Seaver, M.D. Greenwood Genetic Center Greenwood, South Carolina Ju¨rgen W. Spranger, M.D. Greenwood Genetic Center Greenwood, South Carolina Cathy A. Stevens, M.D. Department of Pediatrics University of Tennessee College of Medicine Chattanooga, Tennessee Roger E. Stevenson, M.D. Greenwood Genetic Center Greenwood, South Carolina Elias I. Traboulsi, M.D. Division of Ophthalmology Cleveland Clinic Foundation Cleveland, Ohio
Rick A. Martin, M.D. St. Louis Children’s Hospital, Medical Genetics Washington University St. Louis, Missouri
Keith Vaux, M.D. Department of Pediatrics Division of Dysmorphology University of California, San Diego San Diego, California
Harlan R. Muntz, M.D. Department of Otolaryngology University of Utah Health Sciences Center Salt Lake City, Utah
Alexandre R. Vieira, D.D.S., Ph.D. Department of Pediatrics University of Iowa Iowa City, Iowa
Albert H. Park, M.D. Department of Otolaryngology University of Utah Health Sciences Center Salt Lake City, Utah
Part I Overview
This page intentionally left blank
1 Human Malformations and Related Anomalies Roger E. Stevenson
M
alformations result from pathologic processes during the embryonic period. The pathologic processes may be inborn, extrinsic, or some combination of the two. There is a narrow period of vulnerability during which developmental processes may be affected adversely, since most human body structures are formed between the second and the eighth weeks of development. Some organs, such as the brain, continue to develop throughout fetal life and even after birth. The small period of vulnerability notwithstanding, a remarkably large number of conceptuses, perhaps the majority, fall victim to disturbances in normal developmental processes. In most instances, the malformed conceptuses or embryos fail to implant or die following implantation.1–17 A minority of these conceptuses continue to develop, but will result in infants born with malformations. In this book, the phrase ‘‘malformations and related anomalies’’ encompasses all types of fetal and embryonic processes that lead to the presence of structural anomalies at birth. In addition to those processes that interfere with normal formation of structures (malformations), there are disruptions (in which normally developing structures are damaged by in utero forces such as vascular accidents or amniotic bands), deformations (in which a normal structure is misshaped by internal or external mechanical forces), and dysplasias (in which cell structure, cell arrangement in tissue, or tissues are disorganized). Among liveborn infants, 2–3% will have major malformations that are detected at birth or in the initial weeks or months of life (Tables 1-1 and 1-2).18–29 Some major malformations escape early detection, but these covert malformations are usually found by age 5 years and equal the number (2–3%) found at birth.30 Some internal malformations fail to cause physiologic disturbance and may be found only incidentally during surgery, scans, radiographs, or autopsy. Among stillborn infants, 15–20% will have major malformations.31–34 An even higher rate of malformations is to be found among spontaneous abortions. All anatomic structures appear to be susceptible to malformations. The frequency with which different structures are The author gratefully acknowledges the contributions of Judith G. Hall, Patrick M. MacLeod, Dagmar Bauer-Hansmann, Mitchell S. Golbus, Richard J. Schroer, Robert A. Saul, and Golder N. Wilson to volume 1 of the first edition of Human Malformations and Related Anomalies, on which this Introduction is based.
found postnatally to be malformed varies significantly, depending to a significant degree on the physiologic impact of the malformation prenatally. Table 1-1 gives the birth prevalence for malformations of the major anatomic structures.22,23,35 Certain birth defects appear to be increasing (e.g., hypospadias and coarctation of the aorta), whereas others are declining in prevalence (e.g., neural tube defects and renal agenesis). Wide fluctuations in prevalence are seen in different locations around the world.35 Nowhere in medicine is a sympathetic and discerning ear more important than in the evaluation of the infant with a birth defect. The family may be devastated by the announcement that the anticipated ‘‘perfect baby’’ has or may have a significant defect. More and more often the anomaly is recognized prenatally. The evaluation must begin at the time the defect is recognized or suspected, although full evaluation may be postponed in some infants until birth or until the infant can be evaluated at a tertiary center if the anomaly is not life threatening. The ideal situation with non– life-threatening defects is that parent–infant bonding proceed without interruption and the infant be discharged from the hospital with the mother. In other circumstances, evaluation must be carried out more urgently. Certain anomalies, particularly cardiac and gastrointestinal anomalies, are potentially lethal if not treated immediately. Other lethal conditions for which no treatment is available need urgent diagnosis to plan appropriate management with the family. Some anomalies may not be life threatening, but evaluation is no less urgent. Notable among these is ambiguous genital development. Malformations have emerged as the most common cause of death during the first year of life in developed countries.36–38 With a preplanned protocol, evaluation of the infant with anomalies who dies can be carried out efficiently and with sensitivity to the family. The protocol should include complete examination, storage of appropriate samples (serum, urine, tissues), photographs, radiographs, and necropsy.39,40 Abortuses and stillborn infants can be evaluated under a similar protocol. Only with knowledge of the nature of the anomalies can accurate information on the cause of death and risk of recurrence be provided for the family. Clinicians attempt to assign causation in all human anomalies for the purpose of gaining a secure foundation for counseling and consideration of future preventive efforts. As desirable 3
Table 1-1. Prevalence of selected major malformations USA: Atlanta*
USA: California{
Canada{
High Prevalence Regionsx
Low Prevalence Regionsx
Rate
Trend
Rate
Rate
Trend
Anencephaly
3.6
;
3.7
2.1
;
Mexico South America
Italy South Africa
Spina bifida
3.8
;
4.3
6.3
;
Mexico South America
Spain England/Wales
Encephalocele
1.6
;
0.9
1.4
Mexico South America
Spain Norway
Hydrocephaly
8.1
;
3.5
7.1
South America France
England/Wales Spain
Anophthalmia/Microphthalmia
2.9
;
1.2
1.1
USA (Atlanta) Ireland (Dublin)
England/Wales Hungary
Anotia/Microtia
1.5
3.3
Mexico South America
Australia England/Wales
Atrial septal defect
25.1
19.7
23.0
:
Ventricular septal defect
37.8
16.0
30.4
:
Tetralogy of Fallot
4.2
2.6
4.2
:
USA (Atlanta) Ireland (Dublin)
England/Wales
Transposition of great vessels
5.4
4.2
4.2
N. Netherlands France
Mexico England/Wales
Truncus arteriosus
0.9
0.6
1.2
Hypoplastic left heart syndrome
3.0
2.5
2.9
USA (Atlanta) France
England/Wales South America
Coarctation of aorta
5.1
:
4.0
4.8
Ireland (Dublin) USA (Atlanta)
England/Wales Spain
Cleft Lip With or Without Cleft Palate
9.0
;
10.4
10.7
Norway Japan
South Africa Canada
Cleft Palate Without Cleft Lip
6.8
4.9
6.3
Malta Finland
South Africa
Esophageal Atresia/Stenosis With or Without Fistula
2.0
1.2
3.4
South America Ireland (Dublin)
England/Wales
Rectal and Large Intestinal Atresia/Stenosis
3.7
2.5
4.5
Neural Tube Defects
;
Cardiac Defects
:
33.7
:
2.3
24.2
Israel Czech Republic
Australia Italy
Renal Agenesis/Hypoplasia
4.5
;
0.5
4.2
Canada Ireland (Dublin)
Hungary Mexico
Diaphragmatic Hernia
2.3
2.5
France Ireland (Dublin)
South Africa Mexico
Bladder Exstrophy
0.1
0.0
Mexico France
England/Wales Japan
Omphalocele
2.6
France South America
Spain England/Wales
Gastroschisis
2.2
4.2
Mexico South America
Spain South Africa
Limb Reduction Defects (Upper)
4.1
3.7
Limb Reduction Defects (Lower)
1.7
Canada France
South Africa Japan
Hypospadias/Epispadias
;
1.3
1.7
g g
: 6.6
4.6
(continued)
4
Human Malformations and Related Anomalies
5
Table 1-1. Prevalence of selected major malformations (continued) USA: Atlanta* Rate
USA: California{
Trend
Canada{
Rate
Rate
Trend
High Prevalence Regionsx
Low Prevalence Regionsx
Chromosome Aneuploidies Trisomy 13
1.5
1.1
1.2
:
Ireland (Dublin)
Hungary
Trisomy 18
2.5
1.8
2.1
:
Ireland (Dublin)
Hungary
Trisomy 21
12.5
10.1
12.4
Ireland (Dublin)
Hungary
*Malformation rates (1996–2000) birth to age 6 years per 10,000 livebirths reported by Metropolitan Atlanta Congenital Defects Program (5 Metropolitan Atlanta counties).22 { Malformation rates (1996–2000) birth to age 1 year per 10,000 livebirths reported by California Birth Defects Monitoring Program (8 counties).22 { Malformation rates (1991–1993) birth to age 1 year per 10,000 births reported by Canadian Congenital Anomalies Surveillance System (Alberta, Manitoba, and Ontario provinces).23 x
High and low prevalence regions from International Clearinghouse for Birth Defects Monitoring Systems.35
Additional prevalence information on specific malformations may be found in the appropriate chapters.
Table 1-2. Incidence of major and minor anomalies Location 18
Marden et al., 1964
Sample Size
Major Anomalies (%)
Minor Anomalies (%)
14.7
USA
4412
2.1
Myrianthopoulos and Chung, 1974
USA
53,257
7.1
Mehes, 198350
Hungary
4589
2.2
17.2
Merlob et al., 198529
Israel
3762
1.6
21.0
Leppig et al., 198951
USA
4305
3.8
40.7
CBDMP, 1994*26
USA
>500,000
2.9
–
291,126
2.2
–
30,940
6.9
35.8
20
25
Stoll, 1995
Europe
Queisser-Luft et al., 200224
Germany
7.26
*California Birth Defects Monitoring Program.
as that goal may be, it is not attainable in every case. The causes of many malformations and recognized syndromes simply are not known. This is the case for approximately 40% of malformations.41,42 Of the 290 malformation syndromes included in Jones’ Smith’s Recognizable Patterns of Human Malformations, 40 (14%) have unknown etiology.43 Assignment of causation of a malformation in one individual may not be possible although the cause of the same malformation is readily determined in other individuals. Lethality has posed a barrier to determining causation of certain malformations and patterns of malformations; sirenomelia and Proteus syndrome are examples (Fig. 1-1).44,45 These conditions generally occur as isolated cases within a family. Affected individuals either die early (sirenomelia) or fail to reproduce (Proteus syndrome). The possibilities that either represents a dominant phenotype caused by a new mutation, a multifactorial phenotype with a low recurrence rate, or a chromosomal disorder caused by submicroscopic deletion that has not been detected with current technology cannot be excluded. Hence, the causes of these conditions will remain unknown until one of these possibilities or another alternative is confirmed and the possible cause or causes can be sorted out.
If heritable factors, environmental factors, or some combination of the two are accepted as the only etiologic possibilities for human anomalies, then one assumes that birth defects of unknown etiology will eventually be explained in terms of one of these three possibilities. Should factors other than hereditary and environmental be identified, the new influence must be woven into the causation schema. Kurnit et al. have suggested that chance may play a significant role in the occurrence of major malformations.46 The field of developmental biology is advancing in remarkable ways. Many of the genes involved in organ formation have been identified in lower animals; these same genes turn out to be important and thus conserved in human development.194 These developmental genes are expressed in a hierarchical manner much like the clotting cascade. Complex controls cause transcription to occur in tissue-specific and time-specific manner during development. Although the precise roles for various molecular phenomena (e.g., alternative splicing, regulatory elements, polymorphisms, receptors, affectors, epigenetic modifications of DNA and histones, processing of RNA) in development are unknown, it is clear that current investigations are directed at delineating a complete molecular embryology. Specific defects in
6
Overview
Fig. 1-1. Sirenomelia (A) and Proteus syndrome (B), a malformation and malformation syndrome of unknown causation. Note that a minority of cases of sirenomelia occurs in infants of diabetic mothers, and some possible cases of Proteus syndrome have had PTEN mutations.
molecular pathways and networks of pathways are now recognized and give greater insight into the etiology of structural anomalies observed at birth. 1.1 Nomenclature Meaningful terminology is fundamental to communication and to most educational processes. The plethora of terms used to describe human morphologic alterations sometimes promotes but often complicates these processes. Understandably, students may be confused by the admixture of commonly used terms. Some provide true descriptions of the alteration (macrocephaly); some bear ethnic, rank, or national connotations (Roman nose); some are colored with mythological imagery (sirenomelia, cyclopia); some imply a specific pathogenesis (oligohydramnios sequence); some imply a specific etiology (warfarin embryopathy); and some give tribute to a discoverer (Meckel diverticulum). The same term can be used in a very restricted sense by one group while having a more generic meaning for the total scientific community. Terms most removed from description of the anatomic alteration are most variable and carry the greatest prospect for continued change in the future. A universally acceptable and permanent terminology for anomalies would appear utopian. No previous system has met with full acceptance. One problem is that the priorities of different groups dealing with congenital anomalies are not the same. Anthropologists, anatomists, radiologists, and pathologists focus on the description of the change; therapists, on the functional implications; embryologists and teratologists, on the mechanisms; and clinicians, on the diagnosis, cause, treatment, and prevention. In each of these areas, a jargon has arisen to serve the perceived requirements of the group. Sometimes the terms used by one group coincide with those used by colleagues with other emphases. In
other situations, the terms used by one group meet indifference or rejection by others. Exclusive claim cannot be placed on any terms, and no group can prohibit use beyond a specified definition. Anatomically based nomenclature for malformations and related structural anomalies emphasizes topography and morphology. The purposes are to identify the anatomic part involved and to describe the alteration of that part. In this system, the development of new terms to describe human malformations would appear unnecessary. Human anatomy does not change, and timehonored terms for each structure are available.47 Morphologic alterations of individual structures can also be defined with simple, biologically correct terms. Should new descriptive terms become desirable, they can be introduced without necessitating revision of the entire system. Because anatomic terms are the least likely to change, they are used in this book. Anatomic alterations include size, shape, symmetry, consistency, density, continuity, patency, color, and position changes. Some are readily determined by gross inspection. Others fall into a continuum nearer the normal than the extreme. Indeed, some can be separated from the normal only by arbitrary convention. As part of the evaluation of an infant or child with malformations, careful measurements of normal and abnormal structures are essential. Norms for every age from embryo to adult are available. Not infrequently disharmonic growth between structures exists in association with congenital malformations. For those structural changes that fall along a continuum, one expects 5% to fall outside 2 standard deviations (SD) of the mean for the population, 2.5% below 2 SD of the population norm, and 2.5% above 2 SD of the norm. It is of interest that this definition of normality results in an incidence of abnormal members among the continuous traits similar to the incidence of major malformations in the newborn population (Tables 1-1 and 1-2). Some continuous traits (e.g., color, density, and consistency) have no standardized measurements from which their norms and standard deviations can be determined. In the clinical setting, assessment of these features is almost invariably subjective. In an anatomically based nomenclature, no consideration is given to causation and pathogenesis, although in certain instances they may be coincidentally accommodated. Macrocephaly is used generically to describe large head of unknown cause and also to describe large head with large brain. Hydrocephaly is used to describe a large head due to ventricular enlargement. Hydrocephaly, however, does not necessarily imply head enlargement, since hydrocephaly can coexist with normal or even small head sizes. This type of duplicity and nuance is to be expected in any system of nomenclature and can be tolerated to some degree. Macrohydrocephaly or hydromacrocephaly to identify large head due to enlarged ventricles becomes too cumbersome. The terminology for anomalies based on morphologic alterations is derived from the Greek language, as introduced by Malacarne in 1798,48 but an increasing drift toward the use of Anglicized terms is evident. With English now being considered the universal scientific language, this trend will likely continue. A mix of English, Latin, and Greek terms will be found in the present text, with the choice of the term being based on familiarity and ease of flow. Malformations, Disruptions, and Deformations
Distinction between pathogenetically different types of structural abnormalities is indicated by the terms malformation, disruption, and deformation.49 Anomalies can be placed into one of these
Human Malformations and Related Anomalies
categories on the basis of the developmental stage during which the alteration took place, the process that caused the change, or the end result. Using these distinctions, malformations arise during the initial formation of a structure. The structure can have a faulty configuration, can be incompletely formed, or can fail to form altogether. Malformations are caused by genetic or environmental influences or by a combination of the two. They result from abnormal processes during the formation of the structures (i.e., during organogenesis). For most structures, organogenesis is complete by 8 weeks postfertilization. However, teeth, brain, and genitalia are notable among the many structures whose formation extends beyond 8 weeks. Disruptions result from abnormal processes that alter normally forming structures during or after formation. A wide range of morphologic changes can occur secondary to disruptions, including alterations of shape and configuration, division of parts not usually divided, fusion of parts not usually fused, and loss of parts previously present. The causes of disruptions are usually environmental, but genetic causes (e.g., genetically programmed loss of blood supply and inherited thrombophilias) are also possible. Mechanical forces can cause compression, hemorrhage, thrombosis, emboli, and other vascular impairments that damage formed structures. The term deformation indicates molding of a part through mechanical forces, usually over a prolonged period of time. Deformations result in loss of symmetry, altered alignment, abnormal positioning, and distorted configuration. They usually occur after organogenesis, often involve musculoskeletal tissues, and require no obligatory underlying tissue defect. Abnormal tissues may, however, be more susceptible to deformation. Deformations are usually reversible postnatally, depending on how long-standing they are and how much growth has occurred subsequent to the initial compressive effects. Deformations are usually due to external forces but can result from edema, which can exert intrinsic compressive forces. These criteria for designating a malformation or disruption have been modified from those set forth by Spranger et al., who represented an International Working Group on Nomenclature of Errors of Morphogenesis.49 According to their definitions, malformations are all genetic in etiology; disruptions occur during or after organogenesis; and deformations are caused only by extrinsic forces. The restriction of malformation to structural defects of genetic origin would appear unwarranted and contrary to historical usage. For instance, it seems entirely appropriate to consider the limb anomalies caused by teratogens such as thalidomide to be malformations since they occur during the period of morphogenesis. Although this tripartite schema was thoughtfully devised and allows for meaningful communication among many who work with human congenital anomalies, universal usage should not be anticipated. The term malformation will be used in a generic sense by many to indicate any structural alteration that occurs during the prenatal period. In defense of this general usage, both scientists and the public understand the general nature of the problem when the term is used. Likewise, the term deformity is used by orthopedists to indicate any anomaly of the skeleton often including problems arising during embryologic development. The value to geneticists of using malformation, disruption, and deformation according to the foregoing definitions is that it allows certain generalizations to be made about the causation, pathogenesis, prognosis, and recurrence of different types of anomalies. It also allows for a more accurate categorization of the structural
7
abnormalities, which improves the prospect of a correct diagnosis. Spranger et al.,49 also described a fourth category of dysplasias in which cellular or tissue disorganization is present. Major and Minor Anomalies
Major structural anomalies have medical and social consequences. The incidences of major defects appear highest among abortions, intermediate in stillborn infants, and lowest among liveborn infants. The incidence of major anomalies recognized at birth among liveborn infants is 2–3% in most series (Table 1-1).18–29 An equal number of additional major anomalies will be recognized by age 5 years (e.g., cardiac defects, absent kidney). This means that by 5 years of age, 1 in 20 or 5% of individuals are found to have a major defect in structural development. Considering the complexity of the developmental processes, it is surprising that the frequency of anomalies is not higher. An evolving understanding of prenatal (and postnatal) human development indicates that the biochemical basis of development and growth changes during different stages of development. A specific gene’s product may have quite different effects in different tissues and at different times in development. Furthermore, a gene, possibly with alternative splicing, is reused in different tissues at different times in development. This suggests that susceptibilities and predispositions to detrimental influences both intrinsic and extrinsic may be very different at different times in development and that the potential for curative or corrective measures will need to be time-in-development sensitive. The control of these processes (e.g., the switch from embryonic to fetal and adult hemoglobin) is still poorly understood. No individual major anomaly has a sufficiently high incidence in the population for it to be considered a structural polymorphism; that is, none has an incidence of greater than 1%. The monopodic, cyclopic, and other malformed races that exist in noncritical accounts of ancient writers must be viewed with skepticism. Minor anomalies are relatively frequent structural alterations that pose no significant health or social burdens (Tables 1-2 to 1-4).18,49–52 They are nonetheless important because their presence prompts a search for coexistent, more important structural anomalies. The presence of two or more minor anomalies is an indication that a major defect or syndrome may be present as well. Minor anomalies often provide critical clues that permit the diagnosis of a specific syndrome or a specific disorder having multiple anomalies. They can also provide a clue to the timing of an insult during prenatal development. Approximately 15% of newborn infants have one or more minor structural anomalies.18,20,24,29,50,51 A higher incidence may be found among premature infants, while babies with intrauterine growth retardation have an even higher rate. The risk of having a major birth defect increases with the number of minor defects present (Table 1-4). Infants free of minor defects have a low incidence (approximately 1%) of major malformations. Infants with one minor defect have a 3% risk of a major defect; those with two minor defects have a 10% risk of a major malformation; and those with three or more minor defects have a 20% risk of a major defect.18,50,51 No clear distinction exists between normal variation and minor anomalies or between minor anomalies and major anomalies. The determinations are often arbitrary. Holmes separates minor anomalies from normal variants by considering as normal those features that occur in 4% or more of the population.52 This is a fourfold greater incidence than the 1% usually required for a
8
Overview Table 1-3. Minor anomalies Cranium and Scalp
Face and Neck
Horizontal palmar crease (single)
Triple hair whorl
Synophrys
Bridged palmar crease
Absence of hair whorl
Flat bridge of nose
Single crease, finger V
Patent metopic suture
Prominent bridge of nose
Metopic fontanel
Hypotelorism
Skin tags (preauricular, ear lobe, others)
Sagittal fontanel
Hypertelorism
Parietal foramen
Nostrils anteverted
Flat occiput
Long nasal septum
Prominent occiput
Epicanthal fold
Frontal bossing
Iris freckles
Flat brow
Upward palpebral slant
Hypopigmented spots Trunk
Extra nipples Single umbilical artery Umbilical hernia
Microtia
Cleft uvula
Darwinian point
Cleft lip microform
Darwinian tubercle
Cleft gum
Lack of helical folding
Long philtrum
Bridged concha
Short philtrum
Ear lobe crease
Smooth philtrum
Ear lobe notched
Microstomia
Ear lobe bifid
Macrostomia
Lop ear
Macroglossia
Cup-shaped ear
Microglossia
Retroverted ear
Broad alveolar ridge
Thickened helix
Micrognathia
Helix excessively folded
Webbed neck
Helix attached to scalp
Redundant neck skin
Sinuses
Ptosis
Branchial
Skin
Overlapping digits
Preauricular
Shoulder dimples
Prominent heel
Ear lobe
Sacrum dimples
Helical
Dimples over other bones
Pilonidal
Sole crease
Diastasis rectus Glandular hypospadias Shawl scrotum Vaginal tag Limbs
Cubitus valgus Tapered fingers Overlapping fingers Broad thumb, great toe Clinodactyly Nails hypoplastic Nails hyperconvex Increased space, toes Syndactyly, toes 2–3
Percent With Major Malformations Marden et al., 196418 USA
Mehes, 198350 Hungary
Leppig et al., 198751 USA
1.4
1.2
2.3
1
2.9
3.8
3.7
2
10.8
12.5
6.7
90
26
3
Pigmented spots
Short palpebral fissures
Table 1-4. Concurrence of minor and major anomalies at birth in three series
0
Nevi
Downward palpebral slant
Ears
Number of Minor Malformations
Hemangioma
19.6
human polymorphism. The level of sensitivity to minor anomalies is set differently by different observers. The difference may partially explain the low incidence of minor defects (7.26%) reported by Myrianthopoulos and Chung for the Collaborative Study in the
United States and the high incidence (39%) reported by Leppig et al.20,51 Minor morphologic features give the most consistent clues to the diagnosis of many multi-anomaly syndromes. Prenatal alcohol syndrome and prenatal hydantoin syndrome, for example, are more commonly diagnosed by a pattern of minor morphologic features than on the basis of major malformations. Mehes50 has found the number of minor anomalies detected to be greatest at the time of birth, with a decrease in the detection of many features by age 1 year. This suggests that certain minor anomalies resolve or become obscured with growth and function. Downslanting palpebrae, horizontal palmar creases, asymmetric ears, preauricular skin tags, and clinodactyly are among those features with similar incidences at birth and at 1 year. A 50% or greater reduction in the prevalences of high-arched palate, low-set ears, and upslanting palpebral fissures occurs by 1 year. This contrasts with the increased detection of major defects during the first year of life.20
Human Malformations and Related Anomalies
Connectional Terms
Because multiple structural anomalies often occur together, a terminology that relates the components has developed.49,53–57 In connectional terminology, anatomic description of the anomalies has been largely abandoned because listing each anatomical feature of the composite becomes cumbersome. Greater emphasis is given to pathogenesis and causation. The terminology relating multiple anomalies has little consensus and great liability for change and perhaps for confusion. These problems have prompted attempts to develop a uniform nomenclature. Over several years, beginning in 1974, a series of workshops were held to construct a classification and nomenclature of congenital anomalies and other human morphologic changes.49,53,58 As new rules regarding nomenclature were published, there was disagreement, and the scientific community became embroiled in a debate.59–61 It would be premature to suggest that this debate has resulted in widely accepted terminology. An equivalent meeting dealing with terminology is reported to have been held among persons themselves affected with congenital anomalies, in London, in 1898.62 The term prodigies, which the participants are said to have found acceptable, has never been adopted in the medical field. Syndrome, association, complex, spectrum, sequence, field defect, and phenotype have all been used to describe some composite of anatomic features. Johannsen63 coined the term phenotype to encompass the outward manifestations produced by an individual gene. The nature of the gene itself was termed genotype. Genotype and phenotype can refer to a single gene and its manifestations (anatomic, biochemical, physiologic), to a related group of genes and their manifestations, or to the entire genetic constitution and all resulting hereditary features. In current usage, phenotype has become a general term for describing a composite of features without regard to the underlying cause. Consistent with this usage, environmental as well as genetic factors can contribute to the phenotype. This more general use of phenotype in many cases suggests that the cause of the features is uncertain or that multiple causes might produce this composite of manifestations. In some cases a modifier is added to indicate pathogenesis, for example, akinesia phenotype to indicate those features that are produced by absence of prenatal movement from any cause. Complex is a general term that is also used to indicate a composite of manifestations. Spectrum is sometimes used to describe entities with multiple features, particularly those in which prominent features can be expressed with considerable variation. Greater specificity is suggested by the term syndrome, which means a group of features seen together in multiple individuals, but it also implies that the composite of features has a common, specific etiology. Use of the term indicates that a specific diagnosis has been made and that the natural history and recurrence risk are known. A well-recognized exception is use of the term to include the multiple features found in several well-delineated disorders, such as Proteus syndrome and Sturge-Weber syndrome.45,64 While the etiologies of these two disorders have not been identified, a single specific etiology is suspected for each. In some branches of medicine, syndrome is used without the specificity suggested previously when used to describe structural anomalies. Association has been used in clinical genetics to identify the nonrandom concurrence of two or more anomalies that occur more frequently than expected by chance alone but for which no etiology has been demonstrated. VACTERL (vertebral, anal, cardiac, tracheo-esophageal, renal, and limb anomalies) association
9
is a well-known example in which the first letters of the anomalies are used to make an acronym. Use of association does not imply a specific diagnosis. Recognition of such statistically related anomalies prompts the search for other defects when one component of an association is noted. It also helps to develop a differential diagnosis for specific entities (in the case of VACTERL: trisomy 18, thrombocytopenia and absent radius, Fanconi anemia, etc). Empiric risks for recurrence may also be given for an association even though no cause for the association has been determined. Furthermore, it may allow for prognosis if no specific diagnosis is achieved. For example, the prognosis for intellectual development for individuals with VACTERL association is generally favorable. Sequence has been used by some to indicate a pattern of anomalies that results from a single primary anomaly or single mechanical factor.43,49 The anomaly or mechanical factor that initiates the sequence may produce multiple secondary anomalies or may produce a secondary anomaly that leads to a tertiary anomaly, and so forth, in cascade fashion. For example, in Pierre Robin sequence, severe micrognathia is the primary anomaly that causes secondary glossoptosis which obstructs palatal shelf closure resulting in a cleft palate. Furthermore, oligohydramnios sequence and fetal akinesia sequence have overlapping features and both are actually deformational processes. Although proposed to identify a pattern of anomalies having uniform pathogenesis (oligohydramnios sequence), in use sequence sometimes implies causation (athyreotic hypothyroidism sequence). Redundancy in using the term sequence when applied to specific disease states such as athyreotic hypothyroidism is obvious. Further confusion can arise because of the longstanding use of sequence for the arrangement of nucleotides and codons in the genome. Finite areas of embryonic tissue develop into multiple and hence related morphologic structures. Damage to or defects in the genes underlying these finite areas or developmental fields can result in multiple structural anomalies. Use of the developmental field concept helps to explain why certain malformations occur together. Designation and understanding of developmental fields require considerable knowledge of embryonic topography and the fate of the component cells, as well as the timing of gene expression and their gene products. To use the concept, an arbitrary time during embryogenesis must be selected at which the dimensions of the developmental field are established and from which the developmental potential of the field is predicted. A polytopic field defect is a pattern of multiple anomalies often in different body areas resulting from disturbance of a single developmental field. This suggests that a specific gene (which is defective) is expressed in multiple body areas, perhaps even at different times. The term monotopic field is used when the repertoire of a developmental field is limited to a single body area; monotopic field defect is used to describe the malformation (usually of a single anatomic structure) that results from a disturbance to that field.54,65,66 Holoprosencephaly with midline cleft palate represents one classical monotopic field defect. Many difficulties arise with the actual use of developmental field to define structural anomalies. Many who work with human anomalies are not facile in linking various anomalies to their precursor embryonic cells and the genes they express. Considerable overlap of developmental fields occurs, depending on the dimensions selected and on the embryonic age at which the field is thought to be established. If the concept were pushed to the ultimate, the zygote would have to be considered the primary field from which the entire embryo develops.
10
Overview
Multiple anomalies can also be related through the time period during which they develop. A single insult during embryogenesis may affect multiple unrelated structures that are forming at the time. Without evidence linking the pathogenesis of diverse and seemingly unrelated components of conditions with multiple features, these components have been considered ‘‘pleiotropic effects’’ of the underlying cause. Pinsky55 has advocated the grouping of discrete syndromes that share a large portion of major features into communities and classes. It was suggested that grouping on the basis of multiple features could assist recall of the member syndromes, bibliographic retrieval, and computer analysis. At the same time the grouping could stimulate ideas about pathogenesis that might apply to a group of disorders sharing similar morphologic features and biochemical developmental pathways. This system could further permit collective statements that would then apply to the group as a whole and more clearly define the similarities and differences of member syndromes. Merits aside, this polythetic system has been slow to gain popularity, in part because it has been presented more as a theoretical system than as a practical system to be readily understood and utilized. However, reexamination may be useful in light of key developmental genes and their pathways such as sonic hedgehog and the fibroblast growth factors and their receptors (e.g., hedgehog community, FGFR community). Naming
The naming of composite entities (syndromes, associations, phenotypes) follows no fixed rules nor has any committee assumed authority for naming. Authors and editors often designate a name in the initial description of an entity, or one arises in a subsequent review. For conditions of known etiology, names that acknowledge the cause would seem to be most appropriate (e.g., trisomy 13 syndrome, prenatal alcohol syndrome). This is not possible for many syndromes caused by single genes, several genes, or for conditions of unknown etiology. Several different approaches have been used in these cases. If the major components are few, their enumeration in the name is possible (hypertelorism–hypospadias syndrome). This can be misleading, however, when the identifying features are not present (e.g., absence of cryptophthalmos in the cryptophthalmos syndrome or absence of camptomelia in camptomelic dysplasia). When the major components are numerous, the name can become tiresome. Use of the first letters of the major features to form a unique acronym has been successful in several instances (e.g., LEOPARD syndrome, CHARGE syndrome).This approach offers the user assistance in recalling the primary features of the entities. Perhaps the most widely accepted practice in naming composite entities has been to use eponyms. Eponymic designation attempts to credit the individual(s) who first described an entity or who first recognized it to be a specific entity. Not uncommonly, earlier reports of an entity are overlooked or not recognized to be that entity, leading to competing names or to compound eponyms (e.g., de Lange syndrome versus Brachmann–de Lange syndrome). Problems are also encountered when a prolific investigator describes more than one entity (e.g., Fanconi anemia syndrome and Fanconi renotubular syndrome). When heterogeneity is found to exist in an established name, renaming becomes necessary (Lawrence-Moon-Bardet-Biedl syndrome now divided into Lawrence–Moon syndrome and Bardet–Biedl syndrome with several subtypes of Bardet–Biedl). These difficulties aside, the use
of eponyms appears well established and will likely be replaced only by naming according to etiology (based on the gene or the environmental insult responsible). The possessive form of eponyms has been dropped in this book in keeping with McKusick’s suggestion. One international committee has published reasonable guidelines regarding the naming of human anomalies.53 Their suggestions include the use of etiologic agents when known (e.g., trisomy 18 syndrome), and eponyms (e.g., Down syndrome) that are well established. Use of the initials of the patient’s family (e.g., BBB syndrome, FG syndrome) and acronyms (e.g., EMG syndrome) that bear no relation to clinical feature was discouraged by this committee. Timing of Structural Alterations
The timing at which an anomaly arises has some importance in descriptive terminology. Postnatal alteration of an anatomic part should be distinguished from prenatal alteration, and prenatal alteration during organogenesis should be distinguished from alteration after organogenesis. Congenital means present at birth. It gives no clue to pathogenesis and causation, nor does it imply development at any particular time during prenatal life. Hence, use of congenital with malformation, disruption, or deformation in the sense described here would be redundant. Congenital anomaly, congenital defect, or congenital abnormality would be more appropriate term combinations since their use would restrict the general terms anomaly, defect, and abnormality to those present at birth. These terms imply a structure problem without specifying the etiology—which can be useful at times. Embryonic staging as set forth by Mall,67 Streeter,68,69 and O’Rahilly70,71 use arbitrary subdivisions of the period from fertilization to the start of fetal life to provide a description of the topographic, morphologic, and cytologic changes that take place during human development. The stages are defined by the composite of morphologic features and hence show some variability in size and chronologic age and in the progress of any single anatomic feature. They infer nothing about the gene expression and flow of biochemical events underlying the morphologic events. The age of an embryo is given in days following ovulation. Embryonic (postovulation) age is thus 2 weeks less than menstrual age (days or weeks following onset of last menstrual period), which is commonly used to date pregnancies in obstetrics and neonatology. Fertilization generally occurs within 24 hours after ovulation, usually in the outer reaches of the fallopian tubes. The initial four stages of human development take place over the first 5 to 6 days and span the early series of divisions of the free-floating conceptus up to and including the early implantation process. In the latter half of this period the conceptus is called a blastocyst, a mass of cells with an internal cavity. The period is called the preimplantation period. Interest in the specific nature of human preimplantation has been highlighted by the increasing use of assisted reproductive technologies (ARTs). Implantation occurs during stages 4–5, which span the period 5.5 to 12 days. The embryonic disc becomes bilaminar (ectoderm and endoderm), with the amniotic cavity developing on the epidermal surface and the yolk sac developing on the endodermal surface during these stages. The phenotypic description of the developing embryo often ignores the placenta which is
Human Malformations and Related Anomalies
simultaneously going through significant morphologic and metabolic change. Stage 23 (56–60 days, or 8 weeks, postfertilization) was considered arbitrarily to end the embryonic period.70,71 The beginning of marrow formation in the humerus was a developmental landmark used to assist in identifying this stage. The first 8 weeks after fertilization, or weeks 2 to 8, are generally considered the period of embryogenesis. The embryo has taken the human form, and most organs are fully formed and located in their final position by the end of this time. Exceptions are external genitalia, abdominal wall, heart, and dental structures and, of course, the brain, which continues its development (partly in response to utilization of neuronal pathways) into childhood. The fetal period begins with week 9 and extends to delivery, usually 40 weeks from the last menstrual period and 38 weeks from fertilization. Growth and maturation of function are the major processes that occur during this period. However, as noted previously, formation of some structures continues into this time and may be influenced by mechanical and flow considerations as well as gene expression (e.g., the heart and joints). External genitalia do not complete differentiation until week 12; hair follicles do not form until week 12; the midgut does not return to the abdominal cavity from the body stalk until week 10; and teeth do not gain their definitive morphology until much later in fetal life. An interesting new field related to fetal determinants of adult health suggests that events during fetal life can have long lasting effects on metabolism later in life. For instance, intrauterine growth retardation is associated with the development of diabetes, coronary artery disease, and hypertension in adulthood. Prematurity is associated with hypertension in adulthood. The mechanisms by which fetal events influence adult health are not yet known.71a In the strict sense, malformations, as previously defined, occur during the period of organ formation. Most will occur during the first 8 weeks of embryogenesis, but exceptions to this are not uncommon in those structures that are still forming after 8 weeks. In general, disruptions and deformations occur following morphologic development and, hence, usually after 8 weeks postconception. Some terms are particularly useful in defining environmental influences that act during gestation and that alter morphology, function, or growth. Teratogen has been used with widely variable meanings.72–74 In this text a teratogen has three features. First, as its derivation (teratos ¼ monster, gen ¼ produce) suggests, the end result of a teratogenic influence will be a morphologic abnormality rather than a functional one (however, of course, both morphologic and functional changes can be expected). Second, teratogens are environmental rather than genetic influences (however, maternal inherited metabolic disorders can have a detrimental effect on the embryo/fetus as in maternal phenylketonuria). Third, teratogens exert their influence following fertilization and before delivery (although the effects may not be obvious at birth as in the case of prenatal diethylstilbestrol exposure). Teratogens have an effect primarily during the first 8 weeks of embryogenesis, causing malformations, but may act at a later point in pregnancy, causing disruptions or deformations as well (e.g., as is seen with maternal warfarin use). These late effects of teratogens can also include malformation of structures that gain their morphology after the usual 8 weeks of embryogenesis. Etiology and Pathogenesis
Etiology simply means cause. For all human anomalies, the etiologic possibilities are limited to genetic (single gene, multiple genes,
11
chromosomal) or environmental (mechanical, infectious, chemical) causes, or some combination of the two. Little regard for etiology is given when naming individual structural anomalies. Etiology can be found, however, in the names of many syndromes (e.g., trisomy 13 syndrome, prenatal alcohol syndrome, X-linked hydrocephaly syndrome). More recently epigenetic influences (not resulting from changes in the structure of DNA, but rather in the control and expression of the genes) have been recognized to play a role in embryonic and fetal development. Pathogenesis indicates the mechanism or process by which a feature is produced. Again, little indication of pathogenesis is incorporated into the names of individual structural anomalies, but considerable emphasis is given in the naming of entities with multiple features (e.g., early amnion rupture, oligohydramnios sequence). As more is learned about the role of gene expression (e.g., alternative splicing, control of genes by RNA and transcriptions factors) as well as specific types of mutations, new nomenclature may emerge as illustrated by McKusick’s new organization of OMIM.101 Histologic Modifiers
Histologic analyses permit the description of the cellular and tissue processes underlying certain morphologic alterations. When known, these processes can be used as descriptive modifiers or to imply pathogenesis75 as in the chondrodysplasias. Aplasia, Hypoplasia, Hyperplasia, and Dysplasia
Aplasia indicates absence of cellular proliferation, hence the absence of tissue mass and, consequently, of an organ or morphologic feature. Hypoplasia indicates insufficient cell proliferation, resulting in a deficiency of tissue mass and ultimately undergrowth of an organ or morphologic feature. Similarly, hyperplasia means excessive proliferation of cells, accumulation of excessive tissue mass due to the increased cell number, and overgrowth of an organ or morphologic feature. Dysplasia as used in clinical genetics implies disorganization of cell structure, disordered cell arrangement in tissues, and faulty tissue organization in an organ or morphologic feature. At the tertiary (organ) level, these terms are best used only when the underlying histology is known. ‘‘Hyperplasia of (an anatomic part)’’ has greatest meaning when it implies that the excessive mass is due to an excessive number of otherwise normal cells. Regrettably, hyperplasia is often used as a mere description of overgrowth without regard to or knowledge of the histology. Worse yet, it is sometimes used to identify the larger of two parts of apparent unequal size without knowledge of the histology of either. At some point in their natural history, many cells become aplastic, that is, they cease to proliferate. Such cells (and tissues) can respond to injury, numerical depletion, hormone stimulation, and increased workload only by increasing their size. Muscle hypertrophy is a well-known example. Other cells retain the ability to divide actively. Endothelium, epithelium, mucosa, cartilage, bone, and connective tissues contain cells that are being constantly replenished by mitosis. The ability to repair damage can be an important cellular response during embryogenesis.72 The point in development at which paralysis of the various human cell types occurs is unknown, as are the signals that deprive cells of their ability to divide. Presumably most cells retain the ability to divide throughout embryogenesis and for variable periods of time thereafter. Hence embryos have the ability to repair and recover from certain insults
12
Overview
as long as the entire anlage is not damaged and as long as there are adequate time and resources to complete the repair before further differentiation is required. Dysplastic cells have altered sizes, shapes, and cytostructures. To the pathologist, these abnormal cells are regressive, often induced by chronic inflammation or irritation, and may progress in a neoplastic direction. No such connotations accompany the term dysplastic when used to describe the cellular, tissue, and organ disorganization found in congenital structural anomalies. These forms of dysplastic change arise during development, are usually genetically determined, and do not progress to neoplasia. The inborn errors of the chondroosseous skeleton constitute a large group of disorders called dysplasias.76,77 Multiple bones are involved, showing microscopic and radiographic evidence of disturbed growth and structure. Chondrocytes, osteocytes, connective tissue, or noncellular matrix can be abnormal, and the transition from cartilage to bone is often disorganized.78 Clinically these skeletal dysplasias are manifested by short stature; abnormal alignment, growth, or symmetry of body segments; or, less commonly, specific malformations (e.g., cleft palate, polydactyly). Agenesis has been used to indicate the failure of an organ to form, and in general it implies aplasia rather than loss through atrophy or disruption. Dysgenesis can be used in a similar fashion to indicate anomalous structure due to disorganization of the component cells and tissues. Atrophy, Hypotrophy, Hypertrophy, and Dystrophy
Atrophy means the degeneration of cells, usually resulting in shrinkage of tissue mass and diminished size of the affected organ or morphologic feature. Like the -plasia terms, atrophy and other -trophy terms are applied at the cellular (primary), tissue (secondary), and organ (tertiary) levels. Atrophy can be characterized by smaller than normal cell size, accumulation of intracellular pigment granules, and replacement of parenchymal cells by fat or connective tissue. Hypotrophy indicates that cells fail to achieve a normal size, and hence tissues, organs, and morphologic features are under grown. Hypertrophy is the enlargement of cells and consequent enlargement of tissue masses, organs, or morphologic features. Dystrophy means a disturbance in cell or tissue growth caused by faulty nutrition. The term has been used most widely, however, for certain heritable conditions of muscle, eye, or nails (e.g., myotonic dystrophy, lattice dystrophy of the cornea, nail dystrophy). In these conditions dystrophy is used without implying that defective nutrition is the underlying pathogenesis. Again, at the tertiary (organ or gross morphology) level, it may not be possible to distinguish enlargement due to hypertrophy from enlargement due to hyperplasia or to distinguish small size due to hypotrophy from small size due to atrophy, hypoplasia, or dystrophy. These distinctions require knowledge of the histologic structure. Accumulation of intracellular or extracellular fluid may alter size without affecting any of the cellular processes. In the absence of histologic information, general terms can be used to describe alterations in tissue bulk; for example, enlarged muscle to incorporate both muscle hyperplasia and hypertrophy or small muscle to encompass the possibilities of atrophy, hypotrophy, hypoplasia, dystrophy, and dysplasia. For practical reasons, the structural anomalies included in this discussion are those that can be detected by clinical observation and gross measurement. It is acknowledged that there exist
domains of microscopic and submicroscopic structural anomalies that are no less important than those mentioned. Histologic appearance is discussed only when those findings appear fundamental to understanding the gross structural alteration. Terms with Negative Impact
In general, structural anomalies are viewed negatively by medical practitioners, affected individuals, and society. Insensitive terminology can further stigmatize those affected and can separate caretakers from affected individuals, those affected from family, and family from society. Terminology should be as neutral as possible while correctly identifying or defining the structural anomaly. The care needed in choosing words when dealing with families or affected members may be obvious. However, terms employed internally in science should also be chosen carefully since these terms find their way to families via medical records, news articles, and courtrooms. It should be acknowledged that some morphologic abnormalities are not viewed negatively by affected individuals. An example is an alteration in size caused by achondroplasia. In this circumstance it is not unusual to find affected persons who want achondroplasia to recur in their biologic offspring, because normal size is less desirable in these particular families.79 Terminology does not remain constant; the nuances and implications of terms change with the generations. Until the early 1900s monster and monstrosity were widely used terms in medical circles to describe malformations or other morphologic changes. Monster has now gained a different nuance, primarily because of its use in movies to depict scary creatures. The new usage does not adhere to either of the word’s origins (to show or to warn), but suggests that those who look abnormal may also act in destructive, frightening, and otherwise offensive ways. Although monster and monstrosity have been used from the first written records of human malformations and into the twentieth century, they have in this century disappeared entirely from medical terminology. Other terms have had only brief life spans. Examples from the five editions of Smith’s Recognizable Patterns of Human Malformations will suffice to illustrate.43,80 In a period of less than 30 years (edition 1, 1970 to edition 5, 1997), repeated changes can be found in the preferred terminology for morphologic entities. Potter’s syndrome (edition 1) changed to oligohydramnios tetrad (edition 2) and then to oligohydramnios sequence (editions 3–5). The preferred term for amniotic bands changed with each edition. Initially, amniotic band syndrome changed to amniotic band anomalads, then to early amnion rupture spectrum, then to early amnion rupture sequence, and finally to amnion rupture sequence. These changes arose from the attempt to add a pathogenetic implication to the identification of the entity. Social sensitivity demands discretion in terminology. Terms that are divisive, derogatory, negative, or degrading should be abandoned. Happy puppet syndrome has been replaced by Angelman syndrome; fetal face syndrome by Robinow syndrome; and elfin facies syndrome by Williams syndrome. A term in common use in the middle of this century, mongolism, or mongoloid idiot, as assigned by Langdon Down for a specific mental retardation syndrome, is discouraged in favor of trisomy 21 syndrome or Down syndrome.81 The designation funny-looking kid (FLK) may be viewed as derogatory by an affected child, family members, and care-takers. The term dwarfism to identify persons with disproportionate skeletal dysplasias has been discouraged for the same reason. Special child or special needs child has been used to indicate children with handicaps. Since
Human Malformations and Related Anomalies
all children are special, the use of this term for a child with a malformation appears inappropriate and patronizing. The designation of syndromes by the initial of the proband (G syndrome, BBB syndrome) has been advocated by Opitz et al.54 While intended to be neutral, this naming schema offers nothing to assist the user in remembering the syndrome, is liable for duplication, and has not found wide acceptance. Anomalad was suggested by Fraser and advocated by Smith53 to indicate a cascade of structural anomalies that derived from a single preceding anomaly or mechanical force. The term was debated for several years and has now disappeared, being replaced by some users with sequence. Polyanomaly has also been suggested to indicate multiple anomalies, specifically those that arise from the same pathogenesis. There is nothing to recommend this term over multiple congenital anomalies, and the term does not flow well. In the last decade, the field of developmental biology has made considerable progress in understanding embryologic development by using animal models. Yeast, flies, worms, and fish have contributed to defining the molecular pathways involved in development of various structures. The conservation of the genes (and gene families) involved is remarkable. This work has a direct effect on understanding human development, which for ethical reasons cannot be studied directly. However, most animal models do not have a fetal period similar to that in humans. The application of these new discoveries of developmental biology to human in utero development and to the historic systems of phenotypic descriptive classification has been relatively slow and will undoubtedly be challenging.
1.2 Classification and Coding Classification
The systematic arrangement of structural anomalies on the basis of morphologic, anatomic, etiologic, or other criteria has been attempted by many observers. The number of classification schemas attests to the likelihood that no system has been entirely satisfactory. Nonetheless, finding some order among human congenital anomalies has utility in assisting human memory and giving insights into the range and nature of human anomalies. A growing utility is now being found for computer retrieval of information. Some admixture between the classification schemas is to be expected in a brief accounting of the types of classifications used in the past. Classification by Cause
One of the oldest classification schemas, that set forth by Empedocles,82 was based on causation. Five causes for human anomalies were recognized: excess semen, deficiency of semen, slowness of movement of semen, abnormal movement of semen, and division of semen into separate parts. Pare´’s classification83 had 13 causes, including abnormalities of semen as well as mechanical injury, uterine compression, maternal impressions, and the supernatural. Cleland’s system, published in 1889, had six causation categories, three leading to anomalies with morphologic deficiencies and three leading to anomalies of excess.84 Classification by Morphologic Alteration
Eight types of morphologic alterations were the major entries in the system of St. Isidore in AD 60085: large size, small size, transformation
13
of a part, transformation of the whole body, transposition of a part, adhesion of parts, mixture of sexes, and the coexistence of multiple anomalies. These types were supplemented by two entries based on the precocious or delayed appearance of features. To this type of classification, Huber86 added union of parts usually separated and closed state of canals usually open. Isidore and Etienne St. Hilaire set forth an extensive classification schema based on alterations of morphology.87 All anomalies were assigned to a kingdom, and the kingdom was subdivided into four divisions, each of which was further subdivided into classes, orders, tribes, families, and genera. Classification by Regional Anatomy
Use of regional anatomy to arrange anomalies first appeared in the 1600s.88,89 The systems used by Taruffi,90 Lowne,91 and Ballantyne92 at the end of the nineteenth century utilized regional anatomy as well. These systems often incorporated subclassifications based on morphologic alteration (e.g., excess or deficiency of parts). Classification by System
Closely related to schemas based on regional anatomy is the use of anatomic systems to organize human anomalies. This variation is the basis of classifications used by Warkany93 in the classic Congenital Malformations, in the International Classification of Diseases (ICD), in the Cardiff and Centers for Disease Control modifications of the ICD, and in the Systematized Nomenclature of Medicine (SNOMED).94–97 Other Classifications
Several additional schemas are of historical interest. The earliest known system separated malformations into those that affected ordinary citizens and those that affected royal families. This was the only arrangement of anomalies to be found in the enumerations of human anomalies in the teratologic records of the Chaldeans.98 Other systems have used viability of affected individuals, time of occurrence during embryogenesis, and various mixtures of the several foregoing schemas.94,96,99,100 The ICD is now undergoing its tenth revision.94 The currently available clinical modification (ICD-9-CM, 2004) as published by the U.S. Government allots 20 categories with accompanying numerical codes for congenital anomalies. Considerable inconsistency has crept into this schema. Initially oriented to systems, there occur drifts into regional anatomy and major divergence into causation (chromosome anomalies) in the nineteenth category. An admixture of systems, specific diseases, specific syndromes, and processes appears in the twentieth category. The system, although having lost its consistency, is widely used because of its acceptance for epidemiologic studies and for insurance categorization; but it does not accommodate a listing of rare but specific anomalies. The British Pediatric Classification modifies the ICD system for anomalies by adding two additional numbers to the code, permitting a further specific subdivision of an ICD category.95 The Centers for Disease Control (CDC) has further modified the ICD and British systems by adding a sixth digit to the code.96 The addition of digits in the British and CDC modifications allows categories of defects to be subdivided into individual anomalies but fails to correct the admixing of causation, pathogenesis, regional anatomy, organ system, syndromes, and diseases in the original ICD system. The Systematized Nomenclature of Medicine has been produced by the American College of Pathologists97 based on their
14
Overview
Systematized Nomenclature of Pathology. This schema utilizes seven sections to permit access from numerous perspectives: topography, morphology, etiology, function, disease, procedure, and occupation. Most useful in relation to structural anomalies are the topographic, morphologic, and etiologic fields. Other systems that deal with certain individual anomalies and syndromes include McKusick’s alphabetical listing of single gene disorders101,102 and Shepard’s alphabetical enumeration of environmental agents.103 Several computerized databases have been developed to assist the clinician in recalling information about entities having one or more morphologic characteristic. The two major systems, London Dysmorphology Database104 and POSSUM (Pictures of Standard Syndromes and Undiagnosed Malformations),105 require entry of the anatomic description (topography and morphology) of individual features and search for entities in which the feature(s) occur.
Table 1-5. Causes of anomalies among liveborn infants Cause
Percent Incidence
Genetic
15–25
Chromosome
10–15
Single gene
2–10
Multifactorial
20–25
Environmental
8–12
Maternal diseases
6–8
Uterine/placental
2–3
Drugs/chemicals
0.5–1
Twinning
0.5–1
Unknown
40–60
Coding
At present there is no comprehensive coding system that is specific for structural anomalies that occur in humans. A five-digit system would be required to assign a unique number to each of the numerous structural variants and anomalies. To add an indicator of the major etiologies would require an additional digit. A further multidigit hindcode would be necessary to link individual anomalies to the various syndromes, diseases, or associations of which they might be a feature. Development of a uniform coding system for human anomalies will undoubtedly be encouraged by the increasing reliance on electronic systems for storage, retrieval, and manipulation of data. 1.3 Genetic Causes of Malformations Current clinical and technological methods can determine the cause of approximately one-half of the anomalies found in newborn infants (Table 1-5). One-half of the identifiable causes are either wholly or partially genetic. The genetic content of egg and sperm brings to the conceptus all instructions necessary for the formation and function of a new life. Disturbances in the amount of genetic material (aberrations in chromosome number or structure) or in the nature of this material (mutations or epigenetic alterations of genes) may preclude normal formation, causing a wide range of malformations or other morphologic changes and an equally broad range of functional impairments. Experience in mammalian cloning and in human in vitro fertilization has indicated that the genetic content of the gametes (DNA) must go through an epigenetic process called ‘‘reprogramming.’’ This process involves methylation of the DNA and its histones, and possibly other epigenetic measures, in order for the early development of a zygote to occur in a normal way before implantation. Without this ‘‘reprogramming,’’ disorders involving genomic imprinting may occur with increased frequency. Chromosome Aberrations and Malformations
Over 75 years passed between Flemming’s observations of chromosomes in the epithelium of the human cornea (1882)106 and the first demonstration (by Lejeune in 1959107) of the chromosomal basis for a human malformation syndrome, although the link between chromosomes and malformations had been suggested in the interim. As early as the 1930s, Waardenburg and Bleyer independently predicted that nondisjunction of chro-
mosomes during meiosis, resulting in abnormal chromosome number, might be the cause of Down syndrome.108,109 Rapid refinement in tissue culture and metaphase preparation and agreement on nomenclature followed Tjio and Levan’s discovery in 1956 that the correct number of human chromosomes was 46.110 Within 3 years chromosome analysis became commonplace in laboratories throughout the world. The discovery of numerical chromosome aberrations followed (Table 1-6), opening an era when an answer to nearly all human maladies, but especially malformations and malformation syndromes, was sought in the chromosomes. A rich yield rewarded investigators who sought the explanation of spontaneous abortion in chromosome analysis.5,13,111–114 In 1961, Penrose and Delhanty demonstrated triploidy in a macerated fetus.112 In reports that followed, chromosome aberrations were found in approximately one-half of early spontaneous abortions. The 45,X karyotype was found most frequently, but tetraploidy, triploidy, and numerous other trisomies not seen in liveborn infants constituted a major portion of chromosomally abnormal abortuses (Table 1-7). Prenatal diagnosis of chromosome aberrations became possible in 1966, when Steele and Breg combined the technique of amniocentesis with culture of amniotic fluid cells.115 The reliability and safety of the combined procedures contributed to rapid acceptance of the techniques for pregnancies determined to be at increased risk of chromosome abnormalities and certain biochemical defects. The utility of chromosomes in expanding the understanding of malformation syndromes reached a plateau in the late 1960s. Table 1-6. Sequence of discovery of chromosome aberrations Year
Chromosome Aberration
1959
Trisomy 21; 45,X; 47,XXY
1960
Trisomy 18; trisomy 13
1961
47,XYY
1963
Del 5p
1965
Del 4p
1969
Fragile X
1971
Trisomy 8
1973
Trisomy 9
Human Malformations and Related Anomalies Table 1-7. Prevalence of chromosomal aberrations among spontaneous abortions Type of Aberration
Percent
All Chromosome Aberrations
40
Trisomies
20
T-16
8
T-13,15,21,22
2*
T-2,7,8,14,18
1*
T-4,9,10,20
0.5*
T-3,5,6,12,7
0.1*
T-1,11,19
<0.1*
Sex chromosome
<0.5
Monosomy X Autosomal monosomy
8 <0.1
Polyploidies
9
Triploidy
7
Tetraploidy Other Rearrangements Mosaicism Unbalanced rearrangement Balanced rearrangement
2 3 2 1 <0.5
*Approximate rate for each of the trisomies named.
Excitement was returned to the field of cytogenetics with the introduction of banding techniques by Caspersson et al. in 1971, demonstration of fragile sites by Sutherland in 1977, and analysis of prophase and prometaphase (high resolution) chromosomes in the early 1980s. The introduction of fluorescence in situ hybridization in the 1990s, and comparative genomic hybridization in the 2000s permitted the detection of deletions and duplications that were beyond the resolution of the light microscope.116–120 Chromosome watching provides only a crude view of genetic events. Best regarded as carrier structures, the chromosomes keep the genes together in a limited number of packets, perhaps maintain the genes in some necessary sequence, and provide for the orderly transmission of the genes they contain to daughter cells through mitotic division and to new offspring through meiotic division. Errors can occur and in fact are commonplace in each of these processes. Nondisjunction or anaphase lag can occur in mitosis or meiosis, resulting in an abnormal chromosome number in daughter cells or gametes.121,122 Translocation, inversion, deletion, and duplication may occur because of faulty crossing-over during meiotic division and result in imbalanced chromosome complement of gametes.123 In at least four circumstances, regions of chromosomes can become altered, rendering the involved region functionally inert. The phenomenon is called ‘‘inactivation,’’ involves no change in nucleotide sequence, and is reversed in gametogenesis prior to meiosis. Inactivation involving most of the X chromosome is a well-documented phenomenon.124 One X chromosome in normal females and all but one X chromosome in individuals with multiple X chromosomes become inactivated during the 1000–2000 cell stage of embryogenesis. Inactivation appears random; that is, either the maternal or the paternal chromosome can be inactivated, but once this is established it remains fixed for all descendants of the initially inactivated cell. With the exception of
15
certain small segments of distal short arm and distal long arm (pseudoautosomal regions 1 and 2), and specific loci elsewhere, all of the X chromosome participates in the inactivation (Fig. 1-2).125 Because of this phenomenon, normal females are genetically mosaic, a portion of their cells having one ‘‘active’’ X chromosome and the remaining cells having the alternative X chromosome active. At the molecular level, X chromosome inactivation is thought to be achieved by methylation of DNA. Inactivation of segments of other chromosomes is presumed to be responsible for partitioning of gene activity temporally (genes that are active during embryogenesis may become inactive thereafter) and by cell type (genes that are transcribed in hepatic cells may not be transcribed in muscle cells and vice versa). Considerable attention has recently been given to the potential of certain genes to be expressed differently depending on whether they were inherited from the mother or the father. This special type of altered gene activity has been called imprinting. As with other types of nonpermanent DNA modification, genomic imprinting may involve methylation of DNA and its histones and generally persists for life, although it may be reversible during gametogenesis and early embryogenesis.126–128 Epigenetic phenomena not only partition gene expression to appropriate tissue types, conserve gene expression for appropriate times in the life cycle, balance the male and female genomes, and perpetuate the requirement for paternal and maternal contributions to offspring, but these phenomena have the capacity to be significant causes of developmental disease and disability. Epigenetic influences are mediated through changes in chromatin structure.129–131 Although the repertoire of epigenetic phenomena
Fig. 1-2. Pseudoautosomal regions of the X chromosome in distal Xp22 and distal Xq28 and loci elsewhere on the X chromosome that escape X inactivation.
16
Overview
that influences gene expression is incompletely known at this time, modification of DNA and histones by methylation or deacetylation have received most attention. Whether epigenetic phenomena will give rise to malformations remains for the moment an intriguing but unanswered question. In the end analysis, chromosome changes of consequence cause an imbalance in a number of genes. Assuming equal size of genes and even distribution along the chromosome, the smallest resolvable chromosome change (one band of a 1000-band microscopic preparation) would affect 30 to 40 genes. Of course, genes are not of equal size, nor are they evenly distributed along the chromosomes. Genes appear to be more concentrated in the guanine-cytosine–rich regions of the chromosome, that is, regions that appear as light bands in giemsa–trypsin preparations and in the telomeres.122 Certain large genes, such as the dystrophin gene, which contains 2300 kb of DNA and spans 2.3 cM of the genome, would occupy most of an average band.132 More than 500 small genes the size of b-globin could crowd into a single average band. Deletion of a representative chromosomal band would leave the individual with only a single copy (hemizygosity) for 30 to 40 genes rather than the normal two copies of each (Fig. 1-3). Deleterious recessive characteristics, if encoded on the normal homolog, could be uncovered and expressed by such a deletion. Phenotype alterations different from those found in the heterozygous state might also accompany the hemizygous state for genes coding for dominant characteristics. Duplication of a ‘‘typical’’ band would, in effect, cause partial trisomy for 30 to 40 genes, allowing for a triple dose of each gene within the duplicated band (Fig. 1-3). Three genes for each locus
over even such a small region appear to be accommodated no more harmoniously than would three partners in a marriage. With the advent of fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) technologies, it has become much easier to identify small, submicroscopic deletions and duplications. It may be anticipated that equal numbers of deletions and duplications occur because of mismatched crossing over during meiosis. This prediction notwithstanding, the number of deletions identified far exceeds the number of duplications. It appears that repeated occurrence of similar sized deletions and duplications occur because there are similar LINE or repeat elements at each end of the segment that leads to mismatching. It is possible for all the genes on a duplicated chromosome or a duplicated chromosome band to be ‘‘normal’’ and yet cause structural and functional abnormalities. This suggests that quantitative expression of genes may be an important determinant of structure and function. In fact, all of human variability may owe more to variation in quantitative expression at each gene locus than to the quality of the gene expression controlled by its nucleotide sequence. Further augmentation or reduction of gene expression may be produced by inactivation or imprinting of genes, chromosome regions, or entire chromosomes.126–128 Chromosome abnormalities of all types exert their influence from conception onward. The possibility that they also influence function and survival of the gametes cannot be dismissed. A great variety of chromosome abnormalities can cause substantial disorganization of the conceptus, embryodysgenesis, and fetal pathology. Malformations, disturbances in growth, mental impairment,
Fig. 1-3. Human female metaphase (left) and karyotype (right). In each, trypsin Giemsa banding is used, and the resolution is 400–500 bands.
Human Malformations and Related Anomalies
and other features usually accompany even the most minute change in the chromosomes.123 Numerical Abnormalities
Reproduction in humans depends on the production of gametes through the process of reduction division, or meiosis. The number of chromosomes in the primordial cell must be reduced by onehalf during maturation of the gametes in the ovary and testis. It is during this process of meiosis that most numerical chromosome abnormalities arise, due mostly to failure of normal disjunction of homologous chromosomes (nondisjunction). When a gamete with other than 23 chromosomes participates in fertilization, the resulting zygote has an abnormal number of chromosomes. The consequence of this is that the pregnancy is usually lost, the conceptus either failing to implant or aborting during the early weeks of formation.9,13–17,123,133–140 With few exceptions, those conceptuses that are maintained are destined to be born with malformations and disturbances of growth and mental function.123,135,136 Trisomies
Aneuploidies are tolerated poorly in humans. Most produce such disorganization of the conceptus that implantation cannot be accomplished and maintained. Trisomy for each autosome has been detected in conceptuses (Table 1-7). Trisomy 16 is the most common autosomal trisomy and one with near total loss during pregnancy.13,138 Trisomy 1 has only recently been found and is the least common autosomal trisomy in abortion tissue.139,140 Although trisomies 13, 18, and 21 regularly cause abortion, they constitute the most common autosomal trisomies among liveborn infants (Table 1-8). Full trisomies for most other autosomes uniformly cause abortions.13,123,132,135,136 Each autosomal trisomy produces a more or less characteristic pattern of malformations.123,135,136 It is well known that the risk for trisomies increases with advancing maternal age, which has led to the availability of prenatal diagnosis for women over 35 years of age and the development of maternal serum screening.
Table 1-8. Prevalence of chromosomal aberrations among liveborn infants Chromosomal Aberration
Prevalence
Trisomy 21
1/700
Trisomy 13
1/7000
Trisomy 18
1/8000
Trisomy 8*
<1/100,000
Trisomy 9
<1/100,000
Monosomy X
1/2500 (females)
47,XXX
1/1200 (females)
47,XXY
1/1000 (males)
47,XYY
1/1000 (males)
Fragile X
1/4000 (males)
48,XXYY
1/25,000 (males)
48,XXXX
<1/100,000 (females)
48,XXXY
<1/100,000 (males)
49,XXXXX
<1/100,000 (females)
49,XXXXY
<1/100,000 (males)
*Usually mosaic.
17
Extra sex chromosomes are among the most common chromosome abnormalities in liveborn infants (Table 1-8). In general, malformations do not accompany the presence of one or more additional X or Y chromosomes. This is due in part to routine inactivation of all except one X chromosome in each cell and the paucity of active genes located on the Y chromosome. Extra sex chromosomes can produce alterations of growth (XXY, XYY, XXX), habitus (XXY), sexual maturation (XXY), and behavior (XXY, XYY). Monosomies
Full monosomies for other than the X chromosome do not exist in liveborn infants.123,135,136,139,140 Autosomal monosomies leave the organism at such risk for imbalance of all gene products in pathways for which genes are carried on the involved chromosome as well hemizygous expression of deleterious genes that they cannot survive the formative and fetal months. Likewise, monosomy for the Y chromosome is lethal in humans since numerous genes on the X chromosome are required for even the rudiments of embryonic development. In contrast, X monosomy is one of the most commonly observed aneuploidies. While highly lethal prenatally (95% of affected conceptuses spontaneously abort), X monosomy has an incidence of 1 in 2500 liveborn females. Probably, Turner syndrome pregnancies that survive to birth are mosaic with some chromosomally normal cells, at least in the placenta. Affected girls show growth impairment, ovarian dysgenesis with failure of sexual maturation, and anomalies of the skeleton, heart, kidneys, and craniofacies.135,136,141 Mosaicism
Numerical chromosome abnormalities can also occur by nondisjunction or anaphase lag subsequent to fertilization, leading to mosaicism.142 The affected individual has two or more chromosomally different cell lines, all derived from a single zygote. One cell line is usually normal. The timing of the misdivision after fertilization, the lineage of the initiating cell, and the viability of the aberrant cell line(s) determine the proportion and type of tissue(s) affected and the impact. Nondisjunction or anaphase lag occurring during the preimplantation and embryonic period can lead to malformations. Misdivision at a later time would not cause malformations, but could cause a mosaic pattern of skin or hair pigmentation, segmental dyssymmetry, and other growth disturbances.143 Mosaicism can be demonstrated in a single cell type (e.g., lymphocytes) or may require examination of different tissues. Cultured lymphocytes and skin fibroblasts are generally used for this purpose.144–146 Mosaicism confined to other tissues cannot be excluded with this approach. Mosaicism for numerical chromosome aberrations occurs sporadically, and transmission to the next generation is uncommon. Only if the germinal cells (oogonia or spermatogonia) are affected with the aneuploidy would there be risk of full aneuploidy in the offspring. Juberg et al.147 have suggested that a predisposition to anaphase lag may explain the recurrence of chromosomal mosaicism within a family. Mosaicism arising during the first few days after fertilization may affect the embryo, the extraembryonic tissues, or both. This phenomenon complicates the use of extraembryonic tissues such as chorionic villi for prenatal diagnosis and may explain survival of fetuses with certain severe trisomies. Kalousek et al.148 have demonstrated that trisomy 13 and trisomy 18 fetuses who survive pregnancy have placentas that are euploid, at least in part. Alternatively, aneuploidy confined to the placenta may explain
18
Overview
growth retardation or spontaneous abortion of chromosomally normal fetuses.149–151 Structural Chromosomal Abnormalities
Structural chromosomal abnormalities presumably arise during meiosis through abnormal pairing of homologous sequences and interchange of genetic material between chromosomes or between parts of the same chromosome. The same mechanism may underlie all types of structural rearrangements: translocations, deletions, duplications, inversions, and insertions. Certain structural rearrangements may remain balanced and nondisruptive, that is, resulting in no total loss or gain of genetic material, occurring between genes, and failing to interrupt the regulatory sequences of adjacent genes. In this circumstance no phenotypic consequence results from the rearrangement. Carriers of balanced rearrangements, however, have a 50% probability of producing unbalanced gametes. Other chromosome rearrangements are balanced but disruptive. A rearrangement of this type bisects a gene, preventing transcription, or disturbs the gene’s regulatory sequence and may be accompanied by phenotypic consequences. Unbalanced rearrangements result in a loss or a gain of chromosome material, or both. They can occur de novo or can result from unbalanced segregation of a balanced rearrangement in one of the parents. Deletions
A deletion is the loss of a portion of a chromosome (Fig. 1-4). Deletions can affect a single gene, being submicroscopic and requiring molecular techniques for detection, or may be large enough to be seen under the microscope.123,152–157 Deletion of a region of a chromosome has the same effect as monosomy. It leaves the involved region of the chromosome unpaired, a situation permitting deleterious genes to be expressed with no possibility of compensation by the missing allele. Table 1-9 gives the most common microdeletions currently recognized.
Fig. 1-4. Deletion. Top: idiograms and photomicrographs of a normal chromosome 5 (left) and a terminal deletion of the short arm of chromosome 5 (right) in a patient with the cri du chat syndrome. Bottom: idiograms and photomicrographs of a normal chromosome 17 (left) and an interstitial deletion of a portion of band p11.2 from the short arm of chromosome 17 (right).
A ring chromosome is formed by fusion of the two ends of a chromosome after deletion of the two telomeres and variable segments of juxtatelomeric genes (Fig. 1-5). Ring chromosomes are unstable, can vary considerably in size in different cells, and tend to be lost during cell division, leading to mosaicism.158 Phenotypic consequences are quite variable, depending on the genetic material deleted. It is unusual for ring chromosomes to persist for more than one generation. Duplications
A portion of a chromosome can become duplicated by unequal crossover involving a normal chromosome, by a cross-over between the breakpoints of a pericentric inversion, or by unbalanced segregation of a translocation (Fig. 1-6).123,159 Trisomy for the duplicated region of the chromosome results in phenotypic changes. Although anticipated with the same frequency as microdeletions, microduplications are recognized less commonly. This may be due to the production of less severe phenotypes, the difficulties of detection with current technologies, or other factors. Translocations
Several types of translocations occur in which chromosome material is interchanged between two chromosomes or transferred from one chromosome to another.160–164 Robertsonian translocations, the most common type, involve only the acrocentric chromosomes (13–15, 21, and 22) and arise by fusion of two chromosomes at the centromere, forming a single composite (compound) chromosome (Fig. 1-7).160 Residual fragments of the short arms of the two chromosomes are lost in subsequent divisions. Loss of the short arms, known to contain redundant ribosomal RNA genes, does not appear to influence health. Carriers of Robertsonian translocations between homologous acrocentric chromosomes produce only abnormal gametes, either containing the compound chromosome or missing one acrocentric altogether. Resulting pregnancies are trisomic or monosomic. Carriers of Robertsonian translocations between different acrocentric chromosomes produce normal gametes (25%), gametes lacking the homolog of one of the acrocentrics involved in the translocation (25%), gametes having the translocation (25%), or gametes that have the translocation plus the homolog of one of the acrocentrics involved (25%). Theoretically, an offspring has an equal chance of being a normal, balanced carrier, trisomic, or monosomic. Empirical observations document the risk for trisomy in offspring to be less than 25% and to differ depending on whether the mother or father is the translocation carrier.164 The risk for Down syndrome among offspring of mothers with balanced 14;21 translocations is 15%. When the father has a balanced 14;21 translocation, the risk decreases to 2–3%. Monosomy 14 and monosomy 21 fetuses are uniformly lost to spontaneous abortion. Reciprocal translocations involve exchange of material between two chromosomes, resulting in the formation of two abnormal composite (compound) chromosomes (Fig. 1-8).161 Balanced and nondisruptive translocations cause no phenotypic effects. One-half of the gametes produced by carriers of a balanced reciprocal translocation will be unbalanced. An insertion is a rare type of nonreciprocal translocation in which a segment of a donor chromosome is inserted into a nonhomologous chromosome.162 In the process, the donor chromosome becomes deleted. The phenomenon requires three breakpoints, one in the recipient chromosome and two in the donor. As with other translocations involving non-homologous chromosomes, this rearrangement can lead to abnormal gametes
Human Malformations and Related Anomalies
19
Table 1-9. Microdeletions associated with malformations and malformation syndromes Syndrome
Location
Findings
Alagille (JAG1)*
20p11.23-p12.2
Dysmorphic facial features, chronic cholestasis, vertebral arch defects, pulmonic stenosis
Albright hereditary osteodystrophy-like syndrome
2q37
Short stocky build, abnormal facies, brachymetaphalangism, seizures, developmental delay
Alpha-thalassemia and mental retardation (ATR-16)
16p13.3
Dysmorphic facial features, alpha-thalassemia, mental retardation
Angelman (UBE3A)*
15q11-q13
Hypotonia, microcephaly, hypopigmentation, ataxic gait, inappropriate laughter, seizures, mental retardation
Cat eye
22q11.2
Coloboma, choanal atresia, learning disabilities, mental retardation
Cri du chat
5p13-p15.2
Microcephaly, hypertelorism
DiGeorge 2
10p13
Dysmorphic facies, conotruncal heart defects, T-cell immune defects
Greig cephalopolysyndactyly (GLI3)*
7p13
Craniosynostosis, polysyndactyly, mental retardation
Langer-Giedion
8q24.1
Trichorhinophalangeal syndrome (sparse hair, bulbous nose, cone-shaped phalangeal epiphyses), multiple exostoses, mental retardation
Miller-Dieker (LIS1)*
17p13.3
Type I lissencephaly, dysmorphic facies
NF1 microdeletion
17q11.2
Neurofibromatosis, early age onset of cutaneous neurofibromas, facial dysmorphism, learning disabilities, mental retardation
Prader-Willi
15q11-q13
Hypotonia, obesity, short stature, small hands and feet, hypopigmentation, hyperphagia, mental retardation
Rubinstein-Taybi (CBP)*
16p13.3
Dysmorphic facial features, broad thumbs and first toes, mental retardation
Smith-Magenis
17p11.2
Dysmorphic facial features, behavioral abnormalities, self-destructive behavior, peripheral neuropathy, mental retardation
Velo-Cardio-Facial (proximal 22q microdeletion, diGeorge)
22q11
Abnormal facies, cleft palate, thymic hypoplasia, hypocalcemia, heart defect
WAGR (PAX6)*
11p13
Wilms tumor, aniridia, genitourinary anomalies, mental retardation
Williams (LIMK1)*
7q11.23
Dysmorphic facial features, infantile hypercalcemia, congenital heart disease, premature aging of the skin, gregarious personality, mental retardation
Wolf-Hirschhorn
4p16.3
Abnormal facies, cleft lip/palate, heart and renal malformations, brain anomalies, genital anomalies, mental retardation
1p36 Deletion
1p36
Hypotonia, growth abnormalities, craniofacial dysmorphism, minor cardiac malformations, developmental delay
Distal 22q microdeletion (ProSAP2 ?)
22q13-qter
Mild facial dysmorphism, hypotonia, severe language delay
Xp22.3 Deletion
Xp22.3
X-linked ichthyosis, epilepsy, ocular albinism, Kallmann syndrome, mental retardation
Xp21 Deletion
Xp21
Muscular dystrophy, glycerol kinase deficiency, congenital adrenal hypoplasia, mental retardation
*Gene in the microdeletion which may be responsible for some or all of syndrome manifestations. Modified from Schwartz and Graf 2002,156 Brewer et al. 1998.154
depending on the segregation of the two chromosomes involved and their homologs. Inversions
In pericentric inversions, a chromosome has breakpoints on both arms, with reversal of the intervening centromeric segment Fig. 1-5. Ring chromosome. Idiograms and photomicrographs of normal chromosome 22 (left) and a ring chromosome 22 (right). The satellites and the telomere of 22q have been lost.
(Fig. 1-9). When balanced and nondisruptive, the rearrangement is benign.165,166 During meiosis I, the inverted chromosome is required to form a loop to pair with its noninverted homolog. If an uneven number of crossovers occurs within the loop, the gamete will be unbalanced, having one part of the chromosome duplicated and another part deleted. Gametes formed with the duplication-deletion chromosomes are unbalanced. Theoretically, one-half of gametes formed by a parent with a pericentric inversion will be unbalanced if crossing-over occurs in the inverted segment. In paracentric inversions, a segment of genes on one arm of a chromosome is reversed.167,168 In the absence of a bisected gene or disrupted regulation of adjacent genes, this rearrangement is benign. As with pericentric inversions, paracentric inversions must form a loop for pairing of sequences along the inverted segment during meiosis. An unequal number of crossovers during this
20
Overview
Fig. 1-6. Duplication. Idiograms and photomicrographs of normal chromosome 1 (left) and duplication of most of the long arm of chromosome 1 (right). The duplicated region extends from the heterochromatic region (stippled) to the terminal band (q44).
pairing can produce two different types of duplication-deletion chromosomes, one of which is acentric and one dicentric. Theoretically, one-half of the gametes produced by a carrier of a balanced paracentric inversion would be unbalanced, having one of these two duplication-deletion chromosomes if crossing-over occurred in the inverted segment. Isochromosomes
Cleavage of the centromere perpendicular to the plane of usual cleavage results in isochromosome formation (Fig. 1-10). This misdivision occurs at metaphase (meiosis or mitosis), leaving the anaphase chromosome with two long arm (q) chromatids or two short arm (p) chromatids rather than one of each. The resulting isochromosome has two identical arms and functionally represents duplication of one arm of the chromosome and deletion of the
Fig. 1-7. Robertsonian translocation. Top: idiograms and photomicrographs of normal chromosomes 14 and 21 (left and middle) and a Robertsonian (centromeric) translocation involving chromosomes 14 and 21 (right). The combined chromosome retains all the active genes on chromosomes 14 and 21. The short arms are genetically inactive and presumed to be lost from most cells. Balanced translocation carriers have the combined chromosome in addition to one normal 14 chromosome and one normal 21 chromosome. A small percentage of patients with Down syndrome have the combined chromosome in addition to one normal 14 and two normal 21 chromosomes. Bottom: idiograms and photomicrographs of normal chromosomes 13 and 14 (left and middle) and a Robertsonian translocation involving these two chromosomes. This is the most common translocation in humans.
other. Autosomal isochromosomes are unusual, but Xq isochromosomes occur not infrequently.169,170 Fragile Sites
Heritable regions of chromosomes that show a tendency to separation, breakage, or attenuation under certain cell conditions have been termed ‘‘fragile sites.’’171,172 Numerous rare and common fragile sites have been identified (Fig. 1-11). Fragile sites vary in
Fig. 1-8. Reciprocal translocation. Idiograms and photomicrographs of normal 9 and 10 chromosomes (left and left center) and the derivative 9 and 10 chromosomes formed reciprocal translocation between the two chromosomes at breakpoints 9q21.2 and 10q21.1 (right center and right).
Human Malformations and Related Anomalies
Fig. 1-9. Pericentric inversion. Idiograms and photomicrographs of normal chromosome 2 (left) and pericentric inversion involving the segment p11 to q13 of chromosome 2 (right). The resulting inversion chromosome 2 has reduced short arm length and increased long arm length.
21
Fig. 1-10. Isochromosome. Idiograms and photomicrographs of normal X chromosome (left) and an isochromosome for the long arms of the X chromosome (right). The original chromosome is presumed to have divided horizontally rather than longitudinally, resulting in a long arm isochromosome shown here and a short arm isochromosome lost from this cell line.
Other Chromosome Aberrations
appearance under the microscope and are enhanced by folate or thymidine depletion of the culture media or by the addition of bromodeoxyuridine, distamicin A, or aphidicolin.172 The fragile site located at q27.3 of the X chromosome has been associated with human dysmorphism and mental retardation, the so-called fragile X syndrome (Fig. 1-12).
Breakage and rearrangement of chromosomes occur in a small group of autosomal recessive disorders. The number of breaks can be increased over the spontaneous number found in cell cultures by exposure to radiation, mitomycin-C, or diepoxybutane.173,174 Chromatid breaks are typically found in Fanconi anemia; breaks, triradial and quadriradial associations between chromosomes,
Fig. 1-11. Schematic of human chromosomes showing locations of major heritable fragile sites. Closed arrows indicate folate-sensitive sites, including the fragile X site Xq27.3. Open arrows indicated sites that are induced by bromodeoxyuridine (BrdU) and distamycin A. Bars indicate
common constitutive fragile sites that are folate sensitive and induced by aphidicolin. (After Jacky P: Fragile X and other heritable fragile sites on human chromosomes. In: The ACT Cytogenetics Laboratory Manual, ed 2. Barch MJ, ed. Raven Press, New York, 1991, p 489.)
22
Overview
Uniparental Disomy
The mechanism underlying these phenotypic changes is unknown, but it appears possible that some parts of the maternal and paternal chromosomes are modified (imprinted) differently during gametogenesis, and the contribution from both parents is necessary for normal growth and development.126 Heterodisomy exists when the homologous chromosomes are different but both inherited from one parent. In isodisomy, both members of a chromosome pair are identical and the individual is homozygous for all genes on the chromosome involved. Both types of uniparental disomy have been identified in humans. Maternal disomy has been found in 10–25% of individuals with Prader-Willi syndrome and paternal disomy in 3–4% of individuals with Angelman syndrome.128,177 Uniparental disomy has also been documented in some cases of Beckwith-Wiedemann syndrome (paternal UPD 11p15.5), Russell-Silver syndrome (maternal UPD 7), and in individuals with short stature, mental retardation, and multiple anomalies.178–180 Uniparental disomy is rare and may result in most cases from trisomy rescue. Isodisomy has been documented to lead to autosomal recessive disorders.181
1.4 Gene Mutations and Malformations
Fig. 1-12. Fragile X chromosome. Idiograms and photomicrographs of normal X chromosome (top left) and fragile site at q27.3 of the X chromosome (top right). Photographs show facial features of males with the fragile X syndrome. Child at age 3 years (bottom left) shows prominent forehead but little other distinctive facial changes. In adulthood (age 37 years, bottom right) the typical facies, with long face, prominent forehead, large ears, and large lower jaw is apparent.
and sister chromatid exchanges in Bloom syndrome; breaks and nonrandom rearrangements of chromosomes 7 and 14 in ataxia– telangiectasia; and breaks in progeria and Werner syndrome. Whether the growth impairment, malformations, and other dysmorphic features in these conditions can be attributed to the influence of these chromosomal changes during development or represent pleiotropic effects of the underlying mutation is unknown. Centromere separations (chromosome puffs), primarily involving the acrocentric chromosomes and chromosomes 1, 9, and 16, have been found in numerous patients with Roberts syndrome (SC phocomelia).175 The centromeric constriction of these chromosomes is lost, and two distinct centromeres in alignment with the two chromatids can be demonstrated with C-banding (Fig. 1-13). Although centromere separation has been noted in normal individuals, those with a variety of hematologic disorders, and in aging women, it is a useful marker to distinguish Roberts syndrome from other limb reduction syndromes. A second type of premature centromeric division that involves all or most of the chromosomes has been described in a syndrome of microcephaly, Dandy-Walker malformation, Wilms tumor, and mosaicism for several different aneuploidies (mosaic variegated aneuploidy).176
Genes are the physical units of heredity by which characteristics are transmitted from generation to generation in all living organisms. They are the functional units of inheritance. Genes constitute the primary elements of the chromosomes along the length of which they are irregularly distributed. An understanding of the function of genes preceded knowledge of the physical nature of genes. To Gregor Mendel, an Augustinian monk from Moravia (present-day Czech Republic), must go credit for discovery of the principles of heredity.182 Working with Pisum hybrids, Mendel found that hereditary characters were transmitted as units that retained their integrity generation to generation, even when their expression was masked by another character. Those characters expressed in the hybrid (heterozygote) he called dominant and those whose expression could be masked in the hybrid recessive: Those characters which are transmitted entire, or almost unchanged in the hybridization, and therefore in themselves constitute the characters of the hybrid, are termed dominant, and those which become latent in the process, recessive. The expression ‘‘recessive’’ has been chosen because the characteristics thereby designated withdraw or entirely disappear in the hybrids, but nevertheless reappear in their progeny. On this basis Mendel could predict the behavior of selected characteristics generation to generation and express the predictions in mathematical terms. His findings were contrary to the prevailing view that hereditary characteristics were blended in each new generation, and his work went unnoticed by the scientific community for 30 years.183–185 Shortly after 1900, examples of Mendel’s dominant and recessive inheritance were suggested as the basis for human disorders. Farabee186 attributed the malformation brachydactyly, found in five generations of a Pennsylvania family, to a dominant hereditary factor (Fig. 1-14). At the same time, Garrod187,188 described three inborn errors of metabolism: alkaptonuria,
Human Malformations and Related Anomalies
23
Fig. 1-13. Roberts syndrome patient showing limb reduction defects and premature separation of the centromere in metaphase chromosome preparation. (Courtesy Dr. G. S. Pai, Medical University of South Carolina, Charleston.)
cystinuria, and albinism. On the advice of Bateson, Garrod indicated that they could be caused by rare recessive factors. He further believed that these conditions and a fourth, pentosuria, which he added later, resulted from blocks in normal enzyme activities, anticipating the relationship between genes and enzymes that would be elucidated some 40 years later.
In 1911, Johannsen189 suggested the term gene be used for a hypothetical unit of heredity, acknowledging that no structure or specific mechanism of action for the unit could at the time be assigned. He also used the terms phenotype to indicate the features caused by a gene and genotype for the gene basis for a given phenotype.
24
Overview
Fig. 1-14. Pedigree of brachydactyly transmitted as an autosomal dominant trait published by Farabee in 1905. This trait was the first recognized to demonstrate that the laws of Mendel applied to humans as well as to plants and the lower animals.
Dysmorphologists, clinical geneticists, endocrinologists, and specialists in metabolism generally focus their studies on the functional and structural consequences of mutant genes. Such genes underlie no small portion of human dysmorphology. They are responsible for 70% of the 290 entries in Jones’ Smith’s Recognizable Patterns of Human Malformations.43 Malformations or other morphologic features are found in 2534 (17%) of the 15,262 entries in Mendelian Inheritance in Man. In 977 of these entries, the responsible gene has been identified or regionally mapped (Table 1-10).102 Because gene ascertainment has depended predominantly on phenotype, it might be anticipated that a significant portion of genes associated with human dysmorphism have already been identified. Molecular techniques developed during the past two decades have revised concepts of gene structure and regulation.190–196 Individual genes have been isolated, cloned, and sequenced. Genes have been shown to vary remarkably in size, to be configured of variable numbers of translated sequences (exons) separated by noncoding intervening sequences (introns), and to be closely flanked by regulatory sequences at the upstream (5') and downstream (3') ends (Fig. 1-15). Messenger RNA, formed of exons spliced together after the introns have been removed from precursor nuclear RNA (Hn RNA), provides the template for polypeptide assembly. It has now been estimated that humans may have as many as 30,000–40,000 gene pairs distributed along the 46 chromosomes.102,197–200 For the most part, genes have come to light only if they produce some distinctive change—morphologic or functional—within an individual. Other than acknowledging the existence of the gene that causes such a distinctive phenotype, little more can be said about most genes. The exact functions of relatively few genes have been determined. With the advent of large-scale mapping and sequencing projects, the capacity to localize gene expression in developing and mature tissue, and the technologies to alter gene expression in experimental animals, this situation will rapidly change.197–200 Molecular pathways, which link genes that influence each other and control the metabolism necessary for structural development, growth, and maintenance, are beginning to emerge.195,196 Extensive characterization of a gene and its chromosomal location, sequence, and gene product may be accomplished before a link between the gene and the human phenotype is recognized. Chromosome rearrangements and linkage analyses have allowed a number of genes that cause human anomalies to be localized
on various chromosomes.101,201 Table 1-10 lists the genes associated with malformations and malformation syndromes and gives the chromosome locations of other genes known to be involved in human anatomical development. Mutations are alterations in the coding sequence or regulatory apparatus of a normal gene. They result in altered amino acid sequences in the polypeptide gene product or in the amount of polypeptide produced. For each gene, the number of possible mutations is great. Many, perhaps most, do not cause phenotypic effects and exist as innocuous molecular polymorphisms in the population. Other mutations interfere with normal biologic processes sufficiently to prevent survival of the organism. Intermediate between these extremes are mutations that produce nonlethal changes in the phenotype. These constitute the single gene disorders that provide diagnostic and research challenges for the dysmorphologists and clinical geneticists. Most genes exist in pairs, or alleles, one located on each member of a pair of homologous chromosomes. The exceptions occur in males, in whom most genes on the X and Y chromosomes are unpaired, or hemizygous. Unless inactivated by one of the mechanisms described previously, all genes are expressed within the metabolic machinery of the cell. This metabolic expression, however, may not be reflected in discernible features (phenotype) of the individual. For this reason, the terms recessive and dominant are useful in the clinical setting to describe the phenotypic consequences of gene mutations. In the strict sense, use of these terms in reference to genes may be considered inappropriate, since expression can be equally evident at the cellular level for genes that produce no phenotypic changes as for those that produce dramatic change. However technically incorrect, common usage permits one to speak of recessive or dominant genes and gene mutations. Dominant Phenotypes
Phenotypic changes produced by a single dose of a given gene are termed dominant or, as noted above, the terms dominant genes and dominant mutations are commonly used to characterize genes that can produce phenotypic manifestations when present in a single dose. To date, dominant phenotypes outnumber recessive phenotypes, a finding likely related to easier ascertainment of the former.101 There is no a priori reason to suspect that the mutations leading to dominant phenotypes occur more frequently than those leading to recessive phenotypes, and work with experimental animals and plants indicates that most mutations are recessive (require a double dose for manifestation).
Table 1-10. Selected malformations and malformation syndromes for which the gene has been identified or localized Disorder
Gene/Locus/OMIM
Disorder
Gene/Locus/OMIM
ADULT (Acro-dermatoungual-lacrimal-tooth
p63, 3q27, 103285
Atrioventricular septal defect, partial, with heterotaxy
CRELD1, 3p25.3, 606217
Aarskog-Scott
FGD1, Xp11.21, 305400
Bamforth-Lazarus
FOXE1, 9q22, 241850
Acheiropody
C7orf2, 7q36, 205000
Bannayan-Riley-Ruvalcaba
PTEN, 10q23.31, 153480
Achondrogenesis
XLC26A2, 5q32-q33.1, 600972
Bardet-Biedl
209900
Achondrogenesishypochondrogenesis, type II
COL2A1, 12q13.11-q13.2, 200610
Type 1
11q13
Achondroplasia
FGFR3, 4p16.3, 100800
Type 2
16q21
Type 3
3p13-p12
Acrocallosal
GL13, 7p13, 200990
Acrocapitofemoral dysplasia
IHH, 2q33-q35, 607778
Type 4
15q22.3-q23
Acrofacial dysostosis, Nager type
9q32, 154400
Type 5
2q31
Acromesomelic dysplasia, HunterThompson type
CDMP1, 20q11.2, 201250
Type 6
20p12
Type 7
4q27
Acrorenalocular
SALL4, 20q13.13-q13.2, 102490
Type 8
14q32.1
Agenesis of the corpus callosum with peripheral neuropathy
SLC12A6, 15q13-q14, 218000
Aicardi
Xp22, 304050
Barth
Xq28, 302060
Beare-Stevenson cutis gyrata
FGFR2, 10q26, 176943 KIP2, 11p15.5, 130650
Alagille
JAG1, 20p12, 118450
Beckwith-Wiedemann
Allan-Herndon
Xq21, 309600
9q34.3, 269700
Albright hereditary osteodystrophy
GNAS, 20q13.2, 174800
Berardinelli-Seip congenital lipodystrophy
FOXL2, 3q23, 110100
Alopecia universalis
8p21.2, 203655
Blepharophimosis, epicanthus inversus, and ptosis, type 1
Alpha-thalassemia/mental retardation
XNP, Xq13, 301040
Borjeson-Forssman-Lehmann
PHF6, Xq26.3, 301900
Amelogenesis imperfecta
Xp22.3-p22.1, 301200
Type A1
IHH, 2q33-q35, 112500
Brachydactyly
Angelman
UBE3A, 15q11-q13, 105830
Type B1
ROR2, 9q22, 113000
Aniridia, type II
PAX6, 11p13, 106210
Type C
CDMP1, 20q11.2, 113100
Anophthalmia 3
SOX2, 3q26.3-q27
Types D and E
HOXD13, 2q31-q32, 113200
Anophthalmos-1
Xq27-q28, 301590
Anterior segment anomalies and cataract
EYA1, 8q13.3, 601653
Anterior segment mesenchymal dysgenesis
FOXC1, 6p25, 601090
Anterior segment mesenchymal dysgenesis and cataract
FOXE3, 1p32, 107250
Antley-Bixler
Branchiooto
EYA1, 8q13.3, 601653
Branchiootorenal and branchiootorenal with cataract
EYA1, 8q13.3, 113650
Campomelic dysplasia
SOX9, 17q24.3-q25.1, 114290
Camurati-Engelmann disease
TGFB1, 19q13.1, 131300
PITX3, 10q25, 107250
Cartilage–hair hypoplasia
9p21-p12, 250250
Apert
POR, 7q11.2, 124015
Cat eye
22q11, 115470
Arthrogryposis multiplex congenita, distal, type 1
FGFR2, 10q26, 101200
Cerebellar hypoplasia
OPHN1, Xq12
Cerebropalatocardiac
PQBP1, Xq11.2
Arthrogryposis multiplex congenital, distal, type 2B (see Freeman-Sheldon)
9p13.2-p13.1, 108120
Arthrogryposis multiplex congenita, neurogenic
Char
TFAP2B, 6p12, 169100
CHARGE
CHD7, 8q12, 214800
5q35, 208100
Chondrodysplasia punctata, X-linked recessive
ARSE, Xp22.3, 302950
Arthrogryposis, X-linked (spinal muscular atrophy, infantile, Xlinked)
Xp11.3-q11.2, 301830
Chondrodysplasia, Grebe type
CDMP1, 20q11.2, 200700
Chondrodysplasia, HunterThompson type
CDMP1, 20q11.2, 201250
Asphyxiating thoracic dystrophy (Jeune)
15q13, 208500
Cleft lip/palate, nonsyndromic
MSX1, 4p16.1, 119530
Atelosteogenesis I, III
FLNB, 3p14.3, 108720
Cleft palate with ankyloglossia
TBX22, Xq12-q21, 303400
Atelosteogenesis II
SLC26A2, 5q32-q33.1, 256050
Atrial septal defect with atrioventricular conduction defects
NKX2E, 5q34, 108900
Cleidocranial dysplasia
CBFA1, 6p21, 119600
Coffin-Lowry
RSK2, Xp22.2-p22.1, 303600
Colonic aganglionosis, total, with small bowel involvement
RET, 10q11.2, 164761 (continued)
25
Table 1-10. Selected malformations and malformation syndromes for which the gene has been identified or localized (continued) Disorder
Gene/Locus/OMIM
Disorder
Gene/Locus/OMIM
Conotruncal anomaly face
TBX1, 22q11.2, 217095
Type 2
COL9A2, 1p33-p32.2, 600204
Contractural arachnodactyly, congenital
FBN2, 5q23-q31, 121050
Type 3
COL9A3, 20q13.3, 600969
COL9A1-related
COL9A1, 6q13, 120210
Myopathy-related
COL9A3, 20q13.3, 120270
Cornelia de Lange (see de Lange) Costello
22q13.1, 218040
Cowden disease
PTEN, 10q23.31, 601728
Craniofrontonasal dysplasia
EFNB1, Xq12, 304110
Craniometaphyseal dysplasia
5p15.2-p14.1, 123000
Craniosynostosis, nonspecific
FGFR2, 10q26, 176943
Crouzon
FGFR2, 10q26, 123500
Crouzon with acanthosis nigricans
FGFR3, 4p16.3, 134934
Currarino
HLXB9, 7q36, 176450
Cutis laxa, AD
ELN, 7q11.2, 123700 FBLN5, 14q32.1, 123700
Cutis laxa, neonatal
ATP7A, Xq12-q13, 300011
De Lange
NIPBL, 5p13.1, 122470
DiGeorge
TBX1, 22q11.2, 188400
Diastrophic dysplasia
SLC26A2, 5q32-q33.1, 222600
Duane-radial ray Dyggve-Melchior-Clausen
Exostoses, multiple, type 1
EXT1, 8q24.11-q24.13, 133700
Exostoses, multiple, type 2
EXT2, 11p12-p11, 608210
FG syndrome
Xq12-q21.31, 305450 Xq28, 300321 Xp22.3, 300406
Fanconi anemia Complementation group A
227650 16q24.3, 227650
B
BRCA2, 13q12.3, 227660
C
9q22.3, 227645
D1
BRCA2, 13q12.3, 605724
D2
3p25.3, 227646
E
6p22-p21, 600901
F
11p15, 603467
SALL4, 20q13.13-q13.2, 607323
G
FANCG, 9p13, 602956
FLJ90130, 18q12-q21.1, 223800
L
2p16.1, 608111
Dyschondrosteosis (see Leri-Weill) Dyskeratosis congenita
DKC1, Xq28, 305000
Dyssegmental dysplasia, Silverman-Handmaker type
HSPG2, 1p36.1, 224410
Fibrodysplasia ossificans progressiva
FOP, 4q27-q31, 135100
Fragile X syndrome
FMR1, Xq27.3, 309550
Frasier, pseudohermaphroditism
WT1, 11p13, 136680
Freeman-Sheldon
11p15.5, 191043
Frontometaphyseal dysplasia
FLNA, Xq28, 304120
EEC (Ectrodactyly-ectodermal dysplasia-clefting)
p63, 3q27, 129900
Ectodermal dysplasia, anhidrotic
ED1, Xq12-q13.1, 305100
GM1-gangliosidosis
GLB1, 3p21.33, 230500
Ectodermal dysplasia, hidrotic
GJB6, 13q12, 129500
Greig cephalopolysyndactyly
GLI3, 7p13, 175700
Ectodermal dysplasia, hypohidrotic with immune deficiency
NEMO, Xq28, 300291
Hand-foot-uterus
HOXA13, 7p15-p14.2, 140000
Ectopia pupillae
PAX6, 11p13, 129750
Hay-Wells
p63, 3q27, 106260
Heterotaxy, X-linked visceral
ZIC3, Xq26.3, 306955
COL1A1, 17q21.31-q22, 130000
Heterotopia, periventricular
FLNA, Xq28, 300049
COL5A1, 9q34.2-q34.3, 130000
Hirschsprung disease
RET, 10q11.2, 142623
Ehlers-Danlos syndrome Type I
COL5A2, 2q31, 130000 Type II
COL5A1, 9q34.2-q34.3, 130010
Type III
COL3A1, 2q31, 130020
Type IV
COL3A1, 2q31, 130050
Type VI
1p36.3-p36.2, 225400
Type VII
COL1A1, 17q21.31-q22, 130060
Type VIIA2
COL1A2, 7q22.1, 130060
Type VIIC
5q23, 225410
Type X
2q34, 225310
Holoprosencephaly 1
HPE1, 21q22.3, 236100
2
SIX3, 2p21, 157170
3
SHH, 7q36, 142945
4
TGIF, 18p11.3, 142946
5
ZIC2, 13q32, 603073
6
HPE6, 2q37.1-q37.3, 236100
7
PTCH, 9q22.3, 601309
Holt-Oram
TBX5, 12q24.1, 142900
Ellis-van Creveld
4p16, 225500
Emery-Dreifuss muscular dystrophy
LMNA, 1q21.2, 181350
Epidermolysis bullosa dystrophica, AD
COL7A1, 3p21.3, 131750
Hydrolethalus
11q23-q25, 236680
Epiphyseal dysplasia, multiple
SLC26A2, 5q32-q33.1, 226900
Hyperostosis, endosteal
LRP5, 11q13.4, 144750
COMP, 19p13.1, 132400
Hypochondroplasia
FGFR3, 4p16.3, 146000
Type 1
Hutchinson-Gilford progeria
LMNA, 1q21.2, 176670
Hydrocephalus due to aqueductal stenosis
L1CAM, Xq28, 307000
(continued)
26
Table 1-10. Selected malformations and malformation syndromes for which the gene has been identified or localized (continued) Disorder
Gene/Locus/OMIM
Disorder
Gene/Locus/OMIM
Hypodontia
PAX9, 14q12-q13, 106600 MSX1, 4p16.1, 106600
Microcephaly, autosomal recessive, type 1
MCPH1, 8p23, 251200
Hypodontia with orofacial cleft Incontinentia pigmenti Type II
NEMO, Xq28, 308300
Type 2
19q13.1-q13.2
FGFR1, 8p11.2-p11.1, 123150
Type 3
9q34
FGFR2, 10q26, 123150
Type 4
15q15-q21
11q23, 147791
Type 5
1q31
Type 6
13q12.2
Jackson-Weiss Jacobsen Jeune (see asphyxiating thoracic dystrophy)
Miller-Dieker lissencephaly
LIS1, 17p13.3, 247200
Kallmann
Xp22.3, 308700
Milroy lymphedema
VEGFR3, 5q34, 153100
Kallmann 2
FGFR1, 8p11.2-p11.1, 147950
Morning glory disc anomaly
PAX6, 11p13, 607108
Klippel-Trenaunay
5q13.3, 149000
Mowat-Wilson
SMADIP1, 2q22, 235730
Kneist dysplasia
COL2A1, 12q13.11-q13.2, 156550
Mucolipidosis II
GNPTA, 4q21-q23, 252500
Mucopolysaccharidosis
Langer mesomelic dysplasia
SHOX, Xpter-p22.32, 249700
Langer-Giedion
TRPS2, 8q24.11-q24.13, 150230
Ih, Ih/s, Is (Hurler, Scheie)
IDUA, 4p16.3, 252800
Laron dwarfism
GHR, 5p13-p12, 262500
II (Hunter)
IDS, Xq28, 309900
Larsen, autosomal dominant
FLNB, 3p14.3, 150250
IIIA (Sanfilippo A)
SGSH, 17q25.3, 252900
Lenz microphthalmia
Xq27-q28, 309800
IIIB (Sanfilippo B)
NAGLU, 17q21, 252920
LEOPARD
PTPN11, 12q24.1, 151100
IIIC (Sanfilippo C)
MPS3C, Chr. 14, 252930
Leprechaunism
INSR, 19p13.2, 246200
IVA (Morquio)
GALNS, 16q24.3, 253000
Leri-Weill (dyschondrosteosis)
SHOX, Xpter-p22.32, 127300
IVB (Morquio B)
GLB1, 3p21.33, 230500
Limb-mammary
p63, 3q27, 603543
VI (Maroteaux-Lamy)
ARSM, 5q11-q13, 253200
Lipodystrophy, familial partial
LMNA, 1q21.2, 151660
VII (Sly)
GUSB, 7q21.11, 253220
Lissenephaly-1
LIS1, 17p13.3, 607432
Lissencephaly
Muenke
FGFR3, 4p16.3, 602849
MULIBREY nanism
17q22-q23, 253250
Norman-Roberts type
RELN, 7q22, 257320
Multiple endocrine neoplasia I
MEN1, 11q13, 131100
X-linked
DCX, Xq22.3-q23, 300067
Multiple endocrine neoplasia IIA
RET, 10q11.2, 171400
X-linked with ambiguous genitalia
ARX, Xp22.13, 300215
Multiple endocrine neoplasia IIB
RET, 10q11.2, 162300
Muscle-eye-brain disease
POMGNT1, 1p34-p33, 253280
Lowe
OCRL, Xq26.1, 309000
Nail-patella
LMX1B, 9q34.1, 161200
Lymphedema and ptosis
FOXC2, 16q24.3, 153000
Nance-Horan
NHS, Xp22.13, 302350
Lymphedema-distichiasis
FOXC2, 16q24.3
Neurofibromatosis, type 1
NF1, 17q11.2 162200
MASA (Mental retardation, aphasia, shuffling gait, adducted thumbs)
L1CAM, Xq28, 303350
Noonan
PTPN11, 12q24.1, 163950
Norrie disease
Xp11.4, 310600
FBN1, 15q21.1, 604308
Oculodentodigital dysplasia
GJA1, 6q21-q23.2, 164200
Mandibuloacral dysplasia
LMNA, 1q21.2, 248370
OSMED
COL11A2, 6p21.3, 215150
Marfan
FBN1, 15q21.1, 154700
Oligodontia
PAX9, 14q12-q13, 604625
Marshall
COL11A1, 1p21, 154780
Opitz BBB
CXorf5, Xp22.3-p22.2, 311200
McCune-Albright
GNAS, 20q13.2, 174800
Osteogenesis imperfecta
McKusick-Kaufman, polydactyly
20p12, 236700
MASS
Meckel Type 1
17q22-q23, 249000
Type 2
11q13, 603194
Type 3
8q24, 607361
Melnick-Needles
FLNA, Xq28, 309350
Menkes
ATP7A, Xq12-q13, 309400
Metaphyseal chondrodysplasia, Murk Jansen type
PTHR1, 3p22-p21.1, 156400
Metaphyseal chondrodysplasia, Schmid type
COL10A1, 6q21-q22.3, 120110
Type I
COL1A1, 17q21.31-q22, 166200
Type II
COL1A1, 17q21.31-q22, 166210
Type III
COL1A1, 17q21.31-q22, 259420
Type IV
COL1A1, 17q21.31-q22, 166220
Osteopetrosis, autosomal dominant Type I Type II Osteopetrosis, autosomal recessive
IRP5, 11q13.4, 607634 CLCN7, 16p13, 166600 GL, 6q21, 259700 CLCN7, 16p13, 259700 TCIRG1, 11q13.4-q13.5, 259700 (continued)
27
Table 1-10. Selected malformations and malformation syndromes for which the gene has been identified or localized (continued) Disorder
Gene/Locus/OMIM
Otopalatodigital
Disorder
Gene/Locus/OMIM
Sjogren-Larsson
17p11.2, 270200
Type I
OPD1, Xq28, 311300
Smith-Fineman-Myers
XNP, Xq13, 309580
Type II
FLNA, Xq28, 311300
Smith-Lemli-Opitz, type I
11q12-q13, 270400
PPM-X (mental retardation with psychosis, pyramidal signs and macroorchidism)
MECP2, Xq28, 300055
Smith-Lemli-Opitz, type II
11q12-q13, 268670
Smith-Magenis
17p11.2, 182290
Pallister-Hall
GLI3, 7p13, 146510
Smith-McCort dysplasia
18q12-q21.1, 607326
Parietal foramina 1
MSX2, 5q34-q35, 168500
Sotos
NSD1, 5q35, 117550
Peutz-Jeghers
19p13.3, 175200
Pfeiffer
FGFR1, 8p11.2-p11.1, 101600 FGFR2, 10q26, 101600
Piebaldism
KIT, 4q12, 164920
Polycystic kidney and hepatic disease
PKHD1, 6p21.1-p12, 263200
Polycystic kidney disease, adult type I
PKD1, 16p13.3-p13.2, 173900
Polycystic kidney disease, adult type II
PKD2, 4q21-q23, 173910
Polydactyly, postaxial Type A3
19p13.2-p13.1, 607324
Types A1 and B
GLI3, 7p13, 174200
Polydactyly, preaxial Type II
7q26, 174500
Type IV
GLI3, 7p13, 174700
Prader-Willi
15q11, 176270
Progeria
LMNA, 1q21.2, 176670
Pseudoachondroplasia
COMP, 19p13.1, 177170
Pycnodysostosis
CTSK, 1q21, 265800
Refsum
PEX7, 6q22-q24, 266500
Robinow, autosomal recessive
ROR2, 9q22, 268310
Rubinstein-Taybi
CREBBP, 16p13.3, 180849
SED congenita (spondyloepiphyseal dysplasia)
Split hand/foot malformation Type 1 with deafness
7q21.2-q21.3, 605617
Type 1
7q21.2-q21.3, 183600
Type 2
Xq26, 313350
Type 3
10q24, 600095
Type 4
p63, 3q27, 605289
Type 5
2q31, 183600
Spondylocostal dysostosis, autosomal recessive, 1
19q13, 277300
Spondyloepiphyseal dysplasia tarda
Xp22.2-p22.1, 313400
Stickler Type I
COL2A1, 12q13.11-q13.2, 108300
Type II
COL11A1, 1p21, 604841
Type III
COL11A2, 6p21.3, 184840
Supravalvar aortic stenosis
ELN, 7q11.2, 185500
Sutherland-Haan
POBP1, Xp11.23, 309470
Symphalangism, proximal
NOG, 17q22, 185800
Synostoses, multiple, 1
NOG, 17q22, 186500
Synpolydactyly with foot anomalies
HOXD13, 2q31-q32, 186000 FBLN1, 22q13.3, 608180
COL2A1, 12q13.11-q13.2, 183900
Synpolydactyly, 3/3’4, associated with metacarpal and metatarsal synostoses Synpolydactyly, type II
HOXD13, 17q22, 186000
SEMD, Pakistani type (spondyloepimetaphyseal dysplasia)
10q22-q24, 603005
Tarsal-carpal coalition
NOG, 17q22, 186570
Tetralogy of Fallot
JAG1, 20p12, 187500
SMD (spondylometaphyseal dysplasia)
COL2A1, 12q13.11-q13.2, 184252
SMED, Strudwick type (spondyloepimetaphyseal dysplasia)
COL2A1, 12q13.11-q13.2, 184250
Saethre-Chotzen Schwartz-Jampel, type 1 Septooptic dysplasia
NKX2E, 5q34, 187500 Thanatophoric dysplasia, types I and II
FGFR3, 4p16.3, 187600
Townes-Brocks
SALL1, 16q12.1, 107480 TCOF1, 5q32-q33.1, 154500
FGFR2, 10q26, 101400
Treacher Collins mandibulofacial dysostosis
TWIST, 7p21, 101400
Trichorhinophalangeal
HSPG2, 1p36.1, 255800
Type I
8q24.12, 190350
3p21.2-p21.1, 182230
Type III
8q24.12, 190351
Shah-Waardenburg
EDN3, 20q13.2-q13.3, 277580
Ulnar-mammary
Shprintzen-Goldberg
FBN1, 15q21.1, 182212
Van Buchem disease
17q11.2, 239100
Sialic acid storage disorder, infantile
6q13-q15, 269920
Van Buchem disease, type 2
LRP5, 11q13.4, 607636
Van der Woude, Type 1
IRF6, 1q32-q41, 119300
Silver-Russell
7p11.2, 180860
Van der Woude, Type 2
1p34, 606713
Simpson-Golabi-Behmel, type 1
GPC3, Xq26, 312870
Velocardiofacial
22q11.2, 192430
Situs ambiguous
NODAL, Chr. 10, 601265
28
TBX3, 12q24.1, 181450
(continued)
Human Malformations and Related Anomalies
29
Table 1-10. Selected malformations and malformation syndromes for which the gene has been identified or localized (continued) Disorder
Gene/Locus/OMIM
Disorder
Vohwinkel with ichthyosis
1q21, 604117
Williams-Beuren
ELN, 7q11.2, 194050
WAGR (Wilms tumoraniridia-genitourinary anomalies-mental retardation)
WT1, 11p13, 194072
Wolf-Hirschhorn
4p16.3, 194190
X-linked hydrocephalus spectrum
L1CAM, Xq28, 303350
Zellweger
PEX1, 7q21-q22, 214100
Waardenburg
Gene/Locus/OMIM
PEX2, 8q21.1, 170993
Type I
PAX3, 2q35, 193500
Type IIA
MITF, 3p14.1-p12.3, 193510
Type III
PAX3, 2q35, 148820
PEX5, 12p13.3, 214100
Waardenburg-Shah
SOX10, 22q13, 277580
PEX10, Chr. 1, 214100
Walker-Warburg
9q31, 236670
PEX13, 2p15, 214100
Weaver
NSD1, 5q35, 277590
PEX16, 11p12-p11.2, 603360
Weill-Marchesani
ADAMTS10, 19p13.3-p13.2, 277600
PEX19, 1q22, 214100
It is anticipated that mutations leading to dominant phenotypes will in most cases affect genes coded for structural proteins. Examples include mutations of collagen genes resulting in Stickler syndrome and osteogenesis imperfecta.202,203 Mutation of Fig. 1-15. The repertoire of DNA in somatic cells is shown in this schematic. Through the process of replication (1), DNA duplicates itself prior to cell division so that identical genetic information can be transmitted to daughter cells. Through the processes of transcription, RNA processing, and translation (2–8) the genetic information is utilized within the cell to synthesize polypeptides or proteins. (Reprinted with permission from Miller WL: J Pediatr 99:1, 1981.)
PEX3, 6q23-q24, 214100 ABCD3, 1p22-p21, 170995
a single gene controls the amount or structure of 50% of the gene product produced, which in the case of structural protein can be sufficient to cause phenotypic changes. For this reason, these mutations are good candidates to cause structural abnormalities during embryogenesis. The study of rare pathologic phenotypes in the population allows certain generalizations about the mode of inheritance to be made. The implications of dominant phenotypes differ depending on whether the responsible gene is located on an autosome or on the X chromosome (Figs. 1-16, 1-17). Characteristics common in autosomal dominant phenotypes include the following. 1. 2. 3. 4.
Males and females are affected in equal proportions. Male-to-male inheritance does occur. Only one parent is usually affected. Each offspring of an affected parent has a 50% risk of being affected. 5. Normal children of an affected parent will not transmit the condition to their children. Characteristics common in X-linked dominant phenotypes include the following. 1. 2. 3. 4.
Males and females are affected in a 1:2 ratio. Male-to-male inheritance does not occur. Affected males transmit the phenotype to all of their daughters. Offspring of affected females have a 50% risk of being affected whether male or female. 5. Only one parent is usually affected. 6. Heterozygous females are affected less severely than are hemizygous males. Pleiotropy
The mutation of a single gene can produce multiple effects (pleiotropism) in the phenotype. These effects may appear unrelated; but in some cases the underlying metabolism or the developmental process by which the features arise during embryogenesis provides an explanation for the pleiotropism. In other cases the explanations remain obscure. Genetic Heterogeneity
Identical or similar phenotypic disturbances can be caused by different gene mutations or chromosome imbalances. When
30
Overview
Fig. 1-16. Autosomal dominant inheritance. Top: pedigree showing autosomal dominant inheritance. Note that males and females are affected and that male-to-male transmission occurs. Middle: segregation of an autosomal dominant trait when one parent is affected. Each child, male or female, has a 50% chance of being affected. Bottom: segregation of an autosomal dominant trait when both parents are affected. Each child has a 50% chance of being affected (receiving the trait from one or the other parent), a 25% chance of being normal, and a 25% chance of being severely affected (receiving trait from both parents).
genetically determined phenotypes mimic each other, they are termed genocopies (e.g., Marfan syndrome and homocystinuria). Environmentally caused mimics of a genetically determined phenotype can occur as well and are termed phenocopies (e.g., the limb malformation condition produced by thalidomide exposure during pregnancy is a phenocopy of the genetic entity
Fig. 1-17. X-linked dominant inheritance. Top: pedigree showing X-linked dominant inheritance. Note males and females are affected, but male-to-male transmission does not occur. Middle: segregation of X-linked dominant trait when the father is affected. All daughters are affected, and all sons are normal. Right: segregation of X-linked dominant trait when the mother is affected. Each son or daughter has a 50% risk of being normal and a 50% risk of being affected.
SC phocomelia). For this reason, precise ascertainment of the cause of a given phenotypic change is fundamental to accurate counseling and rational preventive efforts. Penetrance
The frequency with which evidence of a mutant gene can be found in the phenotype is called penetrance. Usually used in reference to
Human Malformations and Related Anomalies
31
dominant phenotypes, full or complete penetrance describes phenotypic effects found in every individual possessing a given gene mutation. Incomplete or reduced penetrance occurs when some proportion of persons possessing a gene mutation show no phenotypic effect. Expressivity
Expressivity indicates the degree to which a mutant gene is manifest in the phenotype. Some degree of variable expressivity can be expected in most phenotypes depending in part on the influence of other genes, various types of inactivation, and environmental forces. Recessive Phenotypes
Phenotypes that require a double dose of a given gene are termed recessive. The abnormal gene product is usually an enzyme or transport protein. In the individual homozygous for these mutations, the structure of all of the gene product or the quantity produced is affected by the mutation. Individuals who have only one mutant gene are called carriers or heterozygotes, have 50% of their gene product affected by the mutation, and generally exhibit no phenotypic consequences. Because of the nature of the gene product affected by these mutations, the recessive phenotypes are often metabolic disturbances that impair function rather than morphology. Morphologic changes, if they occur, usually develop after embryogenesis or even postnatally. Exceptions to this generalization include extra digits in Carpenter syndrome, radial aplasia in Fanconi pancytopenia syndrome, marked prenatal growth impairment in achondrogenesis, and brain malformations seen in the congenital disorders of glycosylation and cholesterol metabolism. Implications of recessive phenotypes also depend on whether the responsible gene is located on an autosomal or a sex chromosome (Figs. 1-18, 1-19). Characteristics of autosomal recessive phenotypes include the following. 1. Males and females are affected in equal proportions. 2. Both parents must be carriers of a single copy of the responsible gene for a child to be affected. 3. Parents (heterozygous carriers) are usually normal. 4. Each child of carrier parents has a 25% risk of being affected, a 50% risk of being a carrier, and a 25% risk of being a nonaffected noncarrier. 5. The rarer the mutant gene is in the population, the greater the likelihood that parents of affected children will be consanguineous. Characteristics of X-linked recessive phenotypes include the following: 1. Only males are fully affected. 2. Sons of carrier females have a 50% risk of being affected. 3. Daughters of carrier females have a 50% risk of being carriers. 4. Male-to-male transmission does not occur. 5. All daughters of affected males will be carriers. 6. Unaffected males cannot transmit the phenotype. 7. A small percentage of females may show mild abnormalities. Carrier detection using biochemical or molecular techniques (linkage or gene analysis) has become possible for many autosomal and X-linked recessive phenotypes (Table 1-10). Such testing will become increasingly important in the prevention of birth defects and functional impairments.
Fig. 1-18. Autosomal recessive inheritance. Top: pedigree showing autosomal recessive inheritance. Note that both parents must be carriers, and the affected offspring may be male or female. Bottom: segregation of autosomal recessive trait in offspring when both parents are carriers. Each offspring has a 25% risk of being normal noncarrier, a 50% risk of being a carrier, and a 25% risk of being affected (inheriting the trait from both parents).
Mosaicism
When mutations occur after fertilization of an egg, a mosaic condition results in which the lineage of one cell harbors the mutation and one cell line remains normal.204 Depending on the type of gene affected, on the timing of the mutation, and on the lineage and viability of the cells bearing the mutation, phenotypic disturbances of various magnitudes can result. Certain conditions of unknown causation have been identified as candidates for single gene mosaicism, primarily because of the clonal or segmental nature of their phenotypic changes. Among these are Proteus syndrome, various pigmentary disturbances, McCune-Albright syndrome, Klippel-Trenaunay-Weber syndrome, and tumors. Germ line mosaicism describes the presence of a mutant germ line that is not found in the individual’s somatic cells. Although rarely documented, this phenomenon may explain the occurrence of several offspring affected with a dominant phenotype born of normal parents. Such has been suspected in some cases of achondroplasia and has been demonstrated by molecular techniques in
32
Overview
reaction (at the cellular level), can shape the entire individual. The power of such mutations to malform if expressed during embryogenesis or to otherwise disturb morphology if expressed later is not ordinarily offset by other genes or by the environment; that is, the penetrance of such abnormal genes is often very high. Polygenic Phenotypes
Although no example of a polygenic phenotype related to human anomalies can be given, it must be surmised that in some cases mutations of more than one gene may collaborate to produce phenotypic changes. Fingerprint patterns appear to be determined polygenically.206,207 It is most appropriate to consider polygenic inheritance in its role as the genetic component of multifactorial causation (see Multifactorial Causation of Human Anomalies, following). Contiguous Gene Phenotypes
Local groupings of separate genes that can be simultaneously affected by microdeletions and possibly by mutations have been termed contiguous gene complexes.152–155 The phenomenon, also termed segmental aneusomy, has been helpful in localizing genes to a specific chromosomal region and in determining their order. It provides a basis for phenotypic variability that might otherwise be attributed to variable expressivity or pleiotropism of a single gene. The phenotypes produced may have diverse components, each of which may be caused by alteration of a separate gene (Table 1-9). Alternatively, mutations can occur independently in any single gene in a contiguous gene complex without disturbing adjacent genes. Multifactorial (Bifactorial) Causation of Human Anomalies
Fig. 1-19. X-linked recessive inheritance: Top: pedigree of X-linked recessive inheritance. Note that males can be affected in multiple generations and that they inherit the X-linked trait from their mothers. Middle: segregation of X-linked recessive trait when the father is affected. All daughters are carriers, and all sons are normal noncarriers. Bottom: segregation of X-linked trait when the mother is a carrier. Each son has a 50% risk of being affected and each daughter is a 50% risk of being a carrier.
the case of osteogenesis imperfecta.205 When the mutation is known, it may be possible to look at sperm from a phenotypically normal father to determine whether he has germ line mosaicism. Alteration of a single gene can have a profound phenotypic effect, indeed as great as adding or deleting an entire chromosome. The effect of a mutation, while limited to a single metabolic
At the interface of genetic etiology and environmental etiology is multifactorial (bifactorial) causation, which requires the combined influences of both. Hereditary and environmental factors collaborate to cause certain malformations, other morphologic characteristics, and functional disabilities. Implicit in the multifactorial concept is the notion that the individual genetic or environmental factors involved lack the power to produce an abnormal phenotype but that multiple factors, heritable and environmental, can do so through their additive influence.208,209 By definition, if genes from two or more loci participate, the genetic component is polygenic. Multifactorial causation is broadly accepted, the evidence for it based on the recurrence risks for certain phenotypes within a family being greater than that for the general population but significantly lower than Mendelian expectation, the high but incomplete concordance in monozygotic twins, and the significantly lower but not negligible concordance in dizygotic twins. Isolated neural tube defects, cleft lip/palate, and certain cardiac defects meet these criteria and are considered to be malformations with multifactorial causation (Table 1-11). No example can be given, however, in which the genetic components and the environmental components have been fully elucidated, although there are suggestions that the combination of maternal smoking and certain predisposing genes may markedly increase the risk for facial clefting. Multifactorial causation is also considered responsible for phenotypes found in the extremes of continuous morphologic variation and for phenotypes found only beyond a developmental threshold. Continuous Traits
Human characteristics that vary by measurable increments across a broad spectrum are called continuous traits. Morphologic features
Human Malformations and Related Anomalies Table 1-11. Incidence of selected malformations which often have multifactorial causation Malformation
Incidence per 10,000 births
Neural tube defects Anencephaly
5
Spina bifida
5
Encephalocele Cleft lip/palate
1 10
Congenital dislocation of the hip
10
Club foot
12
Pyloric stenosis
30
Cardiac defects
70
included among the continuous traits are head circumference, height, and interpupillary measurement. No abrupt change separates normal from abnormal (Fig. 1-20). Abnormalities of these characteristics are arbitrarily defined as those variations that fall beyond 2 SD in either direction from the mean for a given population. Hence, macrocephaly can be defined as head circumference or volume greater than 2 SD above the mean, microcephaly as head circumference or volume less than 2 SD below the mean, short stature as height less than 2 SD below the mean, and so forth. It should be cautioned that phenotypes defined as abnormal in this system should not be considered absolute, fixed for all time and all populations.210 Rather, they should be considered abnormal only for a given subpopulation, at a given point in time, and in relationship to parental background. Threshold Traits
Traits that do not vary continuously but appear only above a given threshold are called discontinuous or threshold traits. Several of the more common human malformations, notably neural tube defects and cleft lip and palate, are included among these traits (Table 1-11). Characteristics that can be expected in multifactorial causation are as follows.
Fig. 1-20. Distribution curve for height, a trait with continuous variation; 95% of individuals will have measurements between the two arrows (mean ± 2 SD).
33
1. Males and females are affected but often with unequal frequencies. 2. There is an increased risk for recurrence in first-, second-, and third-degree relatives of an index case: 2–5% for firstdegree relatives, about one-fourth as high for second-degree relatives and one-tenth as high for third-degree relatives. (Edward’s approximation211 states that the recurrence risk for first-degree relatives is Hp, where the incidence in the population is p.) 3. The recurrence risk doubles after a second first-degree relative is affected. 4. The recurrence risk increases with severity of the phenotype in the index case. 5. The recurrence risk increases if the index case is of the sex less frequently affected. The nature and number of genes and environmental factors involved in the production of any multifactorial malformation cannot be given. The concept that a vast number of genes and environmental factors must be operative is probably incorrect. Assuming equal environmental and genetic contributions to a hypothetical malformation with a recurrence risk of 2–5%, the number of genes involved in producing the malformation can be as few as three. The only requirement of the environmental factor is that it be operative during the period of embryogenesis. One might suspect nutritional variations to be a strong environmental contributor prenatally, as they are in many multifactorial phenotypes postnatally. 1.5 Environmental Causes of Malformations The uterus serves to shelter, nourish, and protect the conceptus until maturity sufficient for extrauterine viability is reached. When any of these basic functions fails, the organism can suffer pathologic consequences. The available safe-guards are simply insufficient to protect against every environmental exposure that may be imposed through the maternal host.212–217 Noxious insults from the environment usually reach the developing organism by way of the vascular system and placenta, less commonly by direct penetration through the uterine wall, and rarely by ascent through the os cervix. Environmental insults after fertilization that produce structural defects are termed teratogens, from the Greek word teratos (monster) and gen (producing). Because of this derivation, it seems inappropriate to classify influences as teratogenic unless they can cause structural defects. However, many teratogens are known to lead to functional as well as structural abnormalities. Agents that cause visual impairments, hearing impairments, or mental retardation are not teratogens unless (in the process) they malform the eyes, ears, or brain. Nor should chromosome aberrations or mutations be considered teratogenic. The term is reserved for environmental insults. Teratogenic potential is largely limited to the period of organogenesis, although certain insults, primarily ones mechanical in nature, can produce deformation or destruction of tissues after the embryonic period. Certain chemicals (e.g., alcohol, warfarin, mercury) and infections (e.g., rubella, herpes, varicella, syphilis) may disturb growth and tissue maturation after the period of organogenesis. By and large, environmental exposures are sporadic events with a low likelihood of recurrence. However, they are likely to
34
Overview
interact with the genotype of both mother and embryo/fetus. Teratogenic effects recur in successive pregnancies only if the environmental exposure and genetic susceptibility recurs. Environmental insults can indirectly affect the conceptus by causing ill health in the mother. General systemic toxicity may accompany radiation exposure or certain infections, leading to abortion although no specific damage has been caused to the tissues of the conceptus. Alternatively, environmental insults can produce chromosome damage or mutation in the developing conceptus that in turn leads to abortion, malformation, or other injury. Radiation and certain chemicals have this potential. Occurring after fertilization, such induced genetic damage will affect only a portion of the cells, will become heritable only if germ cells are involved, and should not be considered teratogenic or hadegenic. Teratogens directly influence development by interfering with cellular metabolism, altering timing, placing pressure on developing parts, disturbing regional vascular supply, and killing cells. Metabolism may be disturbed by altering the availability of essential nutrients, inhibiting enzyme activities, blocking mitosis, interfering nonmutationally with nucleic acid function, and impairing membrane function, osmolar balance, and energy production.215,217 A certain degree of protection against prenatal environmental insults may be afforded by the genetic constitution of a conceptus. This can be surmised from the variable rates at which identical insults induce malformations in different strains of experimental animals218 and in dizygotic twins. It explains in part the variable rates of specific malformations among the different human races.219 However, some teratogens have sufficient potency that they cannot be neutralized by genomic protection. Thalidomide apparently represents such a teratogen. It must be suspected that the genotype of the mother can also diminish or enhance the susceptibility to teratogenic influences as well. The time during pregnancy when the environmental exposure occurs greatly influences the effects. An insult that produces teratogenic effects during organogenesis may have no apparent later effects or may influence subsequent growth and physiologic function. For example, prenatal rubella infection during the first 2 months produces cardiac defects; infection after the fourth month produces deafness; and infection at any time causes growth impairment. For teratogenic effects to occur, the environmental agent must gain access to the conceptus or induce disturbances in the mother that are then reflected in the conceptus. Certain chemical agents, because of their size, transport, or binding properties, do not reach the conceptus even though they may be present in the maternal circulation. Many hormones are typical of this phenomenon. They exert their influence via metabolic changes in the mother that can then be imposed transplacentally. Most teratogenic influences are dose dependent: the greater the exposure, the greater the likelihood of adverse effects and the greater the severity of the effects produced. Radiation
Radiation, a ubiquitous environmental influence, has the potential to produce fetal death, growth impairment, somatic abnormalities, mutation, chromosome fragmentation, and malignancy. Ionizing radiation from any source—natural, conventional x-ray machines, isotopes, or nuclear explosions—carries this potential. Radiation-induced pathology in the conceptus presumably arises because of impairment of cell division, cell death, mutation, and chromosome damage.220
All persons are inescapably exposed to low doses of naturally occurring radiation. At the surface of the earth the magnitude of this exposure is about 125 mrad per person per year, but can vary several fold in different locations around the world. A rad is the unit of absorbed energy equivalent to 100 ergs per gram of tissue. For example, from a chest radiograph, an individual receives onethirtieth of a rad of radiation to the chest wall. Nearly one-half of naturally occurring radiation derives from the land, the structures thereon, and the air; 30% from cosmic sources; and 20% from ingested radionuclides. Less than 5% of radiation in the general environment derives from nuclear-powered reactors or residual fall-out from nuclear explosions. The discovery of x-rays in 1895 and subsequent efforts to exploit the properties of ionizing radiation for diagnostic and treatment purposes have increased the average exposure 50–100% over the natural background radiation. An approximation of the radiation dosage to the fetus or embryo from diagnostic radiographic examinations of the mother can be deduced from the ovarian dosages given in Table 1-12.221 Although the total human exposure to intrauterine radiation fortunately is limited, sufficient data have been gained from medical radiation and from the nuclear explosions at Hiroshima and Nagasaki to delineate the major effects on the conceptus. By the time of birth, the usual infant will have received about 90 mrad of radiation from the natural environment and possibly an equal amount from medical procedures. The effects from this low level of radiation exposure are not measurable. Although the low level of radiation exposure may contribute in some minor way to mutation rate, it does not make a discernible contribution to the abortion, congenital malformation, and growth impairment rates or to any other measure of ill health in the embryo or fetus. Much higher exposures are required to reach the threshold of overt effects. Each year approximately 15–20% of women between ages 15 and 35 years will have abdominal or pelvic radiographs. The radiation dosage from such exposures is usually low, but always causes alarm if the woman is subsequently found to be pregnant. The radiation doses received by the uterus during various medical procedures are listed in Table 1-12.221 The most commonly encountered exposure is a dose of 0.5 to 2 rads from intravenous pyelography, barium enema, or pelvic computerized tomography. With these levels of exposure no gross defect or growth impairment is to be expected in the offspring regardless of the time of the exposure; however, the possibility of intrauterine growth retardation has recently been raised.221a The possibility of mutational injury must be considered, but no practical means of detecting such injury currently exists.222 Mutations to the germ line of the in utero embryo or fetus can lead to a transgenerational effect. Progressively greater resistance to the lethal effect of radiation is gained as the conceptus passes through the preimplantation, embryonic, and fetal periods. Exposure during the preimplantation period either kills the conceptus or leaves no overt trace of injury, suggesting that the teratogenic and lethal doses do not differ significantly during this time. Radiation doses in excess of 10 rads may be lethal during the first week postfertilization. The minimum lethal dosage steadily increases from 25 to over 100 rads between the first and last weeks of embryogenesis. In the early decades of this century x-rays were used to induce abortion. In the majority of cases (96%), a single dose of 360 rads to the uterus prior to 14 weeks gestation resulted in abortion.223 Impairment of growth is the most sensitive measure of radiation effect on the embryo and fetus.220 During embryogenesis,
Human Malformations and Related Anomalies
Table 1-12. Estimated ovarian radiation dose from various diagnostic radiographic procedures
Examination
Estimated Ovarian Radiation Dose (millirads)
Barium Enema Total
805
Radiography
439
Fluoroscopy
366
Upper Gastrointestinal Series Total
558
Radiography
360
Fluoroscopy
198
Intravenous or retrograde pyelography
407
Hip
309
Abdomen
289
Lumbar spine
275
Cholecystography
193
Pelvis Thoracic spine
41 9
Chest Radiography Photofluorography Fluoroscopy Skull
8 8 71 4
Cervical spine
2
Upper extremity (excluding shoulder)
1
Shoulder
<1
Lower extremity (excluding hip)
<1
Penfil RL, Brown ML: Genetically significant dose to the United States population from diagnostic medical roentgenology, 1964. Radiology 90:209, 1968.
35
dosage and less concentration in the thyroid gland. Diagnostic procedures with isotopes other than 131I are unlikely to expose the fetus to hazardous levels of radiation. Microwaves, Shortwaves, and Radiowaves
Radiation from exposure to radiowaves, shortwaves, and microwaves can produce tissue heating, and, hence, may disturb embryonic development. Shortwave radiation can penetrate deeply enough into solid tissues to reach the human fetus and, thus, is a greater potential hazard than microwaves.231,232 Microwaves have limited penetration power, reaching 3–4 cm below the skin surface, and thus have limited access to the human embryo and fetus. Microwave ovens and diathermy machines produce radiation in this wave length (2450 mHz). There is no current evidence indicating that radiowaves, shortwaves, or microwaves can cause nonthermal injury to the developing embryo. Magnetic Fields
Human exposures to magnetic fields result primarily from video display terminals and magnetic resonance imaging (MRI) machines. Neither type of exposure has caused malformations, but the risk for pregnancy loss may be increased.233 Ultrasound
Diagnostic ultrasound is used in the majority of pregnancies during the first and second trimesters. Although usually performed to determine fetal age, ultrasound is also used to document fetal movement, placental location, number of fetuses, number of corpus luteum, growth increments, and certain malformations. Such examinations use ultrasound in microsecond pulses separated by 1–2 sec pauses and have not been associated with any adverse effect on the fetus.234 Continuous wave ultrasound can, of course, disrupt cellular structure and can generate tissue destruction through thermal effects. McLeod and Fowlow235 described growth impairment, microcephaly, sacral dysgenesis, and developmental impairment in an infant born following therapeutic ultrasound to the psoas bursa of the mother at days 6 to 29 postovulation. Hyperthermia and Hypothermia
25 rads or more are required to impair growth. Some degree of recovery from growth impairments caused during embryogenesis may be anticipated postnatally. Fifty or more rads are required to impair fetal growth. Growth impairment during this period is less likely to improve during the postnatal period. The brain and eyes sustain the brunt of radiation injury during embryogenesis.224–228 Dosages in excess of 25 rads are required for discernible damage. Microcephaly, hydrocephaly, microphthalmia, optic atrophy, retinal dysplasia, and cataracts have all been reported, usually following exposures to 100 rads or more.224–226 Skeletal, visceral, and genital abnormalities have been noted less commonly. Growth impairments always accompany these more specific abnormalities. Isotopes
Radiation from radionuclide use during pregnancy occurs much less commonly than radiation from x-rays. Various 131I preparations commonly used before the 1970s for isotopic scanning have the disadvantage of concentration in the thyroid gland. If administered to a pregnant woman after 10 weeks gestation in sufficiently high doses, 131I can ablate the fetal thyroid gland, resulting in hypothyroidism.229,230 131I has been largely replaced by technetium pertechnetate, which causes less total radiation
Elevation of maternal temperature, primarily from sauna or hot tub bathing and from infection, has been implicated as a hazard to the human embryo.236–238 Although much of the information on this subject has been retrospectively collected, its consistency with results from animal experiments makes hyperthermia a plausible teratogen. Abnormalities have been experimentally induced in a variety of species by raising the core temperature of pregnant dams with pyrogens, external heat sources, microwaves, and shortwaves. Abortion can result from heating prior to implantation, and abortion, resorption, malformation, growth impairment, perinatal death, and functional impairments can result from heating after implantation. Early in embryogenesis, the central nervous system appears most vulnerable, presumably because of its rapid rate of mitosis. Heat injury to this target tissue is manifested by temporary interruption of mitosis and cell death of periventricular cells and, to a lesser extent, of deeper mesenchymal cells.239 Depending on the timing, duration, and degree of hyperthermia, growth impairment and various structural changes can be produced. Smith and associates provided suggestive evidence that in humans 11% of pregnancies resulting in anencephaly and 7% of those resulting in spina bifida had a history of temperature elevation during the first few weeks of gestation.236–238 They subsequently found that a maternal temperature elevation of 1.58C or
36
Overview
more, prolonged for 1 day or longer between weeks 4 and 14, could result in more subtle damage to the conceptus. All infants born after such exposures were mentally retarded, usually showing other evidence of neurologic insult, including hypotonicity, hypertonicity, contractures, and seizures. Microcephaly was found in two patients and neuronal heterotopias were present in the two patients at autopsy. Facial changes, predominantly seen in those exposed prior to 7 weeks’ gestation, included microphthalmia, micrognathia, midface hypoplasia, abnormal pinnae, and cleft lip and/or palate. Maternal hyperthermia has also been noted in the pregnancy history of infants born with Mo¨bius syndrome (oromandibulo-limb hypogenesis syndrome).240,241 In light of these findings, it is reasonable to treat elevation of maternal body temperatures to avoid potential damage to the fetus while also determining the cause of fever in the mother. Prolonged and limited periods of hypothermia have been associated with fetal death and malformations in experimental animals as well. Damage from gestational hypothermia has not been reported in humans.
Infectious processes influence the developing organism through a number of well-defined and theoretical mechanisms.212–214,242,247 Cell death and depletion result in tissue or organ hypoplasia and generalized growth impairment. Continuing nonlethal infection of cells can impair mitosis, which again inhibits local and overall growth. Vasculitis can lead to microinfarcts, calcium deposition, and cavitation of tissues. Suppressed hematopoiesis and hemolysis can cause anemia and increased cardiac burden. Cytokines associated with maternal infections may have very different effects in the developing conceptus. With the exception of T. pallidum, organisms that cause septicemia can cross the placenta at any stage during pregnancy. The time of infection to some degree influences the effects on the fetus, as does the fetus’ immunologic response to the infection. Infectious processes can further influence pregnancy maintenance and development of the conceptus by causing hyperthermia, general toxicity in the mother, or mutation or chromosomal damage in the conceptus.247 Viruses
Prenatal Infections
A substantial dichotomy often exists between the severity of infection in the maternal and prenatal organisms. Covert maternal infection is the rule. In contrast, the embryo or fetus may sustain devastating injury to all organ systems. Not uncommonly, the first evidence that the mother has harbored an infection comes with the birth of the affected infant. A wide spectrum of microbial organisms can adversely affect the embryo or fetus.212,242–246 It must be suspected, in fact, that any organism that can gain access to the conceptus can act as a pathogen. Women acquire certain important infections, including syphilis, gonorrhea, herpesvirus, cytomegalovirus, human immunodeficiency virus (HIV), and chlamydia, through venereal transmission. Other infections can be acquired through respiratory spread (rubella, varicella, coxsackievirus, parvovirus), through contact with infected blood products (HIV, hepatitis virus, malaria), through cat litter exposure (toxoplasma), or through uncooked meat (toxoplasma).212,242–246 In virtually all circumstances the conceptus becomes infected through hematogenous spread. Organisms causing maternal septicemia cross the placenta and reach fetal tissues through the fetal circulation. In some cases a placentitis may become established as an intermediate state that seeds the umbilical vessels. Less commonly, organisms from the genital tract may reach the placenta and fetal membranes by retrograde migration. Early postnatal infections can be established through direct contact with microorganisms in the lower genital tract during birth; this mode is responsible for many newborn herpes simplex virus, chlamydial, monilial, streptococcal, and other bacterial infections. Both the maternal cytokines that are a response to the infection and the infectious agent may lead to abnormalities in the embryo or fetus. Twenty-five percent of women between ages 15 and 35 years lack immunity for viral organisms known to be embryopathic or fetopathic. A primary infection by these organisms can result in maternal septicemia and the accompanying risk for transplacental spread. Recurrence in subsequent pregnancies should not be anticipated. Since prior infection with certain organisms, including Treponema pallidum, gonococcus, streptococcus, and herpesvirus does not confer immunity, all women are susceptible to infection or reinfection during pregnancy. All women as well are susceptible to HIV infection. Recurrence or persistence of infection through several pregnancies is possible for organisms of this type.
Cytomegalovirus
Once considered a uniformly fatal process, prenatal cytomegalovirus infection is now known to cause remarkably diverse pathology.247–252 In its most severe form, cytomegalovirus causes intrauterine growth retardation, hepatitis, meningoencephalitis, and pneumonitis. Growth impairment continues postnatally. The necrotizing meningoencephalitis results in microcephaly, periventricular calcification, mental retardation, seizures, deafness, and motor deficits (Fig. 1-21). Uncommonly, obstructive hydrocephalus occurs. Optic atrophy and chorioretinitis can leave residual visual impairment. Other findings include hepatosplenomegaly, thrombocytopenia, localized purpura, and hemolytic anemia. Morphologic features, inguinal hernias, microcephaly, hydrocephaly, and microphthalmia result from the continuing infectious damage rather than from developmental disturbance during the period of organogenesis. Milder infections can cause functional deficits without morphologic changes. Subclinical cases with neither morphologic nor functional changes have been documented with serologic testing. Herpesvirus
Type I herpes simplex virus generally infects the cornea, the skin of the face and upper trunk, and the oral mucosa; type II usually infects the genitalia. The type can be determined by serologic and virologic methods. Type II herpesvirus (genital type) appears to be the more important in prenatal infections. Antibodies against the two types cross react, but the antibody of one type does not prevent infection by the other type, although spread of the virus may be limited. It has been suggested that transplacental infection might occur only in the absence of prior maternal infection by either type. Of the few case reports of herpes simplex virus infection during early gestation, only the reports of Schaffer253 and South et al.254 can be accepted without reservation. In both infants the virus significantly involved the central nervous system with residual microcephaly, cerebral calcifications, microphthalmia, retinal dysplasia, tone disturbance, and seizures. Vesicles containing the virus were present on the limbs of both infants at birth. Late infection is usually contracted at birth rather than prenatally. Severe infection occurs, nonetheless, with most cases
Human Malformations and Related Anomalies
37
Fig. 1-21. Prenatal cytomegalovirus infection. Left and middle: dense periventricular calcification in severely microcephalic infant. Right: marked microcephaly, spasticity, and mental retardation in a 30-month-old male with prenatal cytomegalovirus infection. (Courtesy of Dr. Charles I. Scott, Jr, A. I. duPont Institute, Wilmington, DE.)
being fatal during the first year of life. The cutaneous vesicle is a hallmark of infection and may be present at birth if infection occurred transplacentally or may develop during the first 2 weeks of life if infection occurred during birth. Widespread infection with tissue necrosis involves most organs, particularly the brain and liver. Varicella-Zoster Virus
Varicella can be transmitted transplacentally at any time during pregnancy. First-trimester varicella can cause meningoencephalitis, cutaneous lesions, and diffuse visceral involvement.254–256 Such infections are usually fatal; those who survive may have residual optic atrophy, microphthalmia, chorioretinitis, cortical atrophy, seizures, or motor disabilities. Similar features have been observed following herpes-zoster infection during the first trimester. Infection with varicella late in pregnancy may cause fetal infection, which is manifest by cutaneous vesicles at birth or during the initial weeks of life.257 Rubeola
While there is no doubt that rubeola virus can reach the conceptus during the phase of maternal viremia, malforming and destructive effects on the fetus have not been recognized. Abortion and stillbirth rates following maternal rubeola are not excessive. Scattered reports of congenital defects have documented no consistent pattern, and the defects should not be considered rubeola defects. Influenza
Following the 1957 influenza pandemic, Coffey and Jessop258 reported an increased incidence of central nervous system malformations among infants born of Irish mothers who had influenza during pregnancy. An increased incidence of malformations was not found in other studies that utilized serologic evidence to confirm influenza virus infection. There is no compelling evidence that points to influenza virus infection as a cause of malformations. Maternal fever and increased drug use often accompany influenza and must be taken into account in cases of malformations following infection during pregnancy.236–238
Mumps Virus
Infection with mumps during pregnancy does not cause malformations but may result in abortion or stillbirth. Patients with endocardial fibroelastosis have been noted to have a positive mumps antigen skin test, but the relationship of mumps virus infection to this cardiomyopathy is obscure.259 The long-term fertility of the male conceptus does not seem to be effected. Rubella
In the decades since Gregg’s report of cataracts in infants born of mothers who had a rubella infection during the first trimester, a vast body of information on the embryopathy caused by this virus has accumulated.260–264 The risk of fetal involvement resulting from maternal infection during the first month is 50% or greater and decreases with each successive month. Infection following the 8 weeks of organogenesis can cause deafness, microcephaly, and mental retardation. Rubella infection during the first trimester is accompanied by abortion (10%) and stillbirth (4%), with higher rates of fetal death during the first 2 months. Characteristically, rubella virus infection during the first trimester affects the developing eye, ear, and heart. Over one-half of infants have unilateral or bilateral hearing loss, primarily the sensorineural type. Likewise, retinopathy, nuclear cataract, glaucoma, microphthalmia, and myopia affect over one-half of infants (Fig. 1-22). Defects of the major arteries far outnumber the intracardiac lesions caused by rubella. Patent ductus arteriosus and pulmonary artery stenosis are the two most common cardiovascular defects. Intracardiac lesions, although less frequent, may be more significant in terms of hemodynamic disturbance. Pulmonary valvular stenosis, aortic valvular stenosis, and ventricular septal defects are the most common intracardiac lesions. Continuing infection impairs growth, interrupts bone growth and maturation, causes pancytopenia, and produces widespread visceral involvement. Surviving infants have residual growth and neurologic impairments. The degree of postnatal growth impairment parallels the degree of mental deficit, presumably reflecting the duration and severity of infection.263 Rarely, some women do not mount a normal immunologic reaction to rubella
38
Overview
tion usually occurs transplacentally, although intrapartum infection may account for some cases. During the first year of life, infected infants exhibit growth retardation, microcephaly, seborrheic dermatitis, adenopathy, and recurrent infections.266–268 Anemia, reversal of the T4:T8 lymphocyte ratio (<1), and hypergammaglobulinemia usually accompany the clinical findings. Mortality is high, with the majority of deaths occurring during the first 2 years of life. Malformations as a part of prenatal HIV infection have not been reported. Facial features consisting of a box-like cranial configuration with frontal bossing, prominent eyes, oblique palpebral fissures, hypertelorism, depressed nasal root, triangular philtrum, and patulous lips have been described in two cohorts of infants and children with prenatally acquired AIDS.269,270 Prudence requires further observation before these morphologic features can be attributed to HIV infection rather than to other environmental or ethnic influences. Other Viruses
Prenatal infections from a number of other viruses have also been documented. They have not resulted in malformations, but they have resulted in significant fetal pathology. Coxsackievirus infections have been associated with fetal pancarditis and meningoencephalitis; poliovirus with abortion, stillbirth, and meningomyelitis; echovirus with disseminated viremia; variola and vaccinia with necrotizing cutaneous and visceral infection; and hepatitis viruses with neonatal hepatitis.212,271–278 The effects of SARS and West Nile virus during pregnancy are not yet known. Chlamydia
Fig. 1-22. Prenatal rubella. Cataracts (top; left removed) and glaucoma (bottom) in prenatally infected children.
Infection with Chlamydia trachomatis is considered to be the most prevalent venereally transmitted disease among pregnant women. While some studies have found infection to be associated with premature rupture of fetal membranes, premature delivery, and perinatal mortality, no association with malformations has been documented.279 Mycoplasma
and may harbor the virus, leading to repeated infection of offspring. Parvovirus
Human parvovirus B19 causes erythema infectiosum in children and a nonspecific arthropathy in children and adults. The virus can also cause erythrocyte aplasia in patients with chronic hemolytic anemias or immunological impairments. As many as one-third of the fetuses born to women who have a primary B19 infection during pregnancy become infected.265 Fetal infection generally results in nonimmune hydrops fetalis and death. The pathogenesis has not been clarified, but presumably involves impairment of erythrocyte production, hemolysis, or direct infection of cardiac muscle alone or in some combination. Malformations do not result from human parvovirus B19 infection. Human Immunodeficiency Virus
In the decade since its introduction into the United States, HIV infection has become the most common serious infection during pregnancy and the most common prenatal infection. From 30% to 50% of infants born to HIV seropositive women will develop AIDS or HIV-mediated disease.266–270 It is thought that prenatal infec-
Placental colonization with Mycoplasma is commonly found at delivery.280 Prematurity and low birth weight may be associated with genital mycoplasmic colonization.281 Malformations are not known to be caused by Mycoplasma. Bacteria
Sepsis from a number of bacterial organisms can cause abortion or stillbirth, but does not cause malformations.212,282 Bacterial infections are of greater concern as a cause of perinatal or newborn infections. Sepsis, pneumonitis, and meningitis can be caused by Eschericha coli and other coliform organisms, Listeria monocytogenes, Campylobacter fetus, non-group A b-hemolytic streptococcus, and Staphylococcus. Neisseria gonorrhea is an important cause of generalized ophthalmitis in the newborn. Tuberculosis can be transmitted transplacentally or postnatally. Spirochetes T. Pallidum
Syphilis is the major spirochetal infection of significance to the fetus. Always one of the most prevalent and devastating fetal infections, it has not disappeared with the advent of effective therapy.283,284 For
Human Malformations and Related Anomalies
unknown reasons, the syphilis spirochete usually does not reach the conceptus during the first trimester; hence, it is not an important cause of abortion or malformation.285 Malformations of the permanent teeth may occur and include abnormal tapering of the incisors, enamel-covered notching of the central incisors, and crowding of the cusps of the first molars (Fig. 1-23).286 These malformations are caused by infection after the period of organogenesis. T. pallidum is disseminated through hematogenous spread to every organ system, but with predilection for skin, mucous membranes, liver, central nervous system, and bones. Most severely involved fetuses die from widespread tissue damage. Hydrops fetalis is a well recognized but uncommon presentation.287 Less severe infection can produce intrauterine growth retardation with or without active signs of syphilitic involvement at birth.212 Scarring or destruction of tissues and incomplete resolution of proliferative processes produce certain morphologic changes after the active infectious stage of prenatal syphilis.288 These predominantly facial changes include frontal or frontoparietal bossing, saddle nose, rhagades, and mandibular overgrowth. Chorioretinal
39
lesions can also occur. Perforation of the palate or nasal septum can result from gummatous tissue reaction and destruction. Saber shins and hydrarthrosis can result from skeletal involvement. Most of these morphologic changes can be prevented or made less severe by early detection and treatment. Leptospirosis and Lyme Disease
Fatal leptospirosis, presumably acquired in utero, has been described in a newly born infant, but was not associated with congenital anomalies.289 Transplacental passage of the Lyme spirochete has been documented, and it has been associated with a variety of adverse pregnancy outcomes.290 A causal relationship between infection during pregnancy and malformations has not been established. Fungi
One-third or more of pregnant woman harbor Candida species in the genital tract. In most instances these organisms are nonpathogenic, existing in a saprophytic relationship with the host. By virtue of their location in the birth canal, they can contaminate the infant during birth and, in rare instances, have reached the
Fig. 1-23. Prenatal syphilis. Four stigmas of prenatal infection with syphilis: Top left: corneal scarring from interstitial keratitis. Top right: enamel-covered notching of permanent central incisors. Bottom left: perforation of the palate from gummatous involvement. Bottom right: saber shins from incomplete resorption of periosteal bone formation. (Courtesy of Dr. James Millar, Centers for Disease Control, Atlanta, GA.)
40
Overview
fetus during intrauterine life. Candida species have not been implicated as a cause of malformations. Chorioamnionitis uncommonly occurs, often related to a retained contraceptive device or to cerclage.291 Extension to the fetus can cause death or early delivery of an infant with disseminated infection. Protozoa Toxoplasma Gondii
Primary maternal infection with T. gondii occurs in 1 per 1000 pregnancies in the United States.212,292 Higher incidences can be found in other countries, notably Mexico and France. Infection is disseminated to the fetus in 40% of the cases. The organisms gain access to the fetal circulation from foci in the placenta and become widely distributed to all tissues. The clinical signs of toxoplasmosis result from chronic destructive infection of the tissues. The height of the tissue reaction occurs during the first few months of life. Thereafter the signs of active infection may not be discernible, even on pathologic examination. However, the consequences, generally cerebral and ocular, may continue to appear over a number of years. Organisms have been recovered from the brain of a congenitally infected infant at age 5 years. Malformations are not a part of the pathology of prenatal toxoplasmosis. Hydrocephaly and microcephaly result from chronic destructive meningoencephalitis and should not be considered teratologic effects of the parasite. Little evidence has been accumulated to demonstrate fetal involvement during the period of organogenesis. The classic triad of congenital toxoplasmosis— chorioretinitis, hydrocephaly, and cerebral calcifications—has become accepted as the most common presentation of infants infected prenatally. This is unfortunate in that it encourages the observer to dismiss the diagnosis if cerebroocular signs are lacking. Signs and symptoms vary considerably in different infants and can change over time in the same infant.292–294 Regardless of the predominant signs in a particular infant, significant residual damage to the central nervous system may become apparent after a period of years. This can occur even in children who show no signs of infection during infancy. The most common residual findings are chorioretinitis, blindness, and impaired intellect (Fig. 1-24).
Malaria
Although placental infection with malaria is a common event, prenatal infection of the fetus is decidedly rare. Infected fetuses can be growth impaired, and the infection usually results in stillbirth or in continuing infection in the neonatal period that is usually fatal.295 Although sickle cell hemoglobin heterozygosity and being a carrier for glucose-6-phosphate dehydrogenase confer resistance to death from malaria, they do not seem to have any protective effect for the fetus. Prion Diseases
Although prion diseases can be inherited, as in the case of Creutzfeldt-Jakob disease, there are no reports of transplacental infection from bovine encephalopathy or scrapi. Prenatal Drug and Chemical Influences
The intimate intraplacental relationship between maternal and fetal circulations that permits the exchange of essential chemical substances also allows chemical disturbances to be reflected transplacentally.212–216 Most soluble constituents of maternal serum cross the placenta by simple or facilitated diffusion. Substances that diffuse poorly because of molecular size, degree of ionization, lipid insolubility, or adverse concentration gradient may be delivered to the fetus by active transport or by pinocytosis. Small leaks in the villous membrane would allow gross cross contamination of maternal and fetal circulations, but this leakage is probably not an important mechanism in the transfer of physiologically active substances. In any given case, the transport of a substance across the placenta may be altered by pathologic changes in the placenta, disturbances in maternal or fetal blood flow, or aberrant metabolism by the mother, fetus, or placenta. Transport is facilitated late in pregnancy by a thinning of the villous membrane. Disorders of fetal metabolism are in most cases compensated for by the mother. Hence the fetus with phenylketonuria or hypothyroidism is protected, at least in part, during intrauterine life. Conversely, the limited metabolic capabilities of the fetus may be insufficient to sustain homeostasis in the face of chemical disturbances imposed by the mother. Both exogenous substances,
Fig. 1-24. Prenatal toxoplasmosis. Left and middle: microcephaly and diffuse cerebral calcifications in a mentally retarded adult with prenatal toxoplasma infection. Right: punched out chorioretinal lesion in macular region. (Courtesy of Dr. David Knox, Johns Hopkins Hospital, Baltimore, MD.)
Human Malformations and Related Anomalies
Table 1-13. Teratogenic drugs and chemicals Teratogenicity Proven/Likely
ACE inhibitors
Lithium
Alcohol (ethyl)
Methimazole
Aminopterin, methotrexate
Methyl mercury
Androgens
Methylene blue
Busulfan
Misoprostol
Carbamazepine
Penicillamine
Carbimazole
Propylthiouracil
Chlorobiphenyls
Tetracycline
Cocaine
Thalidomide
Coumarin
Toluene
Cyclophosphamide Diethylstilbestrol
Trimethadione, paramethadione
Diphenylhydantoin
Valproic acid
Fluconazole
Vitamin A
cephaly, neural tube defects, urogenital abnormalities, hemangiomas, and radial ray deficiencies.299 Frank mental retardation occurs in one-half of children with prenatal alcohol syndrome. Mental retardation can be accompanied by muscle weakness, poor coordination, tremors, hyperactivity, reduced attention span, speech impairment, strabismus, and sensorineural and conduction hearing deficits. Structural and functional impairments occur in up to one-half of infants born of alcoholic women who drink heavily (3 oz absolute alcohol daily) during pregnancy. Functional and growth disturbances without other morphologic changes can occur in infants whose mothers drink moderately (1–2 oz absolute alcohol daily). No adverse effects have been documented in infants of mothers who drink less than 1 oz absolute alcohol daily. The possibility that subclinical damage may be reflected later in school and work performance cannot be excluded. Because of our limited understanding of the effects of prenatal exposure to alcohol, total abstinence from alcohol during pregnancy is a wise precaution. Cocaine
Iodides Isotretinoin, etretinate Teratogenicity Controversial/Doubtful
Agent Orange
41
Metronidazole
Aspartame
Oral contraceptives
Aspirin
Retinoids (topical)
Bendectin
Rubella vaccine
Cigarette smoking
Spermicides
Corticosteroids
Streptomycin
Lead
Vitamin D
Marijuana
Zinc deficiency
usually in the form of drugs, and metabolic deficiencies and excesses reflecting maternal disease states are important in this regard. Drugs and chemicals known to have teratogenic potential are given in Table 1-13. Alcohol
In 1973, Jones et al.296 called attention to the effects of prenatal exposure to alcohol, renewing concerns about alcohol use during pregnancy that had existed since the early Greek city-states.297,298 They described a pattern of malformations and other morphologic changes, growth impairment, and cognitive defects among infants of chronic alcoholics. This prenatal alcohol syndrome is now recognized as one of the most common causes of birth defects among patients with mental retardation. Reduced head circumference, length, and weight present at birth persist postnatally. Facial characteristics, largely reflecting impaired brain growth, consist of small eyes and short palpebral fissures, ptosis, epicanthus, midface hypoplasia, long and smooth philtrum, and thin upper lip (Fig. 1-25). Atrial and ventricular septal defects are the most common of a wide variety of cardiac defects. Radioulnar and cervical vertebral fusions, camptodactyly and other joint contractures, hip dislocation, deformations of the feet, hypoplastic distal phalanges and nails, and altered palmar creases are skeletal components of the full syndrome. Less common defects include protuberant ears, cleft lip/palate, hydro-
During the 1980s, cocaine became one of the most commonly used recreational street drugs among pregnant women. One in 10 women in the United States use cocaine during pregnancy. Among the wide range of abnormalities now being reported in infants of cocaine users, most appear related to the propensity of the drug to affect the cardiovascular system.216,300–303 A 10-fold increased risk of stillbirth relates almost exclusively to abruptio placenta. Vascular-based disruptions, skull defects, cutis aplasia, porencephaly, ileal atresia, visceral infarcts, genitourinary abnormalities, and limb reductions constitute most of the structural defects. Intrauterine growth impairment and cardiac defects have also been reported. Collectively these defects affect less than 10% of infants. A similar low percentage of infants exhibit withdrawal symptoms during the neonatal period. Necrotizing enterocolitis has been reported as a possible postnatal vascular complication. The incidence of sudden infant death syndrome appears to be increased. Cigarette Smoking
Increased pregnancy loss accompanies maternal cigarette smoking.216,304,305 Abruptio placenta and placenta previa account for most fetal and neonatal deaths, although the specific mechanism by which smoking causes fetal loss is unknown. Uterine ischemia with secondary decidual necrosis results from smoking and offers a plausible explanation for the increased risk of abruptio placenta. The fetus grows more slowly when the mother smokes.216,304,306,307 The growth impairment parallels the amount of smoking. Infants of mothers who smoke more than one pack (20 cigarettes) per day weigh up to 300 g less than expected. The growthretarding properties of smoking probably act throughout pregnancy. Certainly weight reduction can be seen in infants born at any time during the third trimester. Altered caloric distribution to the fetus, placental dysfunction, fetal hypoxia, and direct chemical toxicity of compounds in tobacco smoke can contribute to prenatal growth impairment. Postnatal catch-up growth occurs during the first year of life. Marijuana
Although a dose-related reduction in birth weight has been found in infants of mothers who used marijuana, neither major malformations nor patterns of malformations have been identified among these infants.308
42
Overview
Fig. 1-25. Prenatal alcohol syndrome. The 3-year-old boy at left has microcephaly, left ptosis, short palpebral fissures (<3rd percentile), smooth philtrum, thin upper lip, fingernail hypoplasia, and developmental delay. The 27-month-old girl at right has short stature, microcephaly, midface hypoplasia, short palpebral fissures (<3rd percentile), smooth philtrum, thin upper lip, and developmental delay. Lysergic Acid Diethylamide (LSD)
Chromosome breakage of leukocytes has been induced in vitro and in vivo by LSD.212,309 The breakage appears transitory and has not been implicated as a cause of malformations or other ill health in infants of mothers who ingested LSD during pregnancy. Several infants of mothers who used LSD have had malformations.212 Although these infants have had no single characteristic malformation, limb and other skeletal anomalies have predominated. The evidence remains insufficient to implicate LSD as a cause of human malformations. Anticonvulsant Drugs Diphenylhydantoin (Dilantin)
Seizure disturbances affect 1 in 300 pregnant women. The majority of affected women require continuous anticonvulsant therapy during pregnancy. Diphenylhydantoin, the anticonvulsant used most commonly, was the first to be suspected of causing intrauterine damage.310 After initial studies linked diphenylhydantoin with cleft lip and palate, a broader syndrome of malformations, other morphologic changes, and functional impairments were attributed to prenatal exposure.311–315 Affected infants have some combination of intrauterine and postnatal growth impairments, microcephaly, hypertelorism, depressed nasal bridge, ptosis, wide mouth, hypoplasia of the distal phalanges and nails, and developmental impairment (Fig. 1-26). Cleft lip and palate and cardiac defects are the most common major malformations. Colobomas, glaucoma, and other ocular abnormalities have been reported, as have diaphragmatic, umbilical, and inguinal hernias. It has been suggested that about 10% of exposed infants will have significant malformations or mental defect, with a somewhat higher percentage having one or more minor features.315 Exposed
infants may also have an increased risk of developing tumors of neural tissue during childhood. Trimethadione, Paramethadione (Triodine, Paradione)
Of the anticonvulsants, trimethadione and paramethadione pose the greatest prenatal hazard.316 One-fourth of pregnancies of women who use trimethadione and paramethadione are spontaneously aborted. One-third of those born die during the first year of life. The majority of liveborn infants have prenatal and postnatal growth deficiency, developmental delay, malformations, and distinctive facies. The distinctive facial features include Vshaped eyebrows with or without synophrys, broad nasal bridge, arched or cleft palate, cleft lip, and malpositioned ears, with anterior cupping and/or excessive folding of the superior helices (Fig. 1-27). A wide variety of major and minor defects in virtually all systems has been reported. Cardiovascular defects, renal malformations, tracheoesophageal anomalies, hernias, and hypospadias are most common. Survivors often have mild to moderate mental retardation and speech impairment. Valproic Acid (Valproate, Depakene)
Reports of an association between valproic acid and spina bifida prompted concern that this anticonvulsant might be an important teratogen.317 The risk for meningomyelocele, primarily lumbar or lumbosacral, appears to be about 1–2% following first-trimester exposure (two- to fourfold higher than the population frequency). Intrauterine growth proceeds normally, but developmental delay, a pattern of craniofacial features, and other malformations have been described.318,319 Bitemporal narrowing, tall forehead with metopic prominence, shallow orbits with epicanthus and infraorbital creases, small nose with flattened bridge, long and flat philtrum, small mouth with thin upper vermilion, rotated pinnae, and micrognathia form a more or less distinctive craniofacial
Human Malformations and Related Anomalies
43
Fig. 1-26. Prenatal hydantoin exposure. A 7-year-old female with prenatal exposure to hydantoin. Fingernails and toenails show marked hypoplasia. Facial appearance and school performance in first grade were normal.
morphology. Cardiovascular defects, oral clefts, inguinal hernias, hypospadias, clubfoot, long thin digits, strabismus, and nystagmus occur in a minority of infants. An overall risk cannot yet be given. Carbamazepine (Tegretol)
Once considered to be the drug of choice for seizure management during pregnancy, carbamazepine has recently been found as the cause of minor facial and skeletal abnormalities.320 In retrospective and prospective observations, Jones et al.320 have found a small percentage of exposed infants to have growth retardation, abnorFig. 1-27. Prenatal trimethadione exposure. Facial appearances of two brothers aged 10 years (left) and 13 years (right) exposed prenatally to trimethadione. Both have V-shaped eyebrows, broad nasal bridge, epicanthus, and low-set retroverted ears with excessively folded superior helices. Both have borderline intellectual function. (Courtesy of Dr. Elaine Zackai, Children’s Hospital of Philadelphia, Philadelphia, PA.)
mal facies, nail hypoplasia, and developmental delay. Craniofacial features include microcephaly, narrow bitemporal diameter, up slanted palpebral fissures, epicanthus, short nose, and long philtrum. Cardiac defects were found in 2 of 8 cases ascertained retrospectively and 1 of 35 cases ascertained prospectively. Methotrexate, Aminopterin
The folic acid antagonists are used primarily in the treatment of psoriasis and certain malignant diseases. Their potent teratogenic properties have been known since the 1950s, when the drug was also used as an abortifacient.321 The folic acid antagonists produce cranial and skeletal malformations (Fig. 1-28).322,323 Bony malformations of the skull include absent or defective ossification, misshapen bones, sutural synostosis, and anencephaly. The globular head, wide-spaced and prominent eyes, depressed nasal bridge, micrognathia, malformed ears, and underdeveloped supraorbital ridges compose a somewhat characteristic facies. Cleft lip and/or cleft palate have been present in several cases. Further skeletal anomalies, including mesomelic shortening of the limbs, dislocated hips and elbows, coalescence of carpals and tarsals, clubfoot, and delayed bone maturation, have been reported. Prenatal and postnatal growth have been severely impaired, but mental development in survivors is only mildly affected.324 Misoprostol
A synthetic analog of prostaglandin E1, misoprostol has been used alone or in combination with mifepristone or methotrexate as an abortifacient, predominantly in South America.325–329 Anomalies, plausibly related to vascular disturbances induced by misoprostol, have been reported in cases where abortion did not occur. They include Mo¨bius facies with cranial nerve palsies, terminal transverse limb defects and other amniotic band-like limb defects, equinovarus foot deformation, arthrogryposis, and hypoplasia of various muscles.
44
Overview
Misoprostol does not appear to cause major malformations, and the overall risk for vascular insults to the fetus following maternal use of misoprostol appears to be low. Thalidomide
Fig. 1-28. Prenatal aminopterin exposure. Photographs at birth and at age 18 months of a girl exposed to aminopterin during the first trimester. Features included globular skull with deficient calcification, low-set ears, ocular hypertelorism, micrognathia, cleft palate, dislocated hips, short forearms, and other minor skeletal anomalies. (Reprinted with permission from Shaw EB, Steinbach HL: Am J Dis Child 115:477, 1968, American Medical Association, copyright 1969.322)
More than any other event, the thalidomide tragedy alerted the world to the teratogenic potential of drugs. A chemical with sedative properties, thalidomide was marketed alone or in various compounds for a wide variety of ailments beginning in 1956. The most extensive distribution was in West Germany, but substantial use occurred throughout Europe and in certain Asian and American countries.330 Thalidomide was available for only 4 years before its teratogenicity was recognized and distribution was halted. Only the unusual and dramatic nature of the malformations accounts for the drug’s teratogenic properties being recognized that quickly. Over 4000 infants are known to have been injured by prenatal exposure. Thalidomide produced malformations limited to tissues of mesodermal origin, primarily limbs, ears, cardiovascular system, and gut musculature.331,332 The types of malformations could be related to the age of the embryo at the time of ingestion. Malformations resulted from repeated use and from single ingestions during the critical period of 20 to 40 days postovulation. Abnormal development of the long bones produced an almost endless and striking variety of limb reduction malformations (Fig. 1-29). Typically the upper limbs were more severely involved than the lower limbs. Of the long bones of the upper limbs, the radius was most frequently involved. However, any of the bones could be defective or, in severe cases, totally absent. The hands in some cases were normally formed; in other cases, the hands lacked thumbs or other fingers; and in still other cases, hands were absent.
Fig. 1-29. Prenatal thalidomide exposure. Left: midline facial hemangioma and upper limb reduction malformation. Middle: microtia. Right: upper limb reduction malformation. (Courtesy of Dr. Helen Taussig, Johns Hopkins Hospital, Baltimore, MD.)
Human Malformations and Related Anomalies
Oligodactyly, syndactyly, and polydactyly occurred. Lower limbs could be similarly affected, but less frequently and less severely. The head and neck escaped gross malformation, and mentation appeared normal. Characteristically, a midline hemangioma extended from the frontal area over the tip of the nose and ended on the upper lip. Ear malformations ranging from agenesis to preauricular tags occurred in one-fifth of cases. Some infants had facial or abducens palsy, usually unilateral. A wide variety of cardiovascular defects were seen, affecting about 10% of infants. Visceral anomalies included agenesis of spleen, gallbladder, and appendix and atresias or stenoses of the esophagus, duodenum, and anus. The mechanism by which thalidomide produced malformations is entirely unknown. Isotretinoin, Vitamin A
Within 1 year of the release of isotretinoin for the treatment of cystic acne, malformations were linked to its use during pregnancy.334 That isotretinoin would affect the developing human was not unexpected because of its known teratogenicity in animals and because of the teratogenicity of the related compounds etretinate and vitamin A in humans. Isotretinoin (Accutane) used during the embryonic period causes an increased risk for spontaneous abortion (40%) and for malformations (25%) among survivors.335–337 Anomalies of the central nervous system, cardiovascular system, and craniofacial structures predominate (Fig. 1-30). Most affected infants have central nervous system defects. Hydrocephaly with or without other structural abnormalities of the cerebrum and cerebellum occurs. The ears are usually small, malformed, or misplaced with atresia of the external auditory canal and underdevelopment of the middle ear. Less common alterations of the craniofacial structures include sloping or narrow forehead, accessory parietal sutures, depressed and wide nasal root, micrognathia, and cleft palate. One-third of the affected infants have cardiovascular anomalies, usually affecting the aortic arch or conotruncal area of the heart. Thymic agenesis, hypogenesis, and/or ectopia may accompany these cardiovascular defects. Isotretinoin defects have been attributed to a disturbance of the migration and influence of the cranial neural crest cells. Lammer et al.338 have also found craniofacial alterations in fetuses exposed only after 60 days postovulation. These infants have prominent metopic sutures, epicanthus, and dimples or creases on the posterior aspect of the ears. Since isotretinoin has a serum
45
half-life of 16 to 20 hr and is not stored in tissue, use prior to conception carries little if any risk during a subsequent pregnancy. Vitamin A intake in excess of 25,000 IU daily during the first trimester has been associated with malformations. Malformations of the central nervous system, facial structures, heart, skeleton, and genitourinary system have been reported.339,340 Although these are insufficient data to conclude that vitamin A is teratogenic, there exists no compelling reason for use of such extraordinary doses during pregnancy. Etretinate
Like its congener isotretinoin, etretinate can cause central nervous system, cardiovascular, and skeletal malformations. It is used primarily in the treatment of psoriasis. In contrast to isotretinoin, etretinate is predominantly bound to lipoproteins and persists in the circulation for years after use. Grote et al.341 have reported unilateral limb defects in a fetus conceived 4 months after the mother’s last dose of etretinate. Vitamin D
Although circumstantial evidence has linked excessive maternal Vitamin D intake and the idiopathic hypercalcemia syndrome (Williams syndrome), most infants born after vitamin D supplementation during pregnancy showed no evidence of the hypercalcemia syndrome. Additionally, excessive pregnancy intake could not be documented in those infants with features present at birth. Williams syndrome is now known to be a genetic disorder, and the possibility that abnormal maternal, fetal, or placental metabolism of vitamin D, calcitonin, or calcium plays a contributory role is considered unlikely. Androgens
Masculinization of the female infant results from exposure to excessive androgens during pregnancy.342–346 Androgens have been used during pregnancy for a variety of reasons, including prevention of abortion. There are currently no acceptable uses of androgens during pregnancy. Contemporary exposures to androgens are more likely to be from endogenous production by maternal tumors or from the use of progestational agents having androgenic activity. Masculinization due to prenatal androgen exposure does not progress after birth, and some measure of regression may occur. Enlargement of the clitoris and labia majora results from androgen
Fig. 1-30. Malformation in an infant exposed to retinoic acid during the first 18 weeks of gestation. Features include hypertelorism, downslanting palpebral fissures, microtia, cleft palate, hydrocephalus, hypoplasia of the cerebellum, and a heart defect. (Courtesy of Dr. Paul M. Fernhoff, Emory University School of Medicine, Atlanta, GA.)
46
Overview
and enlargement of the clitoris and labia majora. The incidence of masculinization varies with the drug, dosage, timing, and duration of usage. The frequency of masculinization following norethindrone (Norlutin) exposure has been reported to be 18%; following ethisterone (Pranone) exposure, 13%; and following medroxyprogesterone (Provera) exposure, 1%.212,343,344 Considerable controversy has surrounded the question of whether progestins cause other malformations.349–354 Several studies have demonstrated an association between progestins and conotruncal cardiac defects,349,350,352,353 neural tube defects,355 limb reduction defects,349,351,356 esophageal atresia,354 and the VACTERL malformations.353 In general, these studies have shown a twofold to fourfold increase in these malformations among infants born of pregnancies in which progestins were used as a pregnancy test, as protection against abortion, or as a birth control measure. Other studies have failed to find such associations.357–359 Further experience is required to determine if there is a causal relationship between progestins and any malformation or whether the associations found in some studies are due to other factors. Diethylstilbestrol Fig. 1-31. Virilization of a female fetus caused by an androgenproducing maternal tumor.
stimulation following formation of the genitalia; labial fusion and inhibition of uterovaginal descent to the perineum requires exposure prior to 10 weeks postfertilization (Fig. 1-31). The severity of these changes depends on the potency of the androgens and on the duration and period of gestation when used. Females exposed to androgen prenatally do not generally experience excessive growth but they may have advanced bone age. The possibility that changes in genital development and bone maturation occur in males has not been investigated. Corticosteroids
Long-standing concern has existed regarding two potential prenatal effects of exogenous corticoids: cleft palate and adrenal atrophy.347,348 One percent or less of infants of mothers receiving corticosteroids will have either of these effects. Importance must be attached, however, to even a low incidence of adrenal atrophy, since it may be life-threatening in the neonatal period. Additionally, the risk of stillbirth appears increased several fold, perhaps to an adverse effect of corticoids on placental function. Progestins
Exogenous sex hormones have been used purposely and inadvertently during pregnancy. Progestin–estrogen combinations have been administered for several days in early gestation as a pregnancy confirmation test, and progesterone and various synthetic progestins have been given on a prolonged basis in an attempt to protect against abortion. Neither use is currently recommended. Estrogen and progestins, used sequentially or in combination as oral contraceptives, may be used for variable periods of time before pregnancy is recognized. While progesterone lacks androgenic properties, certain synthetic progestins have sufficient androgenic activity to cause mild virilization in the user and, when used in pregnancy, to masculinize the female fetus.343,344 Prenatal masculinization is not unlike that caused by maternally administered androgens; that is, manifested by labial fusion, persistence of the urogenital sinus,
As many as 2 to 3 million pregnant women received the synthetic estrogen diethylstilbestrol over a 25-year period prior to 1971.360 In early pregnancy it was used primarily as prophylaxis against pregnancy loss in women who had experienced recurrent abortions. Alarm about prenatal diethylstilbestrol exposure came with the Herbst and Scully361 report of vaginal adenocarcinoma in young women whose mothers had received the drug. Further studies have documented structural changes in the genital tract and abnormalities of menses; reproductive impairment may also be related to prenatal diethylstilbestrol exposure. Over one-half of women exposed prenatally to diethylstilbestrol will have vaginal adenosis in which mu¨llerian mucosa persists over the cervix and upper vagina. Disorganization of the fibromuscular structure of the cervix produces irregular surface anatomy with ridges, protuberances, and sulci. The uterus may be hypoplastic with abnormal configuration and synechiae of the cavity. The fallopian tubes are short and narrow, with short ostia and absent fimbria. These abnormalities contribute in part to excessive menstrual irregularities, impaired fertility, ectopic pregnancies, and preterm deliveries. Approximately one-third of males exposed prenatally to diethylstilbestrol have some abnormality of the reproductive system.362 These abnormalities include small penis with hypospadias or meatal stenosis, cryptorchidism, small testes with induration of the capsule, and epididymal cysts. Impaired sperm production accompanies these structural changes. Angiotensin-Converting Enzyme Inhibitors
Hypoplasia of the skull and renal dysgenesis have been reported among infants exposed during the second and third trimesters to angiotensin-converting enzyme (ACE) inhibitors.363,364 Oligohydramnios and neonatal anuria have been attributed to the renal dysgenesis. Thioureas
Propylthiouracil and other thiourea compounds interrupt thyroxin production by blocking both the iodination of tyrosine and the coupling of diiodotyrosine. They are widely and effectively used in the therapy of hyperthyroidism. Niswander and Gordon365 found hyperthyroidism in 1 of every 500 pregnancies. Thioureas readily cross the placenta and can cause goiter and hypothyroidism
Human Malformations and Related Anomalies
in the fetus.365–367 Thiouracil goiters are usually mild to moderate in size and do not compromise the respiratory and alimentary tracts in otherwise normal infants. With the exception of umbilical hernias, any of the signs of hypothyroidism can be present. Goiter and other signs of hypothyroidism spontaneously regress over a 2to 6-week period, and regression can be hastened by thyroxin supplements.366 Limited follow up has not shown residual growth or mental impairments. Carbimazole, Methimazole
Eighteen cases of embryopathy have been noted among infants exposed to carbimazole or methimazole prenatally.368–370 Distinctive findings were scalp aplasia cutis, choanal atresia, esophageal atresia/tracheoesophageal fistula, and athelia/hypothelia. Facial findings included short flared eyebrows, short upslanting palpebral fissures, broad nasal bridge, hypoplastic alae nasi, and small ears. A minority had heart defects and delayed development. Iodides
Inorganic iodides have been used as a mucolytic agent for various respiratory ailments and to suppress hyperfunction of the thyroid gland. Iodides readily cross the placenta and in excess can interfere with fetal thyroid function. Inhibition of organification, coupling of iodotyrosines, and release of thyroxin by the thyroid gland all contribute to the iodides’ goitrogenic effect. The massive fetal thyromegaly produced by iodides is unequaled by any other goitrogenic agent or disease.371 The goiter may be sufficiently large to cause polyhydramnios prenatally and respiratory and alimentary obstruction postnatally (Fig. 1-32). Although no permanent thyroid dysfunction should be anticipated, transient hypothyroidism or, less commonly, hyperthyroidism can occur in the neonatal period.
Babies prior to 1976), 18 (10.8%) had malformations.372 Thirteen of the malformed infants had cardiovascular malformations, and four of these were the Ebstein anomaly. Additionally, one of six stillborn infants in the series had tricuspid atresia. Subsequent study has concluded that the overall risk for malformations is only slightly increased, and there is no increased risk for Epstein anomaly.373 Infants exposed to lithium may experience transient lethargy, hypotonia, cyanosis, poor feeding, and poor respiratory efforts during the early neonatal period.
Mercury
Two serious incidents of food contamination with alkylated mercury, a potent neurotoxin, have occurred during the past three decades.374,375 In both instances disturbances of neurologic function were documented in infants who were exposed prenatally. In the 1950s, methylmercury sulfide and methylmercury chloride were discharged in the Minamata Bay (Japan) by a vinylchloride and acetaldehyde plant.374 Residents of the area who consumed large amounts of fish and shellfish from the polluted waters accumulated toxic levels of mercury and suffered neurologic impairments. Similar wide-spread exposure occurred in 1972 among rural Iraqis who ingested bread prepared from wheat treated with the fungicide methylmercury.375 Prenatally exposed infants exhibited a wide range of neurologic abnormalities: mental retardation, speech and language delays, visual and hearing impairments, weakness, ataxia, gait disturbance, involuntary movements, swallowing dysfunction, hyperreflexia, and emotional lability (Fig. 1-33). Morphologic changes of the central nervous system included microcephaly, heterotropias, and other abnormalities of
Lithium
The major use of lithium salts in medicine is in the treatment of manic-depressive illness. Of 166 infants exposed to lithium during pregnancy (cases reported to the international Registry of Lithium
Fig. 1-32. Immense goiter (left) in infant born of mother taking iodides during pregnancy. The firm goiter compromised respiration. The infant also had hypothyroidism and cardiac failure but responded to thyroxin therapy. Goiter had greatly resolved by age 2 months (right). (Reprinted with permission from Senior B, Chernoff HL: Pediatrics 47:510, 1971.371)
47
Fig. 1-33. Infant with marked neurologic impairment following prenatal exposure to the fungicide methylmercury. (Courtesy of Dr. Sami Elhassani, Mary Black Hospital, Spartanburg, SC.)
48
Overview
cytostructure. Irregular tooth size and malocclusions were also found in affected children. Warfarin
Anticoagulants are used prophylactically following cardiac valve transplantation and in the treatment of thrombophlebitis, thrombosis, embolus, and polycythemia. Warfarin and other related vitamin K antagonists cross the placenta and can cause spontaneous abortion, malformations, and fetal anticoagulation.376–378 The sentinel signs of embryonic pathology, nasal hypoplasia, and skeletal stippling depend on exposure during the critical period of 4 to 6 weeks postovulation (Figs. 1-34, 1-35). Mid-trimester exposure can result in optic atrophy, brain anomalies, and mental impairment. Third-trimester exposure can anticoagulate the fetus, predisposing to perinatal hemorrhage. In warfarin embryopathy, the nose appears small, with depression of the nasal bridge and accentuated demarcation between the alae nasi and the tip of the nose. Choanal stenosis may coexist. Prenatally, the restricted nasal airway may contribute to the increased frequency of polyhydramnios and postnatally to respiratory embarrassment and death. Calcific stippling occurs primarily in the tarsals, proximal femurs, and paravertebral processes but may be present in other areas of the skeleton and in the laryngeal and tracheal cartilages. Brachydactyly and small nails, with greater severity in the upper limbs, have been present in about one-half of affected infants. Optic atrophy, microphthalmia, and blindness can result from exposure during the first or second trimester. Mortality is high (20%) among affected infants, and one-third of survivors will be mentally retarded. A variety of structural anomalies of the brain (e.g., DandyWalker malformation, agenesis of the corpus callosum), microcephaly, optic atrophy, visual impairment, seizures, hypotonia, and mental retardation have been noted among infants exposed to warfarin throughout pregnancy and among infants exposed only after the first trimester. Others with intracranial hemorrhage in the perinatal or postnatal periods have developed hydrocephaly and mental retardation. Chlorobiphenyls
Epidemics of reversible skin eruptions due to the ingestion of cooking oil contaminated with polychlorinated biphenyls have occurred in Japan and Taiwan.379,380 The persistence of these chemicals in tissues for a number of years has resulted in the
Fig. 1-34. Prenatal warfarin exposure. Infant was exposed throughout pregnancy. He has marked nasal and midface hypoplasia, narrow nasal passages, brachydactyly, and nail hypoplasia. Development was normal at age 7 months. (Courtesy of Dr. J.M. Pettifor, Johannesburg, South Africa.)
prenatal exposure of many infants. Affected infants have lower birth weights, cutaneous and mucosal hyperpigmentation, gum hypertrophy, natal teeth, hepatomegaly, nail dystrophy, acne, and conjunctivitis. The generalized increase in mucocutaneous pigmentation (cola-colored babies) appears accentuated over the face and gums, digits, nails, and genitals. Neonatal acne resolves with or without scarring, but the hyperpigmentation persists. A minority of affected infants have ocular hypertelorism, flaring of the eyebrows, cranial chair loss, scalp calcifications, hirsutism, chipping of the teeth, clinodactyly, chronic respiratory infections, and developmental delay.
Fig. 1-35. Prenatal warfarin exposure. Radiographs show irregular ossification (stippling) of the tarsal bones (left) and articular or periarticular calcification along the vertebral column (right).
Human Malformations and Related Anomalies
Fluconazole
Fluconazole is an antifungal agent which in chronic high doses (400 mg/d) during pregnancy has been associated with craniofacial, cardiac, and skeletal malformations.381–384 Craniofacial anomalies included brachycephaly, craniosynostosis, frontal cranioschisis, trigonocephaly, shallow orbits, hypoplasia of the midface and nose, cleft palate, and micrognathia. Tetralogy of Fallot, atrial and ventricular septal defects, and hypoplasia of the pulmonary artery have been reported. Among the wide variety of skeletal anomalies are shortening of the limbs, digit hypoplasia, thinning the bowing of the long bones, fractures, and humeroradial synostosis. The craniofacial findings and humero-radial synostosis have prompted comparisons to Antley-Bixler syndrome. Aleck has pointed out that Fluconazole inhibits lanosterol 14 alphademethylase, an enzyme that has been found deficient in patients with Antley-Bixler syndrome.384 Other Drugs
Questions about the safety during pregnancy of a number of other drugs and chemicals have been raised by retrospective studies and isolated case reports.213,216,385–390 Further investigations have failed to confirm any association between certain of these substances and adverse pregnancy outcome. For other substances, the body of information remains insufficient to form reliable conclusions. Prenatal Hormonal Influences Diabetes Mellitus
Distinguished as being the most common hormone deficiency during pregnancy, diabetes mellitus is the prototypic maternal metabolic disease that influences the health of the embryo and fetus. The maternal disease varies considerably in its severity and its impact on the conceptus. The chemical imbalance inherent in diabetes is readily reflected transplacentally, placing stress on fetal homeostatic mechanisms. Diabetic pregnancies are subject to secondary complications that can further jeopardize the fetus. Since diabetes mellitus can exist throughout pregnancy, prenatal consequences include malformations, growth disturbances, stillbirth, and homeostatic derangements that can persist into the newborn period. Infants born of mothers with diabetes mellitus types 1 and 2 grow excessively before birth, presumably because of excessive glucose availability and fetal hyperinsulinism.391–393 The macrosomia is generalized, affecting linear growth and weight, and with the notable exception of the brain it is shared by most internal organs (Fig. 1-36). In contrast, infants born of diabetic mothers with vascular complications can be growth impaired during fetal life. In neither case does the altered growth rate continue postnatally. Gestational diabetes that does not develop into type I or II diabetes probably poses little risk to the conceptus; but because it is difficult to distinguish what type the mother has, all diabetes during pregnancy is treated with caution. An overall threefold increase in malformations occurs among infants of diabetic mothers, with a direct correlation between the severity of malformations and the degree of control of maternal diabetes.394–401 Defects of the heart, central nervous system, kidneys, and skeleton predominate. Abnormalities of the major arteries, particularly transposition of the great vessels and conus arteriosus, ventricular septal defects, and dextrocardia occur with
49
greatest frequency, but a variety of cardiovascular defects have been reported. Anencephaly, spina bifida, hydrocephaly, and holoprosencephaly are the major central nervous system malformations that occur in infants of diabetic mothers. A spectrum of malformations involving the lower spine has been associated with diabetes mellitus. Collectively termed ‘‘caudal regression syndrome,’’ the spine may have faulty segmentation or may terminate altogether in the lumbar or sacral region with disturbance in neurologic function below the level of spine disruption (Fig. 1-37). Anal and urethral sphincters may be incompetent, and motor function of the lower limbs may be impaired. Defective development of the long bones, joint dislocations, and malpositions can result as well. Sirenomelia occurs as a part of this spectrum of defects, and malformations of the lower and upper extremities can occur independently of the caudal regression syndrome. Femoral hypoplasia (usually proximal) can occur with or without caudal regression. A characteristic proximally placed large toe is a rare anomaly most often associated with maternal diabetes. Although an overall increase in many types of malformations occurs among infants of diabetic mothers, holoprosencephaly and caudal regression syndrome in particular might be considered ‘‘diabetic malformations’’ because they occur with several hundredfold increase in these infants. Yet it is appropriate to remember that most cases of these uncommon malformations occur in nondiabetic pregnancies.212,394 Other significant difficulties encountered by the infants of diabetic mothers include hyperbilirubinemia, hypocalcemia, hypoglycemia, cardiomyopathy, vascular thromboses, respiratory distress syndrome, and birth injury . Hypothyroidism
Since thyroxin fails to cross the placenta in early pregnancy and fetal synthesis of thyroxin begins after the first trimester, it may be surmised that organogenesis and early fetal growth proceed independently of thyroid hormone. Further evidence that thyroid hormone is not necessary for early development is the birth of normally formed infants to untreated cretinous and myxedematous women.402 Later in pregnancy thyroid hormone does become important to fetal growth, osseous development, and neuronal maturation. However, the fetus should be capable of supplying its own hormone by the time the hormone is needed. Thyroid hormone may have some function in the maintenance of the placenta as demonstrated by an increased risk of abortion in pregnant women who have low thyroxin levels.403 The exact relationship between hypothyroxemia and abortion in these pregnancies has not been clearly delineated. Pregnancies in women with frank and untreated hypothyroidism do not consistently terminate in abortion. Only in cases in which the fetal thyroid gland has been impaired by antithyroid drugs (e.g., propylthiouracil, carbimazole, iodides), radioactive iodine, or possibly maternal antibodies does one expect effects on the fetus.367,404 Hyperthyroidism
Transfer of maternal thyroxin to the fetus is negligible during early pregnancy. Free thyroxin can cross the placenta, but the relative thyroid-binding globulin capacity favors the mother. During the final weeks of pregnancy, fetal thyroid-binding globulin may compete more favorably and thyroxin may be transferred to the fetus. Triiodothyronine is less bound by thyroidbinding globulin and can more freely cross the placenta in all stages of pregnancy. Thyroid-stimulating hormone does not cross
50
Overview
Fig. 1-36. Infants of diabetic mothers. Left: general appearance of infants of mothers with class A, B, or C diabetes mellitus. They appear excessively nourished and pass the initial extrauterine hours in a limp and quiet manner unless disturbed by stimuli from the environment or by their own respiratory distress, hypoglycemia, or hypocalcemia, Right: plethoric and cushingoid facies.
Fig. 1-37. Caudal deficiency in a 3-year-old child whose mother had diabetes mellitus. The spine ends at L2, and the ilia are fused in the midline.
the placenta. Immunoglobulins that stimulate the thyroid gland do cross the placenta and may potentially stimulate the fetal thyroid gland.405–407 Most cases of hyperthyroidism during pregnancy are due to Graves disease. In untreated state, fetal death often follows. The
presence of thyroid-stimulating globulins in Graves disease places the fetus at risk for thyrotoxicity regardless of the treatment status of the maternal disease. When maternal hyperthyroidism is treated, two contrasting influences can affect the fetus. If thyroidstimulating globulins are present, hyperthyroidism can be induced
Human Malformations and Related Anomalies
51
Hyperparathyroidism
Since most hormones and tropic substances cross the placenta with difficulty, if at all, hyperfunctioning endocrine glands exert their influence indirectly. Fewer than 100 cases of maternal hyperparathyroidism, usually due to parathyroid adenomas, have been reported.413 The excessive production of parathyroid hormone results in maternal hypercalcemia, which is reflected transplacentally in fetal hypercalcemia that in turn depresses the fetal parathyroid gland. This simplistic schema may in fact be much more complicated, involving 1,25-dihyroxyvitamin D3 synthesis, hypomagnesemia, and/or end-organ responsiveness to parathyroid hormone as well. Maternal hyperparathyroidism results in excessive abortion and stillbirth and, because of suppression of the fetal para-thyroid gland, predisposes the newborn to hypocalcemia and tetany. Cushing Syndrome
Hyperfunction of the adrenal gland during pregnancy may be caused by tumor or hyperplasia.414 One-half of the pregnancies will result in abortion or perinatal death. Maternal overproduction of adrenocortical steroids can suppress the fetal adrenal gland, which becomes manifest in the neonatal period as adrenal insufficiency. Overproduction of Sex Hormones Fig. 1-38. Small for gestational age infant born of a mother with hyperthyroidism. Infant had transient signs of hyperthyroidism: agitation, tachycardia, tachypnea, and excessive hunger.
in the fetus. Alternatively, the fetal gland can be suppressed by transplacental passage of antithyroid medications. Neonatal thyrotoxicosis induced by transplacental thyroidstimulating globulins usually is a transient phenomenon, commonly lasting several months.408,409 Most affected infants have goiter, exophthalmos, restlessness, and tachycardia (Fig. 1-38). They may have excessive length, but are thin. Less than one-half will show periorbital edema, ravenous appetite, temperature elevations, cyanosis or cardiac failure, and hepatosplenomegaly. Craniosynostosis has been reported in several infants.410 In some instances the neonatal thyrotoxicity persists, suggesting in these cases a heritable thyroid dysfunction rather than a transient influence of exposure to thyroid-stimulating globulin(s).411 Goiter, hypothyroidism, and scalp defects have resulted from the use of antithyroid medications during pregnancy.
During pregnancy, the serum concentrations of progesterone and estrogen are higher than at any other time during life. Transplacental hormones can cause breast engorgement, neonatal vaginal bleeding, and the cutaneous eruption herpes gestationis. Breast engorgement occurs in male and female fetuses during the final 4 to 6 weeks of gestation. At term the usual breast nodule measures 5 mm more and regresses over the first postnatal months. Some infants have excessive breast enlargement and may produce a few drops of milk. Vaginal bleeding related to estrogen and progesterone withdrawal may occur during the neonatal period, beginning in the first week of life and rarely lasting beyond a couple of days. Androgens produced by arrhenoblastoma or luteoma of pregnancy can masculinize female fetuses. The full extent of masculinization, usually some degree of clitoral hypertrophy and labial adhesion, will be apparent at birth. Androgen-secreting adrenocortical adenomas have also resulted in masculinization of female fetuses. Although overproduction of androgens also occurs in the adrenogenital syndrome, fetuses born of such pregnancies have not shown masculinization or other ill effects. Herpes Gestationis
Hypoparathyroidism
Infants of mothers with untreated hypoparathyroidism may have transient hyperparathyroidism during the fetal and neonatal periods.412 The fetal parathyroid hyperplasia occurs in response to low maternal and fetal serum calcium concentrations mediated by the maternal parathyroid dysfunction. Excessive fetal parathyroid hormone predominantly affects the skeletal system, but other systemic effects of fetal hypercalcemia may result as well. All bones show demineralization, and subperiosteal reabsorption occurs in the long bones. Long bones may also show considerable bowing, and fractures may be present. Intrauterine growth retardation, pulmonary artery stenosis, ventricular septal defects, and muscle hypotonia have been described in individual cases.212
A curious erythematobullous eruption associated with pregnancy, herpes gestationis causes intense pruritis as its major symptom.212,415 The natural confinement of the condition to pregnancy and the artificial induction of lesions with progestational steroids provide justification for considering it a hormonally induced entity. The name herpes gestationis is inaccurate since it incorrectly suggests that the eruption is somehow associated with herpesvirus. Herpes gestationis occurs once in every 10,000 pregnancies and can recur in consecutive or nonconsecutive pregnancies. Lesions usually erupt at 4 to 5 months’ gestation but can appear as late as 2 weeks after delivery. About 10–20% of infants born of affected mothers will have lesions at birth or will develop lesions within the first 48 hours of life. The bullous lesions clear
52
Overview
spontaneously within 1 week. These lesions may be related to fetal maternal microchimerism.415a Maternal Phenylketonuria
Before treatment with a phenylalanine-limited diet was practiced, most people with phenylketonuria became severely mentally retarded during childhood and few went on to reproduce. The offspring of those women who did become pregnant were also mentally impaired. Substantial experience with pregnancy in phenylketonuric women has confirmed that the metabolic derangements in untreated maternal phenylketonuria almost invariably injure the offspring.416–419 Infants born of mothers with untreated phenylketonuria have intrauterine and postnatal growth retardation, microcephaly, mental retardation, and cardiac defects, the frequencies of these impairments being directly related to the maternal phenylalanine level (Fig. 1-39). When the maternal phenylalanine level exceeds 20 mg/d1, 92% of infants have mental retardation; 73%, microcephaly; 40%, intrauterine growth retardation; and 12%, cardiac malformations. One-fourth of pregnancies are spontaneously aborted. Rigid compliance with dietary treatment beginning before conception offers the only hope of decreasing this high incidence of malformation and other impairments among the offspring of phenylketonuric women. Other Aminoacidopathies
Only limited data exist concerning pregnancies in women with various aminoacidopathies other than phenylketonuria. With the Fig. 1-39. Three-year-old male with microcephaly, mental retardation (IQ 55), short stature, and seizures. Infant was born of a woman with phenylketonuria who received no treatment during pregnancy. Her three other pregnancies resulted in one abortion and two microcephalic infants.
exception of hydrocephaly in two infants born to mothers with homocystinuria and Hartnup aminoaciduria, adverse affects on pregnancy outcome have not been reported.420–422 Phytoestrogens
Concern has been expressed because of an increasing occurrence of hypospadias that environmental estrogens as well as phytoestrogens may be responsible; however, the correlation of hypospadias with intrauterine growth retardation seems more likely. Prenatal Nutrient Deficiencies Folic Acid
Insufficient availability of folic acid and/or other vitamins has been suggested as a cause of defects in neural tube closure as well as other birth defects.423–425 On the basis of this suggestion, the effects of supplementation of high-risk pregnancies with a folic acid–containing multivitamin, or folic acid alone, in the periconceptional period (4 weeks before conception until 8 weeks after) was studied in Great Britain. Smithells et al.424,425 used a multivitamin supplement (Pregnavite), and Laurence et al.426 used a supplement of folic acid alone. In both studies, supplementation was found to protect against recurrence of neural tube defects (NTDs) in infants of mothers who had previously had an infant with an NTD, reducing the recurrence rate to less than 0.5%. A number of retrospective studies have supported the British findings.427,428 One retrospective study in the United States failed to find any protection against NTDs from preconceptional vitamin usage.429 Conclusive evidence that the use of periconceptional folic acid (alone or in multivitamins) lowered the risk of recurrence of NTDs was provided by the Medical Research Council study in 1991.430 Similar protection against the initial occurrence of NTD cases using a multivitamin with folic acid was found by Czeizel and Dudas one year later.431 The successful use of folic acid supplementation to lower the occurrence of NTDs has been reported from the Americas, Australia, and China.432–435 Fortification of cereal grain flours with folic acid has been required in the United States since January 1998.436 A large number of breakfast cereals have also been fortified with 400 mcg folic acid per serving. The combination of supplement use, flour fortification, and consumption of fortified cereals has resulted in a twofold to threefold increase in serum and erythrocyte folate levels in the United States.437 These combined measures have resulted in an overall reduction of 19% in the rates of NTDs.438 A number of studies have suggested that folic acid may protect against other malformations.439–442 Reduction in the risks for the occurrence of cleft lip with/without cleft palate, conotruncal heart defects, limb reduction defects, and urinary tract defects has been reported in several studies. It should be noted that infants born of women frankly folate deficient during pregnancy have not been found to show any measure of ill health, including intrauterine growth retardation, neural tube defects or other malformations, or hematologic abnormalities.443 Several infants born after exposure to the folic acid antagonist aminopterin have, however, had neural tube defects.212 Oxygen
Chronic intrauterine hypoxia occurs in a number of circumstances. Cigarette smoking and certain pulmonary, cardiovascular, and hematologic disorders prevent the mother’s blood from being consistently and completely oxygenated.444–447 Chronic
Human Malformations and Related Anomalies
hypoxemia also occurs in women who live at altitudes greater than 2000 m.448–449 These situations limit adequate oxygen delivery to the fetus. Chronic fetal hypoxia can also result from placental dysfunction, preeclampsia, and nontoxemic hypertension. Impairment of intrauterine growth results from chronic mild hypoxemia, regardless of the cause. In several circumstances a direct correlation has been demonstrated between the degree of hypoxia and the severity of growth impairment. For pregnancies at high altitude, birth weights decrease 100–200 g for every 1000 m above sea level. Alzamora et al.450 also found an increased incidence of patent ductus arteriosus and atrial septal defects among infants born at high altitudes. A progressive decrease in birth weight has also been directly correlated with diastolic blood pressure in hypertensive mothers and with the degree of oxygen desaturation in mothers with cyanotic heart disease.451 Neill et al.446 noted dramatic intrauterine growth retardation among infants of mothers with cyanotic heart disease whose hemoglobin level was greater than 18 g/dl, hematocrit greater than 65%, and oxygen saturation less than 65%. Infants of mothers with less severe cyanotic heart disease had less severe intrauterine growth retardation. Neill et al. also noted an increased risk of abortion, fetal death, and preterm delivery of pregnancies complicated by maternal cyanotic heart disease.446 Acute intrauterine hypoxemia can cause fetal death or neurologic impairment. This outcome may follow umbilical cord occlusion and premature placental separation.
53
Fig. 1-40. Coarse facies, anteverted nostrils, large tongue, umbilical hernia, and muscular appearance of male infant with hypothyroidism. (Courtesy Dr. Charles I. Scott, Jr, A.I, du Pont Institute, Wilmington, DE.)
Vitamin D
Rickets has been present in newborn infants of mothers with osteomalacia and of women not overtly vitamin D deficient.452 Clinical signs of rickets—rachitic rosary, Harrison groove, delayed maturation of skull bones with large fontanels, and expansion of the osteochondral junctions—may be obvious at birth. Alternatively, radiographic histologic evidence may be found in the absence of physical findings. Dental enamel deposited during the period of intrauterine deficiency will be hypoplastic, dentin will be unevenly calcified, and the predentin will be excessively wide. The fetus may be endangered by hypocalcemic tetany in utero or by uterine tetany or dystocia secondary to pelvic contracture. Calcium
Maternal hypocalcemia can result from hypoparathyroidism, inadequate dietary calcium or vitamin D, and heritable vitamin D deficiencies. Although there is a calcium gradient favoring the fetus, fetal hypocalcemia can occur and result in osteopenia, rickets, or osteitis fibrosa, depending on the degree of calcium deficiency and other compensatory homeostatic hormonal changes.453 Iron
The fetus effectively parasitizes the mother’s iron stores regardless of the state of her iron homeostasis. At birth the hemoglobin level of the fetus appears to be unrelated to anemia in the mother. In maternal iron deficiency, the placenta is often large, apparently to try to compensate for the maternal anemia. Studies done in South America suggest that the higher the level of anemia in the mother, the lower the intelligence of her offspring.453a Iodine
The iodine-deficient woman who is pregnant may fail to provide sufficient mineral to the fetus.454 The fetus suffers the same pathologic consequences of the deficiency as the mother and can be
born with goiter and signs of cretinism (Fig. 1-40). Features of cretinism, retarded bone growth and ossification, epiphyseal dysgenesis, myxedema, constipation, umbilical hernias, and cutaneous mottling will be present at birth or soon after in the untreated infant. If the condition is untreated, mental retardation is the most important sequela. Prenatal Mechanical Influences
The maternal pelvis, abdominal wall, uterus, and amniotic fluid participate in protecting the conceptus against mechanical injury. Each becomes less protective as pregnancy advances. By midtrimester, the fetus lies outside the safety of the pelvis. The abdominal wall and the uterus become progressively thinner as the conceptus grows, and the ratio of amniotic fluid to mass of fetus decreases steadily. Prior to 8 weeks postfertilization, amniotic fluid makes up 95% of intraamniotic volume. The amniotic fluid component of intraamniotic volume decreases to one-half by 14 weeks and to one-third by 36 weeks. Some degree of intrinsic protection against mechanical injury may also be provided by the plasticity of embryonic and early fetal tissues and by their capacity to repair local damage. Mechanical forces can alter prenatal development by direct trauma to tissues, by interruption of blood supply, by constraint, and by damaging the placenta or cord. About 6–7% of women sustain physical injury during pregnancy.455,456 Vehicle accidents account for the majority of such injuries, with falls, gunshots, stabbings, and physical abuse constituting other significant causes. Little role has been demonstrated for these external forces as a cause of malformation except in the case of attempted termination of pregnancy where congenital contractures have been reported.456a Penetrating and blunt trauma can cause death by damaging the fetus, placenta, or cord. Rare instances of similar injury have resulted from amniocentesis.
54
Overview
Fig. 1-41. Deformations caused by intrauterine mechanical forces. Cephalic molding (A) and nasal deformation (B) can occur from prolonged constraint in a malformed uterus or from the forces of delivery. Clubfoot and other limb deformations (C) occur from prolonged constraint. Fetuses with neuromuscular impairments are at greater risk for such deformations.
A greater potential for mechanical alteration of morphology comes from within the mother. The same structures that surround and protect the conceptus against mechanical injury can, in certain circumstances, impose constraints detrimental to development.
craniofacial and limb deformations in twins. Although there is increased risk of malformations and disruptions in twins, these have been related to other factors, usually vascular, rather than mechanical, forces.
Malformations of the Uterus
Vascular Compromise
The size of the intrauterine cavity and its ability to accommodate the growing conceptus may be limited by malformations of the uterus. Uterine malformations are associated with greater risks of spontaneous abortion, malpresentation, stillbirth, and premature delivery. One-third of liveborn infants have craniofacial or limb deformations, evidence of late intrauterine constraint (Fig. 1-41).457,458 Craniofacial asymmetry, torticollis, scoliosis, excessive folding and flattening of the ears, flattening of the nose, joint contractures, and limb edema have been reported. Compression earlier in pregnancy can impair peripheral circulation, particularly in the limbs. Graham and associates458 have attributed limb hypoplasia and various limb reduction abnormalities to early constraint caused by malformations of the uterus.
Either inherited abnormalities of vascular formation or thrombophilias can predispose to in utero vascular accidents. Hunter’s preliminary study suggests that thrombophilias may predispose to limb anomalies, terminal transverse limb deficiencies in particular,461a Shalev and Hall’s study of familial vascular compromise suggests that inherited hypoplasia of blood vessels may affect growth of the shoulders.461b
Fibroids
Fig. 1-42. Growth curves from 24 weeks to term for singletons, twins, triplets, and quadruplets. (Adapted from McKeown and Record.461)
Because they occupy space in the uterine cavity, fibroids limit space for placentation and growth of the conceptus. Growth deficiency, deformations, and disruption of the limbs similar to those caused by compression in the malformed uterus have been reported. Twins
The human uterus has a limited capacity to accommodate twins and other multiple pregnancies. Mechanical forces undoubtedly contribute in some measure to the increased risk of growth deficiency, prenatal and postnatal mortality, malformations, disruptions, deformations, and premature delivery in such pregnancies (see also Chapter 34).459,460 However, changes in maternal metabolism in twin pregnancy also undoubtedly have effects on fetal growth and outcome. Fetal growth is influenced by the number of fetuses present. The growth deceleration that occurs at about 36 weeks in singletons takes place at about 30 weeks in twins, 27 weeks in triplets, and 26 weeks in quadruplets (Fig. 1-42).461 Some contribution to growth deficiency in twins may be related to mechanical constraint, but the greater influence must be assigned to placental function. Constraint is likely the major contributor to
Amnion Disruption and Amniotic Bands
The amniotic system provides the innermost and perhaps the most substantial of the safeguards against prenatal mechanical injury. Within the amniotic membrane, the developing organism
Human Malformations and Related Anomalies
55
Fig. 1-43. Facial features of a 23-week-old fetus with Potter syndrome secondary to type IIB cystic dysplasia. Note the prominent lower palpebral folds (arrows), flattening of the nose, and low-set and flattened ears (E). (Courtesy of Dr. Will Blackburn, Fairhope, AL.)
is suspended in an aqueous medium by a mobile and elastic cord, free of impingements that could impair symmetric growth or limit movement. Failure of this system can be catastrophic, causing a striking array of structural anomalies. Inadequate production or chronic loss of amniotic fluid allows the uterus to compress the more pliable parts of the external fetal anatomy. Typically the facies are flattened, with depression of the tip of the nose and abnormal folding of the ears (Potter facies), the feet and hands are malpositioned, and the skin is excessively wrinkled (Fig. 1-43).462–465 In the absence of amniotic fluid, the lungs remain underdeveloped and ill-prepared for neonatal respiratory function.
The amniotic membrane participates directly in the production of abnormalities through several mechanisms.463–465 Strips, strands, or sheets of amnion may separate partially or completely from the amniotic membrane and become suspended in the amniotic fluid. These amniotic ‘‘bands’’ may encircle digits or entire limbs, eventually compromising blood supply to the distal part. Growth and development of limbs thus entangled may become disrupted, with residual constriction rings, syndactyly, and amputations (Fig. 1-44). Bands of amnion may also be swallowed. If the band is attached to the amniotic membrane, the fetus becomes tethered and through continued swallowing efforts pulls itself to the point of
Fig. 1-44. Amniotic bands. Left and middle: fetus with ring constrictions, digital fusions, and amputations secondary to amniotic bands. Note string of amnion attached to dorsal aspect of digits. Right: ring constrictions and amputations in a 27-year-old man.
56
Overview
Fig. 1-45. Amniotic rupture and bands in two fetuses. Left: unusual cranial lobation, fusion of cranium to placenta, and omphalocele. Right: cleft lip, cranial fusion to placenta, and digital amputations with amniotic bands between right hand and placenta.
attachment. The strong amniotic tether can cut into orofacial structures, leaving clefts unrelated to lines of embryonic fusion (Fig. 1-45). Bizarre lobation of the cranium can result from twisting of the fetus, and cranial tissues can fuse to the amnion and placenta. In other circumstances, the amnion may rupture, collapsing more or less in toto about the embryo or fetus. This blanket of amnion deprives the developing organism of free movement and holds it close to its placental attachment. Anomalies related to amnion rupture depend on the time of rupture, the presence of amniotic bands, the degree of compression exerted by surrounding structures, and the occurrence of adhesions. Amnion rupture during the period of embryogenesis presumably causes malformations through adhesions and compression of the gelatinous embryonic tissues. Later amnion rupture disrupts structures already formed through direct compression and vascular compromise of exposed parts. Graham and associates458 include limb reduction defects, body wall deficiencies, neural tube defects, postural deformations, scoliosis, and growth deficiency among the effects of acute or prolonged compression related to amnion rupture. Affected infants may also have band-related anomalies and short umbilical cords. The etiology of amnion disruption is unknown, but does not appear to be genetic. It occurs more often in young primagravidas and in pregnancies that follow miscarriage. Prenatal Immunologic Influences
The extent to which immunologic processes influence human development is unknown. A growing body of information implicates immune mechanisms as an important cause of infertility.466–468 Certain maternal immunologic diseases, notably lupus
erythematosus, are associated with excessive pregnancy wastage. The possibility that subclinical disease contributes in some substantial way to pregnancy loss overall cannot be dismissed. Maternal antibodies transferred transplacentally can interfere with a wide variety of systemic functions in the fetus and continue for variable periods postnatally. The role of immune processes in causing congenital anomalies is less clear. Prenatal immunologic influences may be mediated by direct attack on tissues of the conceptus, particularly the placenta, by transplacental transfer of globulins that may attack fetal cells from within, and by transfer of immunocompetent cells that provide a nidus for initiating graftversus-host disease. It is now known that fetus and mother regularly exchange cells, and that if these cells are stem cells, they may take up ‘‘permanent’’ residence. It is unclear what role such cells play in either maternal, newborn, or later autoimmune disorders.415a Rh Isoimmunization
Hydrops fetalis is the end result of severe fetal involvement by Rh isoimmunization. The preceding cascade of events is initiated by Rh-positive fetal erythrocytes gaining entry into the circulation of a previously sensitized Rh-negative mother (Fig. 1-46).469 Maternal IgG antibodies to the Rh antigens cross the placenta and attach to fetal erythrocytes. Destruction of these erythrocytes, primarily by the spleen, causes anemia. When the fetal hematopoietic response cannot compensate for the anemia, cardiac failure and universal edema ensue (Fig. 1-47). Fetomaternal incompatibility for erythrocyte antigens other than the Rh and ABO antigens can also cause hemolytic disease, but prenatal hemolysis sufficient to produce hydrops fetalis is distinctly uncommon.470
Human Malformations and Related Anomalies
57
Platelet Isoimmunization
Maternal antibodies against fetal platelets can lead to prenatal and transient postnatal thrombocytopenia.471 The hazard of hemorrhage, particularly intracranial, appears to be greatest during the perinatal period. Prenatal hemorrhage and infarction can occur, however, with residual hydrocephaly and porencephaly. Thyroid Antibodies
Fig. 1-46. Schematic showing events leading to Rh disease of the fetus (erythroblastosis fetalis).
A number of thyroid antibodies have been described and are widely used for diagnostic purposes.472,473 At least two types of thyroid antibodies can influence fetal thyroid function. Thyroidstimulating immunoglobulins bind the thyroid-stimulating hormone receptor and stimulate thyroid function. These antibodies are present in Graves disease, are 7S in size, cross the placenta, and can stimulate the fetal thyroid. Affected fetuses develop goiter and hyperthyroidism, which may persist for several weeks or months postnatally. A second type of thyroid antibody is inhibitory in nature. This antibody also binds to the thyroid-stimulating hormone receptor but blocks thyroid function, producing hypothyroidism. This blocking immunoglobulin also crosses the placenta and may cause cretinism in the fetus. Although the thyroid gland may not be visible on radioactive scanning during the early months of life, thyroid function will return once the antibodies have dissipated, generally a matter of several months. Lupus Erythematosus
A potentially serious disorder may be seen at birth or soon thereafter in a minority of infants of mothers with systemic lupus erythematosus. Congenital heart block, hepatosplenomegaly, lupus erythematosus rash, pancytopenia, and stippled epiphysis are the major features.474,475 The hematologic findings resolve over the first couple of months, and the rash resolves by 6 months. Heart block becomes manifest by bradycardia before or after delivery and is permanent. One-third of infants with heart block also have cardiac malformations and endocardial fibroelastosis. An excessive frequency of abortion and stillbirth has also been reported. Although two-thirds of mothers of affected infants are asymptomatic, Ro antibodies (antibody to Sjo¨gren syndrome A antigen) will usually be present in mothers and infants. Antinuclear antibody and La antibody (antibody to Sjo¨gren syndrome B antigen) may be present as well. Some individuals with this selflimited syndrome in the neonatal period develop other signs of systemic lupus erythematosus in adolescence or early adulthood. Pemphigus Vulgaris Fig. 1-47. Newborn infant with hydrops fetalis secondary to Rh incompatibility.
ABO Incompatibility
Fetomaternal incompatibility for ABO antigens is the most common blood group incompatibility, occurring in 20% of pregnancies.212 Only a small percentage of ABO incompatible pregnancies results in fetal hemolysis, this occurring most commonly in A or B fetuses of mothers with blood group O. Fetal hemolysis is rarely sufficient to stress the cardiovascular system and lead to hydrops fetalis.
Infants of mothers with pemphigus vulgaris may have bullous or erosive lesions at birth, presumably the result of transplacentally acquired pemphigus antibodies.476 Skin lesions are typical of pemphigus vulgaris, having acantholytic cells, neutrophils, eosinophils, and blisters above the basal layer and leukocyte infiltrates deeper in the dermis. IgG and C3 are deposited in the intercellular spaces of the dermis. Some infants are small for gestational age, and the risk of stillbirth appears to be increased. Liveborn infants generally have a benign course, with spontaneous and permanent resolution of the skin lesions within the first couple of weeks of life. Myasthenia Gravis
Ten percent of infants born of mothers with myasthenia gravis will exhibit signs of myasthenia during the first weeks of life.212,477 These infants are inactive, have hypotonia, and suck, cry, and
58
Overview
swallow poorly. Although the face is expressionless due to the temporary myopathy, ptosis and ocular motor palsies do not usually occur. Most infants have no structural anomalies, although deformations due to fetal inactivity have been reported. Transplacental passage of antimuscle antibodies or other humoral factors have been suspected but not proven to be the cause of transient neonatal myasthenia gravis. Engraftment of Foreign Cells
Three possibilities exist for fetal exposure to foreign immunocompetent cells. Maternal cells may gain access to the fetal circulation through leaks in the villous membrane or through fetomaternal vascular anastomoses. In twin pregnancies, vascular anastomoses in the placenta may allow sharing of blood cells. This sharing usually occurs only in monozygotic twins; therefore, the admixing of cells is with the same genotype. Intrauterine transfusion in the treatment of fetal anemia can also be the source of foreign cells. Establishment of the viable grafts from each of these sources has occurred.477–482 Although immunodeficiency of the fetal host has been documented or suspected in most cases of intrauterine engraftment with foreign cells, viable grafts have occurred in apparently normal fetuses. Graft-versus-host disease has occurred only in instances of intrauterine engraftment of maternal cells. Ill effects from graft-versus-host disease usually develop after birth, but some affected infants are growth deficient, with pancytopenia and scaling dermatitis at birth. Malformations have not been associated with intrauterine engraftment of foreign cells. 1.6 Human Anomalies with Unknown Causes The era of molecular medicine promises to bring additional insights into the mechanisms by which malformations occur. A number of molecular pathways in development are now partially understood, showing that interruption of various components of the genetic–metabolic machinery that supports normal embryonic development can lead to malformations. While none of the pathways is fully and incontestably delineated, at least the skeletons of a number of pathways are known.196 The major molecular players, the anatomical correlates, and the embryological timing are known for limb development, for example (see Chapters 20–22). A role for chance in the causation of morphological characteristics and malformations has been proposed by Kurnit et al.46 For example, chance variations in the way early embryonic cells migrate, divide, or adhere may be magnified as anatomical defects or functional impairments in the fully formed individual. 1.7 Detection, Diagnosis, Evaluation, Management Prenatal Diagnosis
Long before the era of pregnancy imaging and invasive diagnostics, physicians depended on auscultation, palpation, and measurement to determine the growth and well-being of the fetus. No means were available in early pregnancy to detect malformations, although certain phenomena, such as excessive or deficient pregnancy size, polyhydramnios or oligohydramnios, or breech presentation, might have suggested the possibility of malformations in the fetus. Late in pregnancy, radiographs were useful in
identifying some birth defects, specifically those that affected the skeleton. The combination of amniocentesis (aspiration of amniotic fluid) and cytogenetic analysis of cultured amniocytes by Steele and Breg in 1966 ushered in an era that utilized invasive techniques to identify malformation syndromes in the fetus during the midtrimester.115 The reliability and safety of amniocentesis coupled with cytogenetic and biochemical analysis led to rapid acceptance of these procedures for high-risk pregnancies. Noninvasive testing using maternal blood (early 1970s) and ultrasonography (late 1970s) added to the prenatal screening and diagnostic armamentarium. Development of transvaginal and transabdominal chorionic villus sampling (CVS) and amniocentesis at 10 to 14 weeks permitted prenatal testing earlier in gestation, often before the pregnancy was recognized by those beyond the family. CVS and early amniocentesis were accompanied by greater risk of pregnancy loss than was traditional amniocentesis. Advances in molecular technologies greatly expanded the number of malformations and malformation syndromes that could be diagnosed prenatally. The possibility that many fetal defects could be diagnosed based on testing of fetal cells retrieved from the mother’s blood has been extensively investigated, but as of this writing is not sufficiently reliable for routine prenatal diagnosis.483–485 Ultrasonography
Although available for obstetrics use since the 1950s, ultrasound imaging for the purpose of identifying malformations came into widespread use only in the 1970s and 1980s. The absence of side effects for the mother or fetus has led to the use of ultrasonographic examination of nearly all pregnancies in developed countries. Although used routinely to assess a number of pregnancy parameters (number of fetuses, amount of amniotic fluid, placental position, fetal cardiac activity, gestational age, presence of uterine or pelvic abnormalities), obstetric ultrasonography also is useful for detection of gross malformations. Ultrasonography has also become an indispensable tool to guide aspiration and biopsy needles for obtaining amniotic fluid, placental, and fetal samples. Transvaginal ultrasound appears to give even higher resolution, particularly early, than transabdominal ultrasound. High resolution ultrasonography can be used for high-risk pregnancies and for followup of suspicious findings on lower resolution ultrasound.486–487 Real-time ultrasound can be used to access normal fetal behavior and movement (e.g., swallowing, breathing and limb movement). Maternal Serum Screening
Elevated maternal serum levels of alpha-fetoprotein were found in the 1970s to be a reliable indication of open neural tube defects and certain other malformations.488 Maternal serum alphafetoprotein screening became the primary method for identifying neural tube defects until replaced by ultrasonography in the mid1990s. Other tests, such as human chorionic gonadotropin, UE3, PAPP-A, and INH, have now been added to maternal serum screening to expand its utility in detecting fetal defects.489 Amniocentesis
Since the late 1960s, amniocentesis coupled with cytogenetic, biochemical, and molecular analyses has been the major method of prenatal diagnosis of malformations and malformation syndromes. The safety of mid-trimester amniocentesis (0.5% or less pregnancy loss over that of control pregnancies not undergoing amniocentesis; near absence of severe maternal complications or fetal injury) and accuracy has led to its widespread acceptance and availability.
Human Malformations and Related Anomalies
Malformations that have a cytogenetic, molecular, or biochemical basis may be prenatally diagnosed via amniocentesis.490 Early amniocentesis (14 weeks or earlier) has become possible with the support of high-resolution ultrasound. A higher rate of procedure-related pregnancy loss and limb anomalies than with transabdominal CVS (vide infra) or traditional amniocentesis (15 weeks or later) has been reported.490,491 Chorionic Villus Sampling (CVS)
The acquisition or biopsy of placental tissue at 10 to 12 weeks can be accomplished by transcervical or transabdominal CVS techniques. Cell cultures established from CVS can be used for cytogenetic, biochemical, and molecular studies. The collective literature gives the impression of a marginally higher rate of pregnancy loss following CVS; a greater risk of mosaicism (involving the placenta), especially involving chromosome 20; and the possibility that the procedure may be causally related to transverse terminal limb reduction defects.492,493 Percutaneous Umbilical Blood Sampling
Fetal blood may be obtained late in pregnancy by ultrasounddirected acquisition of umbilical cord blood. Cultured lymphocytes can be subjected to chromosome or molecular analysis and whole blood/plasma/serum for a variety of hematological, immunological, microbiological and other assays. Biopsies of solid tissues (e.g., skin, muscle) for microscopic examination has been performed in the second and third trimester via catheter or fetoscope.494
59
Assessment of Embryonic and Fetal Growth
Measurements become important very early in pregnancy. The general well-being of the embryo or fetus is often judged by size alone. Most insults to the rapidly growing prenatal organism will impair growth. The embryonic period (especially weeks 2–8) has been divided into stages on the basis of size (greatest length or crown– rump length) and progress of morphologic development.495 These stages, arbitrarily assigned, provide an orderly reference against which the growth and morphology of individual embryos can be compared. The changes in proportion and scale of different body segments are among the most remarkable of prenatal events. Growth in the prenatal period is truly phenomenal, from a single-celled organism weighing approximately 0.0000006 g at conception to a differentiated human being with billions of cells that weighs close to 3500 g at birth. Crown–rump length progresses from 0.4 mm at stage 7 (about 16 days postovulation) to 30 mm at stage 23 (end of embryonic period, about 56 days) to 51 cm at birth (about 280 days). During the previable fetal period (8–24 weeks postovulation), a dramatic weight gain occurs in comparison to the length gain (weight increases approximately 164 times, and crown–rump length increases approximately 7 times; Fig. 1-48).495,496 Once viability is possible (accepted as approximately 24 weeks’ postovulation or 26 weeks’ gestation as calculated by the first day of the last menstrual period), linear growth and weight are roughly
Fig. 1-48. Fetal weight, crown–rump (CR) length, and crown–heel (CH) length for days 56–168 postovulation. (From Saul et al.496)
60
Overview
Fig. 1-49. Comparison of third-trimester fetal growth (length, right; weight, left) showing proportionate (3rd, 50th, and 97th percentile) changes over time. (From Saul et al.496 based on data from Usher and McLean.525)
parallel (Fig. 1-49), with proportionate growth continuing until birth. Scammon and Calkins497 have published measurements of numerous external features of more than 400 fetuses. These measurements can be used to assess anomalous growth in relation to gestational age or crown–heel length. Measurements of skeletal structures and of certain soft tissues and viscera have been made in utero during ultrasound examination.498 Standard curves have been constructed from the measurements and provide a basis for prenatally identifying overall growth impairments or specific anomalies. Postnatal Diagnosis
The goal of evaluation of the infant with a structural anomaly is to arrive at a specific diagnosis, following which the prognosis can be projected, a management plan formulated, and recurrence risks discussed with the family. If the pathogenesis can be determined, it may be helpful in understanding the anomaly and explaining the defect to the family. History
The agenda in evaluating the infant with a birth defect is little different from that used in general medical evaluations. In most medical diagnoses, history-taking plays an extraordinarily powerful role. The diagnosis is suggested by the history more often than by any other diagnostic adjunct. In the case of anomalies, the diagnosis may be immediately obvious to parents and physician alike because of prior occurrence in the family. Often, however, the history is less revealing. Nevertheless, attention must be given for clues in the history that help establish a diagnosis. Advanced
maternal age suggests an increased risk of a chromosomal cause for the anomaly; advanced paternal age suggests an increased risk for a new dominant single gene defect; kinship between the parents signals the possibility of an autosomal recessive gene defect. A history of abortions or stillbirths suggests the possibility of recurrence of a heritable defect—chromosomal, single gene, or multifactorial. Pregnancy history may likewise yield subtle clues to diagnosis. Fetuses that move poorly in utero may signal brain anomalies, other neuromuscular defects, limb malformations, or short limb skeletal dysplasias. Breech position may indicate constraint or a neuromuscular abnormality that impaired the ability to achieve cephalic presentation. Excessive low back pain associated with lack of movement may indicate constraint. Polyhydramnios indicates lack of fetal swallowing or gastrointestinal absorption of the amniotic fluid because of central nervous system or gastrointestinal anomalies. Oligohydramnios may signal obstructive urinary tract anomalies or anomalies of the kidneys. Certain maternal diseases and exposures during pregnancy alert the clinician to the possibility of particular anomalies; maternal diabetes and alcohol ingestion are the two most frequently encountered. When evaluation for congenital anomalies is requested, the defect may be obvious or there may be circumstances that only suggest the possibility of an anomaly. The latter is often the case in the neonatal period. Table 1-14 lists findings in the newborn that may prompt a search for occult anomalies. The manner in which the newborn adapts to postnatal life often suggests the possibility of an occult anomaly. The infant who has difficulty with breathing, feeding, or with maintenance of
Human Malformations and Related Anomalies Table 1-14. Findings in the newborn that prompt a search for occult anomalies Older parents Family history of anomalies, abortions, or stillbirths History of teratogenic exposures History of oligohydramnios or polyhydramnios History of decreased fetal movement Prematurity or postmaturity Breech presentation Overgrowth or undergrowth for gestational age Discordance of measurements Three or more minor anomalies Failure of neonatal adaptation Persistent hypotonia or hypertonia
muscular tone is particularly suspect. Anomalies of the central nervous system, other neuromuscular impairments, and cardiac defects may create problems in transition to postnatal life. In the older infant and child, developmental progress becomes a more important clue to the possibility of occult anomalies, particularly those involving the nervous system and special senses. In spite of the powerful role of history taking in establishing a diagnosis, the clinician must be aware that historical clues and familial features may be misleading. The history of prenatal distress may incline one to think of hypoxia or physical injury but may occur in the fetus with an intrinsic defect as well. Facial features that appear unusual may be familial rather than a sign of a syndromic complex. A negative history of drug exposure does not preclude drug ingestion during the pregnancy. Likewise, a history of exposure to a chemical during pregnancy does not mean that the exposure caused the fetal defect. Only when the pregnancy history is congruous with the physical defects can one accept the cause-and-effect relationship. Examination
Major anomalies that affect topographic anatomy become obvious on physical examination. Minor anomalies may require more careful attention, including measurements and comparisons to normal growth charts, but can provide equally important clues to diagnosis. Photographs of various anomalies are part of the documentation and are useful over time to document a changing natural history. Evaluation of the volar dermal ridges and creases may be helpful in certain syndromes. Both the nature of the anomalies and the composite of anomalies have diagnostic importance. The presence of three or more minor anomalies should prompt a search for occult major malformations. Childhood is marked by rapid changes in topographic features, growth, and developmental abilities. Features diagnostic at birth may not have been apparent in the mid-trimester fetus, and they will not remain the same throughout childhood and adolescence.499–503 Many conditions with diagnostic facial features in late childhood, adolescence, or adult life can appear entirely normal at birth. Numbered among these are individuals affected with Williams syndrome, fragile X syndrome, storage disorders, Angelman syndrome, Prader-Willi syndrome, and muscular dystrophy (Figs. 1-12, 1-50). Conversely, distinctive features in an infant may become less distinctive as the years pass, as is the case with Aarskog syndrome and Kabuki syndrome (Fig. 1-51).
61
At different ages, diagnosis depends on different features (Figs. 1-52, 1-53). At birth, infants with 45,X Turner syndrome have lymphedema, excess nuchal skin, and coarctation of the aorta; during childhood they have stunted growth; and at adolescence they fail to mature sexually.504 In fragile X syndrome, the infant is generally large at birth; delayed developmentally, particularly in speech, during the early years; displays facial characteristics of the syndrome in mid-childhood; and has macroorchidism in the postpubertal years.503 Infants with certain storage diseases may exhibit excessive growth, umbilical hernia, and hepatosplenomegaly at birth. During childhood they develop contractures or other skeletal abnormalities, eye abnormalities, developmental impairment, and slowing of growth. Physical observations should include detection of major anomalies, notation of minor defects and variations, assessment of growth (head circumference, weight and height or length), measurement of individual features that appear abnormal, and an estimate of developmental status. Unusual or repetitive behaviors should be noted. Repeated observations over a period of years may ultimately lead to a diagnosis not initially obvious or to revision of an incorrect diagnosis. Comparison of minor features, particularly facial characteristics, with those of the parents and siblings often permits separation of family features from those that may be of diagnostic importance. Review of photographs of family members taken at the same age as the patient can be helpful. Dysmorphology
The study of abnormal morphology is in large part the study of disharmonic growth.505–507 Individual morphologic features become distinctive because of their size in relation to other features around them. Downslanting palpebral fissures result from undergrowth of the malar region (zygoma) in relation to the frontal region (frontal bone). Micrognathia results from undergrowth of the mandible in relation to the maxilla. Macroglossia is overgrowth of the tongue in comparison to the oral cavity. This is not to say that absolute undergrowth or overgrowth does not occur in these circumstances, but only that the disharmony of growth is the phenomenon that provokes identification of features as dysmorphic. A large tongue accommodated in a large mouth in a large craniofacies will not likely be singled out as a dysmorphic feature. Dysmorphology employs both gestalt and measurements in assessing patients with anomalous development. Major anomalies pose little difficulty and in general do not require measurement. More subtle alterations of morphology may be discerned by the eye, but confirmation by measurement substantiates the clinical observation. Standards of Measurement
The establishment of normal values for traits that vary continuously is based on the measurement of the trait in a large number of individuals. Unbiased estimates may be obtained by randomly sampling the population in question. In many cases, if sufficient data are accumulated, continuous variables are distributed in a manner that approximates a normal distribution curve. The distribution can be further described by two parameters, the mean and the standard deviation.508 Data that describe normal distributions have been well characterized mathematically and are available in tabulated and graphics forms, allowing generalizations to be made about the distributions of the traits. For example, for a trait exhibiting a normal distribution, two-thirds or 68% of the observations will
Fig. 1-50. A–D: Williams syndrome showing evolution of facial features at 6 months (A), 12 months (B), 4 years (C), and 20 years (D). E–H: Prader-Willi syndrome with 15q interstitial deletion. (E) 9-month-old female with hypotonia and feeding difficulties requiring tube feedings. Slight cupid’s bow configuration to the upper lip is present but the facies appear normal otherwise. (F) 3-year-old male with history of hypotonia, feeding difficulties requiring tube feedings until age 6 months, and developmental delay. He has esotropia, cupid’s bow configuration to upper lip, and short stature. (G) 9-year-old girl with moderate obesity, short stature, small hands and feet, and (H) same girl at age 16 years showing morbid obesity.
Human Malformations and Related Anomalies
63
Fig. 1-51. Aarskog syndrome in 3 males at ages 2 years, 18 years, and 60 years. The triangular facial configuration with prominence of the forehead and hypertelorism becomes less apparent with increasing age.
Fig 1-52. Turner syndrome (45,X karyotype) at ages 3 months and 3 years. In infancy, this girl appeared normal except for epicanthal folds and puffiness of the hands and feet. By age 3 years she had short stature and webbing of the neck had become prominent.
fall within ± 1 SD of the mean, and 95% will fall within ± 2 SD (Fig. 1-20). In many cases, abnormal physical measurements are arbitrarily considered to be those values that lie in the upper and lower 2.5% of the distribution or that are greater than 2 SD from the mean. Microcephaly is defined as a head circumference less than 2 SD below the mean; macrocephaly as greater than 2 SD
above the mean. Functional deficits can be defined in these terms as well. Scores of less than 2 SD on standardized intelligence tests arbitrarily define mental retardation within our population. A formidable body of human anatomic measurements (taken during the prenatal period and during infancy, childhood, and, to a lesser extent, adult life) has been accumulated.496–498,509–511 It might be assumed that the growth standards were derived from
64
Overview
Fig. 1-53. Four males with fragile X syndrome at ages 3 years (A), 7 years (B), 23 years (C), and 41 years (D). Prominence of the forehead is evident from early childhood, but enlargement of the lower jaw develops in late adolescence or adulthood.
data collected with rigidly controlled protocols, which entails placing the subject in a natural and relaxed position, having measurements taken by an experienced observer, and using the most precise instruments. Calipers are used for taking measurements less than 30 cm, and rigid measuring devices (measuring table or stadiometer) are used for measuring length or height. Certainly many of the standards were prepared in this optimal fashion. However, that is not always the case. It is advisable for the users of growth
standards to become familiar with the population from which the data were collected, with the method of data collection, and with the number and experience of individuals collecting the data. Ethnic differences occur in many measurements; however, well established ethnic norms are rarely available. Growth references for certain uncommon populations may derive from pooled data. This applies particularly to growth references for skeletal dysplasias and syndromes.496,512,513 The data
Human Malformations and Related Anomalies
may come from many sources, collected over a period of many years, and are usually collected by a number of different observers in a number of different settings. Unfortunately, heterogeneity of the subject population may not be rigidly excluded. While such standards are not optimal, they may be the only reference available for certain populations. Many genetic texts contain standards for growth during the childhood years but lack information on mature measurements. This deficiency is removed in part by the data in the Natick Anthropometric Survey.511 In the latest (1988) survey, 132 different measurements were taken of 2208 females ages 18 to 50 years and of 1774 males ages 17 to 51 years. Seventy-eight percent of all subjects were ages 20 to 35 years. The sample was composed of persons in the U.S. Army. Among the men, 66.1% were white, 25.8% were black, and 3.8% were Hispanic. Among the women, 51.6% were white, 41.8% were black, and 2.6% were Hispanic. Obtaining accurate measurements is not easy. Features with clearly defined boundaries can be measured relatively precisely. Human topography is characterized by curvilinear structures and hence provides a greater challenge. Curvature of body surfaces, tone difference, and subject cooperation also influence the accuracy of measurements. Often the setting in which the person is evaluated does not permit the use of the most accurate instruments and may be compounded by insufficient lighting, lack of cooperation, and insufficient time to achieve the accuracy desired. These difficulties aside, the clinician is called upon in a variety of settings to obtain measurements for use in diagnosis. Usually straight rulers, flexible tapes, and scales are the only measuring devices available. With knowledge of the proper anatomic landmarks and care in taking measurements, the clinician can make reliable observations under less than ideal circumstances. That there is some limitation of comparison of these values with those carefully collected in the research setting must, however, be acknowledged. Other Methods of Measurement
Photogrammetry has been used as an alternative to direct measurement. Standardized photographs are taken to depict features of interest. A scale is included to permit various features to be measured on the photograph. With the features converted into a two-dimensional image, measurements are easily made by hand or by computer. This method requires a standardized photographic assembly, is costly, and does not provide measurements immediately for the clinician. More recently, computer programs can simulate three dimensions and volumes. Radiocephalometry provides another method for assessment of craniofacial anomalies.514–516 Based on standardized positions and radiographic techniques, various landmarks of the craniofacial skeleton are identified and measurements taken. Radiocephalometry has utility in defining the anatomy in craniofacial syndromes and in planning reconstructive surgery. It requires standardized equipment, is tedious, and is not readily adaptable to most clinical settings. Radiographs are necessary for the measurement of most components of the skeleton. They permit individual bones to be measured for comparison to age-specific population data and permit one skeletal feature to be compared with others in the same individual. The latter use detects disharmonic growth. Radiography has been most successfully employed in comparisons of the tubular bones of the hand, a procedure termed metacarpophalangeal profile analysis.517 Most syndromes with abnormalities of the hands will have a more or less distinctive profile.
65
Fig. 1-54. Computed three-dimensional reconstruction of cranial tomography demonstrating skull with left coronal synostosis. (Courtesy of Dr. Michael W. Vannier, Washington University Medical Center, St. Louis, MO.)
Computed tomography and magnetic resonance imaging can be used for two-dimensional viewing and for three-dimensional reconstruction of most anatomic parts (Figs. 1-54, 1-55).518–522 The imaging systems give the clinician a view of many features that are normally hidden. Three-dimensional reconstructions are helpful in planning surgery and in projecting the results anticipated from surgery. Growth in Infancy and Childhood
Growth is a complex phenomenon, largely determined by the genetic constitution but also easily influenced by many environmental insults. Growth is mediated through hormonal stimulation of various tissues, particularly the chondroosseous skeleton. Nonspecific impairments of growth can be caused by a wide range of environmental influences, including nutrition, oxygen supply, infection, systemic disease, numerous drugs and chemicals, and emotional deprivation. Unlike prenatal environmental insults to growth, postnatal insults generally affect growth overall rather than that of isolated features. An exception to this generalization is the coarsening of lower facial features and gum hypertrophy caused by prolonged postnatal exposure to the hydantoins.523 Growth during infancy and childhood is expected to proceed at an orderly and predictable pace. Standards for growth of most anatomic features are available.496,498,509,510,524–532 Feingold and Bossert513 studied over 2400 individuals, newborn to age 14 years, and constructed growth curves for many different anatomic features. These and other growth references have been published as monographs.496,509 Most growth curves are prepared from measurements of a cross section of the population and with few exceptions are referenced against age. Growth in Individuals with Skeletal Dysplasias and Malformation Syndromes
Growth in many malformation syndromes, skeletal dysplasias, and metabolic disorders proceeds at a rate different from that of the general population. For most of these disorders, insufficient cross-sectional or longitudinal data have been collected to permit the construction of growth curves.496,512,513 For those conditions for which curves are available, growth can be monitored and the success of various treatments analyzed. Growth curves for children with achondroplasia, the most common form of short-limb dwarfism, have been available since 1978 and are immensely useful in evaluating such patients. Horton et al.512 collected growth data on over 400 patients with achondroplasia and constructed growth curves for stature, growth
66
Overview
Fig. 1-55. Three-dimensional reconstruction of computed tomography imaging of cranium of infant with osteogenesis imperfecta. Anteroposterior view (left) and vertex view (right) show marked deficiency of cranial ossification.
velocity, upper/lower segment ratios, and head circumference. The curves for stature and head circumference in Fig. 1-56 demonstrate the marked discrepancy between the expected growth in achondroplasia and the normal growth in the general population. Following the growth of achondroplastic children using normal growth curves is of limited benefit, but comparisons with the growth curves of other children with achondroplasia can be very instructive. Individuals with achondroplasia usually have significant macrocephaly. Comparing their head growths to those of other individuals with achondroplasia can often reassure the family and thus avoid unnecessary diagnostic tests. Furthermore, if any growth-promoting intervention is used, the change in growth should be compared with that expected in achondroplasia without the intervention. Meaney and Farrer513 have cataloged the information available on growth in a number of different genetic and congenital disorders. Their exhaustive tabulation reveals that all too often insufficient data are available to prepare clinically useful growth curves such as those available for achondroplasia. Table 1-15 lists those conditions for which growth information has been compiled and charts have been adapted for clinical use. The most
useful curves are available in the collected works of Saul et al.496 and Hall et al.509 In many cases the available growth data must be considered preliminary because the studies did not include as many observations as broad collaborative studies have provided. Such broad studies are needed to understand the natural history of pathologic states and to provide the necessary information for counseling patients with abnormal growth and their families. Laboratory Testing and Imaging
Diagnostic technology has received considerable attention during the past few decades. Radiographs and other imaging procedures are used to define anomalies; cytogenetic, molecular, and biochemical testing screen for underlying chromosomal and gene errors; and computer data banks synthesize information. It may seem that the clinician’s role in the evaluation may be displaced by these techniques. To the contrary, the physician geneticist remains central to the evaluation process. Of equal importance to the clinician’s roles in arriving at a correct diagnosis and providing information for the family, is the development of a long-term relationship with the family. This has particular importance because of the pace at which new knowledge, diagnostic techniques,
" Fig. 1-56. Composite of growth curves for individuals with achondroplasia: stature (top) and head circumference (bottom). Females, left; males, right. Shaded areas represent normal growth; mean ± 2 SD are shown for achondroplasia. (From Saul et al.496 based on data of Horton et al.512)
67
68
Overview Table 1-15. Conditions for which growth curves are available Achondroplasia Amyoplasia de Lange syndrome Diastrophic dysplasia Distal arthrogryposis
Table 1-16. Indications for chromosome analysis Individual with
Features of recognizable chromosomal syndrome Mental retardation of unknown cause Unexplained major and minor anomalies Multiple congenital anomalies
Fragile X syndrome
Abnormalities of sexual development, including ambiguous or hypoplastic genitalia and failure of sexual maturation at puberty
Marfan syndrome
Unexplained abnormalities of growth
Multiple pterygium syndrome
Certain malignancies
Noonan syndrome
Unexplained failure of neonatal adaptation
Prader-Willi syndrome
Features of mosaicism (hypomelanotic spots, streaky pigmentary disturbance, asymmetry)
Pseudoachondroplasia Rubinstein-Taybi syndrome Sickle cell disease
Couples with
Spondyloepiphyseal dysplasia
Repeated spontaneous abortions
Trisomy 13
Infertility
Trisomy 18
Offspring with a chromosomal duplication, deletion, or other rearrangement
Trisomy 21 (Down syndrome) Williams syndrome From Saul et al. 1998.496
and prevention strategies are being devised. The sensitive clinician also orchestrates the evaluation in such a manner as to be most efficient and least stressful to the emotions and finances of the family. Laboratory and imaging technologies play important roles in the diagnosis of the infant with anomalies. These roles will likely increase as an understanding of the molecular basis for anomalies is gained. Testing is appropriately used, first, to confirm a suspected diagnosis and, second, as a diagnostic probe. Most genetic testing is noninvasive. Selection of tests should be made judiciously, nonetheless, if for no other reason than the costs involved. In most cases laboratory testing involves blood samples, urine specimens, or tissue biopsy. The ability to perpetuate genotypically stable cell lines (as fibroblasts or lymphoblasts) has been of great utility in the study of infants with anomalies and other heritable disorders. Cells from these cultures may be frozen and later thawed and subcultures reestablished for analysis. This has been particularly helpful in those cases in which the patient has died and in situations where there is the need to transport diagnostic materials to some distant site. Chromosome Analysis
Chromosome aberrations, in particular aneuploidies and deletions, cause a number of malformation syndromes.123 Less commonly, chromosome abnormalities may be found in apparently isolated malformations. Chromosome preparations may be made from cultures of lymphocytes, skin and other solid tissues, amniotic fluid cells, and chorionic villi. Chromosome preparations can also be made on bone marrow and chorionic villus cells without culture. The quality of such preparations is less satisfactory than that of preparations from cell culture. Table 1-16 lists many conditions in which chromosome analysis may be indicated. None of these conditions has a consistent chromosomal etiology, but this possibility may need to be excluded when another etiology has not been established.
Family Members of
An individual with inherited chromosome duplication, deletion or other rearrangement Pregnancy Products
Abortions Unexplained stillborns Hydropic placentas
Biochemical Tests
Biochemical testing of infants with structural anomalies is not very helpful in identifying causes of the anomalies. Usually, infants and children with metabolic disorders do not have structural anomalies or other dysmorphic features. Important exceptions do occur. Metabolic disorders are an important cause of nonimmune and noninfectious hydrops fetalis (Table 1-17).533 Some infants with metabolic disorders have structural anomalies or distinctive anatomic features at birth (Tables 1-18 and 1-19), and others develop distinctive features with the progression of the metabolic disorder.533–539 Defects of neuronal migration and other structural abnormalities of the brain have been noted in a number of inborn errors of metabolism (Table 1-18). Disorders of cholesterol metabolism, fatty acid oxidation, glycoprotein glycosylation, and peroxisomal metabolism in particular may be accompanied by anomalies at birth. Persons with lysosomal storage diseases typically develop abnormal features with the passage of time. Hence, infants with Hurler disease (MPS 1-H) may have excessive weight, macrocephaly, hernias, macroglossia, and hepatosplenomegaly at birth or during the very early months of life. During childhood they develop gibbus deformation, stiffness of the joints, corneal clouding, and short stature. Other storage diseases appear entirely normal at birth but develop many of the same features during early childhood. A large and complex group of metabolic disorders—the congenital disorders of N-glycosylation (CDGIa-g, CDGIIa-d) and O-glycosylation (Walker-Warburg syndrome, muscle-eye-brain disease, progeroid type of Ehlers-Danlos syndrome, hereditary
Human Malformations and Related Anomalies Table 1-17. Heritable metabolic causes of hydrops fetalis Mucopolysaccharidoses Sly disease: MPS VII Morquio disease: MPS IV Mucolipidoses II: I-cell disease GM1 gangliosidosis Galactosialidosis Sialidosis: neuraminidase deficiency Infantile sialic acid storage disease Nieman-Pick Farber Gaucher Congenital disorders of glycosylation Hematologic disorders a-thalassemia G6PD deficiency Pyruvate kinase deficiency Glucose phosphate isomerase deficiency
multiple exostosis), which may have variable structural anomalies (Table 1-18)—is currently being delineated at the biochemical and molecular level. Traditionally the study of hormones and enzymes, metabolism has expanded to the study of gene products that are involved in the structure of various tissues. These structural proteins— collagen, fibrillin, elastin, and others—have proven important in the pathogenesis of a number of syndromes.540–546 Defects in different collagens have been demonstrated in a number of skeletal dysplasias (see Chapter 22); defective fibrillins have been found in Marfan syndrome and Beals syndrome; defective elastin has been found in supravalvular aortic stenosis and Williams syndrome.540–545 A battery of simple biochemical tests can be performed on urine specimens to screen for a variety of metabolic disorders.547 These tests are not specific and should be used only as screening tests. Most laboratories include the following tests: Benedict’s test (detects reducing sugars), dinitrophenylhydrazine (detects ketoacids), toluidine blue spot test (detects mucopolysaccharides), the nitroprusside test (detects cystine and homocystine), nitrosonaphthol test (detects tyrosine metabolites), and ferric chloride (detects phenylalanine and histidine metabolites). These tests have only limited use in the evaluation of the child with congenital anomalies. With the exception of the mucopolysaccharidoses, the conditions detected by these screening tests do not commonly have anomalies. Some laboratories include an oligosaccharide screen in the urine metabolic screen.548 This test may be positive in several lysosomal storage diseases (mucolipodosis II, GM1 gangliosidosis, GM2 gangliosidosis, fucosidosis, mannosidosis, glycogen storage disease type II, galactosialidoses, sialic acid storage diseases, and aspartylglucosaminuria), conditions that, like the mucopolysaccharidoses, may have hernias, hepatosplenomegaly, and excessive intrauterine growth. Urine screening tests may be performed on random specimens or timed collections. Other inborn errors of metabolism associated with malformations or dysmorphic features (Table 1-18) may require specific testing of blood, urine, or cultured cells.
69
Molecular Analysis
A vast number of conditions with structural anomalies have now been associated with mutations in specific genes; others have been localized to more or less discrete regions of the genome (Table 1-10). Molecular technologies can be employed in the diagnosis, carrier testing, and prenatal detection of many of these conditions. The pace of gene discovery and linkage to developmental anomalies has been quickened by the Human Genome Project and related research. As one consequence, molecular diagnostics and molecular cytogenetics have become formidable components of current overall laboratory testing technologies. The addition of microarray technologies promises to expand the utility of these technologies. Molecular Chromosomal Studies
Techniques to identify specific sequences of DNA have led to an ever expanding suite of diagnostic tests.549–551 Fluorescence probes have been developed, using a wide range of colors (flors), to identify unique sequences. These can be utilized directly on interphase nuclei or chromosome preparations (e.g., fluorescent in situ hybridization—FISH) to visually identify deletions, duplications, and translocations (Fig. 1-57). They are also used to order genes along the chromosome. Comparative genomic hybridization utilizes a normal reference panel of DNA to identify missing or extra DNA.550 Since it is done utilizing chromosomes, the molecular mapping of these abnormalities determines which chromosome(s) is affected. It is more accurate than analysis of extended chromosome preparations, but less accurate than targeted fluorescent probes. However, it is a useful screening technique. Microarrays of multiple DNAs, RNAs, and proteins allow testing for multiple sequences simultaneously. These have enormous potential for identifying specific mutations in a pathway, expression of specific genes in a time specific tissue, specific manner and defining differences between normal and pathologic states. Imaging
Sonographic and magnetic resonance imaging are to the soft structures of the body what radiographs have been to the skeleton. The anatomy of internal soft tissues, previously hidden to a large degree, can now be studied with noninvasive techniques. Heart anatomy can be defined without catheterization; spine and brain anatomy can be outlined without pneumoencephalography or vascular imaging; the kidneys can be seen without contrast infusions. Most imaging of non-skeletal internal structures can now be done without radiation exposure by using sonography and magnetic resonance. Radiographs are necessary in the evaluation of the skeletal dysplasias. Functional imaging studies will help to define the differences in congenital anomalies and disorders involving behavioral abnormalities when compared to normal. Photography
Photography provides an easy means of documenting distinctive anatomic features and recording changes that take place over time. Features of interest should be photographed against a neutral backdrop. A scaled background can be used to give an estimate of size. Measurements of various features can be taken from photographs made under standardized conditions. Elimination of shadows that obscure details of various features may be achieved by indirect illumination. Clothing, jewelry, or makeup that cover the feature(s) of interest should be removed.
Table 1-18. Inborn errors of metabolism associated with brain malformations Defects of Neuronal Migration Metabolic Error
Lissencephaly/ Pachygyria
Polymicrogyria
Cortical Heterotopias
Dysgenesis of Corpus Callosum
Cerebellar Malformation/ Dysplasias
Holoprosencephaly
þ
þ
þ
þ
þ
þ
þ
Dysplasia of Olivary Nuclei
Hypoplasia of Temporal Lobes
Amino Acids Nonketotic hyperglycinemia
þ
þ
Cholesterol Smith-Lemli-Opitz
þ
þ
þ
Fatty Acid Oxidation þ
Carnitine palmitoyl transferase 2 Glutaric acidemia 2
þ
þ
þ
Glycosylation Congenital disorders of N-glycosylation Congenital disorders of O-glycosylation
þ
þ
Mitochondrial þ
Fumarase deficiency Pyruvate dehydrogenase deficiency
þ
þ
þ
þ
þ
þ þ
þ
þ
Respiratory chain enzyme deficiency Organic Acidurias Ethylmalonic acidemia*
þ
Glutaric acidemia 1 Peroxisomal Zellweger
þ
þ
þ
Infantile Refsum
þ
þ
þ
þ
Infantile adrenoleukodystrophy Functional enzyme deficiency
þ
þ
þ
þ
þ
þ
þ
þ þ
Chondrodysplasia punctata Others þ
Menkes Adenylate succinate lyase deficiency *Associated with neural tube defects Adapted from Nissenkorn et al., 2001.538
þ
þ
þ
þ þ
Human Malformations and Related Anomalies
71
Table 1-19. Inborn errors of metabolism associated with malformations and dysmorphic features Inborn Errors
Structural Anomalies
Biochemical Findings
Adenylate Succinate Lyase Deficiency
Lissencephaly, hypoplasia of cerebellar vermis
ADSL deficiency (urinary metabolites)
CDG I (a,d,e,f,g Subtypes)
Variable microcephaly, agenesis of corpus callosum, cerebellar hypoplasia, hypertelorism, colobomas, optic nerve atrophy, retinitis pigmentosa, short stature, short limbs, inverted nipples, abnormal fat disposition, joint contractures, ichthyosis, depending on subtype
Abnormal sialidation of serum transferrin (detected by isoelectric focusing)
CDG II (a–d Subtypes)
Variable coarse facies, short stature, short limbs, large and low-set ears
Abnormal sialidation of serum transferrin in subtypes a and d (detected by isoelectric focusing)
Walker-Warburg Syndrome
Lissencephaly, encephalocele, microphthalmia
–
Muscle-Eye-Brain Disease
Hydrocephaly, cerebellar hypoplasia, glaucoma, muscle dystrophy
–
Progeroid Type of Ehlers-Danlos Syndrome
Short stature, scant scalp hair, aged appearance, elastic skin, hypermobile joints, osteopenia
–
Hereditary Multiple Exostoses
Congenital Disorders of N-Glycosylation
Disorders of O-Glycosylation
Short stature, exostoses
–
DOOR (deafness, onychodystrophy, onycholysis, mental retardation)
Short broad nose, ptosis, absence of fingernails and toenails, triphalangeal thumbs
Elevated a-ketoglutarate
Errors of Cholesterol Synthesis (SmithLemli-Opitz, CHILD, Greenberg dysplasia, chondrodysplasia punctata, Antley-Bixler, desmosterolosis, lathosterolosis, mevalonic aciduria)
Craniofacial, brain, skeletal and genital anomalies
Low cholesterol with elevated precursors
Glutaric Aciduria 2
Large fontanel, agenesis of corpus callosum, renal cysts, lissencephaly, cerebellar dysgenesis
Acidosis, hypoglycemia, elevations of glutaric acid
Lysosomal Disorders (mucopolysaccharidoses, mucolipidoses, gangliosidoses, sialidoses)
Coarse facies, hernias, hepatosplenomegaly, dysostosis multiplex
Elevated urinary mucopolysaccharides, abnormal oligosaccharides
Menkes
Kinky hair with pili torti, cortical heterotopias, dysgenesis of the corpus callosum and cerebellum
Low serum copper and ceruloplasmin
Peroxisomal Disorders (Zellweger, infantile adrenoleukodystrophy, infantile Refsum)
Distinctive facies, brain anomalies including migration defects and dysgenesis of the cerebellum and corpus callosum, corneal clouding, hepatomegaly, renal cysts, stippling of epiphyses, joint contractures
Elevated very long chain fatty acids, plasmalogens
Note: Structural anomalies have also been reported in patients with nonketonic hyperglycinemia, fumarase deficiency, multiple acyl CoA dehydrogenase (MCAD) deficiency.
1.8 Discussions with the Family Communication of information to the affected individual and family is perhaps the most important responsibility of the physician. The physician must be comfortable explaining the heritable or environmental basis of anomalies when an etiology is established and must be knowledgeable about the potential for prevention through various pregnancy alternatives, including prenatal diagnosis. The accuracy of the information provided by the physician must be assured by careful attention to the details of the case and by a continual awareness of new knowledge. The physician responsible for determining the cause of anomalies must become accustomed to the use of the phrase, ‘‘I don’t know.’’ The search for the cause of human anomalies fails in about one-half of cases (Table 1-5).40–42 Even without knowing the cause, information gained during the evaluation may benefit the family. Based on experience with similar cases, the prognosis may be reasonably stated and the recurrence risk given. In the course of the evaluation, the physician and
coworkers develop an interest in the affected individual and family, gain a feeling for the impact that the defect may have on family members, and assume a position of trust and confidence from which continuing support can be given. Sensitivity assists the physician in relating to the family. Much has been said in favor of having a team of specialists from different disciplines participate in the evaluation and management of certain anomalies.552–554 One advantage is bringing the various medical, surgical, and paramedical personnel to one site. When the availability of specialists and the logistics make this impractical, it is optimal for one physician to assume responsibility for coordinating all aspects of the complex evaluation. Attention should be given to support of the family unit and amelioration of the guilt that often develops in one or both parents. Paramount among the questions asked by the affected individual or parents are what is the defect, why did it happen, and will it happen again? In the best of circumstances, all these questions can be answered. In the worst, none can be answered completely. In any circumstance, an approach to management of the anomaly must be worked out with the family. The family may
72
Overview
Fig. 1-57. Fluorescence in situ hybridization (FISH). Left: 2 interphase nuclei with FISH using probes specific for the alpha satellite region (D18Z1) of the centromere of chromosome 18, indicating trisomy 18. Right: 2 metaphase spreads with chromosome 17s identified by FISH using the RARA probe (17q21.1) (arrowheads) and presence of the Smith-Magenis region (7p11.2) on only one of the two chromosomes, diagnostic of the Smith-Magenis syndrome. (Courtesy of Dr. Barbara DuPont and Sydney Ladd, Greenwood Genetic Center, Greenwood, SC.)
elect to have the support and advice of family members, friends, clergy, or others. When appropriate, members of the extended family may also be brought into the evaluation. When a diagnosis cannot be made, the physician or family may wish to consult other geneticists and dysmorphologists. This may be accomplished by direct consultation in another center or by correspondence. If done by correspondence, the sharing of photographs of features is a tremendous asset to the consultant. Regular follow-up is critical to optimizing the potential of an eventual diagnosis. These follow-up visits also emphasize to the family that interest in their child’s welfare continues. References 1. Hertig AT, Rock J, Adams EC, et al.: Thirty-four fertilized human ova, good, bad and indifferent, recovered from 210 women of known fertility. Pediatrics 23:202, 1959. 2. Roberts CJ, Lowe CR: Where have all the conceptions gone? Lancet 1:498, 1975. 3. Wilcox AJ, Weinberg CR, O’Connor JR, et al.: Incidence of early loss of pregnancy. N Engl J Med 319:189, 1988. 4. Poland BJ, Miller JR, Harris M, et al.: Spontaneous abortion: a study of 1,961 women and their conceptuses. Acta Obstet Gynecol Scand Suppl 102:1981. 5. Boue J, Boue A, Lazar P: The epidemiology of human spontaneous abortions with chromosomal anomalies. In: Aging Gametes. RJ Blandau, ed. Karger, Basel, 1975, p 330.
6. Kalousek DK, Pantzar T, Tsai M, et al.: Early spontanous abortion: morphologic and karyotypic findings in 3912 cases. Birth Defects Orig Artic Ser 29:43, 1993. 7. Shepard TH, Fantel AG, Fitzimmons J: Congenital defect rates among spontaneous abortuses: twenty years of monitoring. Teratology 39:325, 1989. 8. Whitaker PG, Taylor A, Lind T: Unsuspected pregnancy loss in healthy women. Lancet 1:1126, 1983. 9. Shiota K, Uwabe C, Nishimura H: High prevalence of defective human embryos at the early postimplantation period. Teratology 35:309, 1987. 10. Miller JF, Williamson E, Glue J, et al.: Fetal loss after implantation. Lancet 2:554, 1980. 11. Rushton DI: Examination of products of conception from previable human pregnancies. J Clin Pathol 34:819, 1981. 12. Harlap S, Shiono PH, Ramcharan S: A life table of spontaneous abortions and the effects of age, parity, and other variables. In: Human Embryonic and Fetal Death. IH Porter, EB Hook, eds. Academic Press, New York, 1980, p 145. 13. Warburton D, Stein Z, Kline J, et al.: Chromosome abnormalities in spontaneous abortion: data from the New York City study. In: Human Embryonic and Fetal Death. IH Porter, EB Hook, eds. Academic Press, New York, 1980, p 261. 14. Eiben B, Bartels I, Bahr-Ponsch S, et al.: Cytogenetic analysis of 750 spontaneous abortions with the direct preparation method of chorionic villi and its implications for studying genetic causes of pregnancy wastage. Am J Hum Genet 47:656, 1990. 15. Hassold T, Chen N, Funkhouser J, et al.: A cytogenetic study of 1000 spontaneous abortions. Ann Hum Genet 44:151, 1980. 16. Tabet AC, Aboura A, Dauge MC, et al.: Cytogenetic analysis of trophoblasts by comparative genomic hybridization in embryo-fetal development anomalies. Prenat Diagn 21:613, 2001. 17. Kajii T, Ferrier A, Niikawa N, et al.: Anatomic and chromosomal anomalies in 639 spontaneous abortuses. Hum Genet 55:87, 1980. 18. Marden PM, Smith DW, McDonald MJ: Congenital anomalies in the newborn infant, including minor variations. J Pediatr 64:357, 1964. 19. Van Regemorter N, Dodion J, Druart C: Congenital malformations in 10,000 consecutive births in a university hospital: need for genetic counseling and prenatal diagnosis. J Pediatr 104:386, 1984. 20. Myrianthopoulos NC, Chung CS: Congenital malformation in singletons: epidemiologic survey. BDOAS X(11):1, 1974. 21. Chung CS, Myrianthopoulos NC: Congenital anomalies: mortality and morbidity, burden and classification. Am J Med Genet 27:505, 1987. 22. National Birth Defects Prevention Network: Birth defects surveillance data from selected states, 1996–2000. Birth Def Res (Part A) Clin Mol Teratol 67:729, 2003. 23. Johnson KC, Rouleau J: Temporal trends in Canadian birth defects prevalences, 1979–1993. Can J Public Health 88:169, 1997. 24. Queisser-Luft A, Stolz G, Wiesel A, et al.: Malformations in newborn: results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990–1998). Arch Gynecol Obstet 266:163, 2002. 25. Stoll C, Eurocat Working Group: Distribution of single organ malformations in European populations. Ann Genet 38:32, 1995. 26. California Birth Defects Monitoring Program: Birth Defects in California: 1983–1990. California Birth Defects Monitoring Program, 1994. 27. Cha´vez GF, Cordero JF, Becerra JE: Leading major congenital malformations among minority groups in the United States, 1981–1986. CDC Surveil Sum 37:17, 1988. 28. Ka¨lle´n B: Population surveillance of multimalformed infants: experience with the Swedish registry of congenital malformations. J Hum Genet 35:205, 1987. 29. Merlob P, Papier CM, Klingberg MA, et al.: Incidence of congenital malformations in the newborn, particularly minor abnormalities. Prog Clin Biol Res 163(C):51, 1985. 30. Graham JM: Clinical approach to human structural defects. Semin Perinatol 15(Suppl 1): 2, 1991.
Human Malformations and Related Anomalies 31. Angell RR, Sandison A, Brain AD: Chromosome variation in perinatal mortality: a survey of 500 cases. J Med Genet 21:39, 1984. 32. Pitkin RM: Fetal death: diagnosis and management. Am J Obstet Gynecol 157:583, 1987. 33. Curry CJR: Pregnancy loss, stillbirth, and neonatal death. A guide for the pediatrician. Pediatr Clin N Am 39:157, 1992. 34. Pauli RM, Reiser CA, Lebovitz RM, et al.: Wisconsin Stillbirth Service Program: I. Establishment and assessment of a community-based program for etiologic investigation of intrauterine deaths. Am J Med Genet 50:116, 1994. 35. International Clearinghouse for Birth Defects Monitoring Systems: Annual Report 1999, with data for 1997. International Centre for Birth Defects, Rome, 1999. 36. Centers for Disease Control and Prevention: Infant mortality statistics from the 2001 period linked birth/infant death data set. Nat Vital Stat Rep 52:1, 2003. 37. Muhuri PK, MacDorman MF, Ezzati-Rice TM: Racial differences in leading causes of infant death in the United States. Paediatr Perinat Epidemiol 18:51, 2004. 38. Serenius F, Winbo I, Dahlquist G, et al.: Cause-specific stillbirth and neonatal death in Sweden: a catchment area-based analysis. Acta Paediatr 90:1054, 2001. 39. Mattos TC, Giugliani R, Haase HB: Congenital malformations detected in 731 autopsies of children aged 0 to 14 years. Teratology 35:305, 1987. 40. Blackburn W, Cooley NR Jr: The delineation of birth defects by fetal autopsy. Proc Greenwood Genet Center 16:15, 1997. 41. Wilson JG: Environment and Birth Defects. Academic Press, New York, 1973. 42. Nelson K, Holmes LB: Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 320:19, 1989. 43. Jones KL: Smith’s Recognizable Patterns of Human Malformations, eds 4, 5. WB Saunders, Philadelphia, 1988, 1997. 44. Stevenson RE, Jones KL, Phelan MC, et al.: Vascular steal: the pathogenetic mechanism producing sirenomelia and associated defects of the viscera and soft tissues. Pediatrics 78:451, 1986. 45. Biesecker LG: The multifaceted challenges of Proteus syndrome. JAMA 285:2240, 2001. 46. Kurnit DM, Layton WM, Matthysse S: Genetics, chance, and morphogenesis. Am J Hum Genet 41:979, 1987. 47. International Anatomical Nomenclature Committee: Nomina Anatomica, ed 6. Churchill Livingstone, Edinburgh, 1989. 48. Malacarne V: Memoires della societes itali, vol IX. 1798, p 49. 49. Spranger J, Benirschke K, Hall JG, et al.: Errors of morphogenesis: concepts and terms. J Pediatr 100:160, 1982. 50. Me´hes K, Stalder G: Minor Malformations in the Neonate. Akade´miae Kiado´, Budapest, 1983. 51. Leppig KA, Werler MM, Cann CI, et al.: Predictive value of minor anomalies. I. Association with major malformations. J Pediatr 110:531, 1987. 52. Holmes LB: Congenital malformations. N Engl J Med 295:204, 1976. 53. Smith DW: Classification, nomenclature, and naming of morphologic defects. J Pediatr 87:162, 1975. 54. Opitz JM, Herrmann J, Pettersen JC, et al.: Terminological, diagnostic, nosological, and anatomical-developmental aspects of developmental defects in man. Adv Hum Genet 9:71, 1979. 55. Pinsky L: The polythetic (phenotypic community) system of classifying human malformation syndromes. BDOAS XIII(3A):13, 1977. 56. Gilbert-Barness E, Opitz JM, Barness LA: The pathologist’s perspective of genetic disease: malformations and dysmorphology. Pediatr Clin North Am 36:163, 1989. 57. McKusick VA: On lumpers and splitters, or the nosology of genetic disease. BDOAS V(1):23, 1969. 58. Merks JH, Karnebeek CD, Caron HN, et al.: Phenotypic abnormalities: terminology and classification. Am J Med Genet 123A:211, 2003. 59. Spranger J, Smith DW: Pro and con the term ‘‘anomalad.’’ J Pediatr 93:159, 1978. 60. Bartsocas CS, Smith DW, Fraser FC: ‘‘Anomalad’’ versus ‘‘polyanomaly.’’ J Pediatr 88:899, 1976.
73
61. Benirschke K, Lowry RB, Opitz JM, et al.: Developmental terms—some proposals: first report of an international working group. Am J Med Genet 3:297, 1979. 62. Fiedler L: Freaks, Myths and Images of the Secret Self. Simon and Schuster, New York, 1978, p 15. 63. Johannsen W: Elemente der exakten Erblichkeitslehre. Jena: Fischer, 1909, p 143. 64. Comi AM: Pathophysiology of Sturge-Weber syndrome. J Child Neurol 18:509, 2003. 65. Opitz JM, Reynolds JF, Spano LM: The Developmental Field Concept. Alan R Liss, New York, 1986. 66. Opitz JM, Gilbert EF: Editorial Comment: CNS anomalies and the midline as a ‘‘developmental field.’’ Am J Med Genet 12:443, 1982. 67. Mall FP: On stages in the development of human embryos from 2 to 25 mm long. Anat Anz 46:78, 1914. 68. Streeter GL: Developmental horizons in human embryos: description of age group XI, 13 to 20 somites, and age group XII, 21 to 29 somites. Contrib Embryol 30:211, 1942. 69. Streeter GL: Developmental horizons in human embryos: description of age groups XIX, XX, XXI, XXII, and XXIII, being the fifth issue of a survey of the Carnegie Collection. Contrib Embryol 34:165, 1951. 70. O’Rahilly R: Developmental Stages in Human Embryos, Part A: Embryos of the First Three Weeks (Stages 1 to 9). Carnegie Institute, Washington, DC, Publication 631, 1973. 71. O’Rahilly R, Muller F: Human Embryology and Teratology, ed 3. Wiley-Liss, New York, 2001. 71a. Barker DJP, Forse´n T, Eriksson JG, et al.: Growth and living conditions in childhood and hypertension in adult life: longitudinal study. J Hypertens 20:1951, 2002. 72. Gilbert SF: Developmental Biology, ed 7. Sinauer Associates, Sunderland, MA, 2003. 73. Friedman JM: Teratogens and growth. Growth Gen Horm 3(4):6, 1987. 74. Smithells RW: The demonstration of teratogenic effects of drugs in humans. In: Drugs and Pregnancy: Human Teratogenesis and Related Problems. DF Hawkins, ed. Churchill Livingstone, Edinburgh, 1983. 75. Robbins SL, Cotran RS: Pathologic Basis of Disease, ed 7. WB Saunders, Philadelphia, 2004. 76. Rimoin DL, Hall J, Maroteaux P: International nomenclature of constitutional diseases of bone with bibliography. BDOAS XV(10):1, 1979. 77. Hall CM: International nosology and classification of constitutional disorders of bone (2001). Am J Med Genet 113:65, 2002. 78. Horton WA: Histochemistry, a valuable tool in connective tissue research. Coll Rel Res 4:231, 1984. 79. van Etten AM: Dwarfs Don’t Live in Doll Houses. Adaptive Living, Rochester, 1988, p 216. 80. Smith DW: Recognizable Patterns of Human Malformations, eds 1–3. WB Saunders, Philadelphia, 1970, 1976, 1982. 81. Allen G, Benda CE, Book JA, et al.: Mongolism. Lancet 1:775, 1961. 82. Empedocles: The Fragments of Empedocles. Translated by WE Leonard. Open Court Publishing, Chicago, 1908. 83. Pare A: On Monsters and Marvels. Translated by JL Pallister. University of Chicago Press, Chicago, 1982. 84. Cleland J: Memoirs and Memoranda in Anatomy, vol l. Williams & Norgate, London, 1899. 85. St. Isidore: Etymologies. Wolff and Kerver, Paris, 1499. 86. Huber JJ: Observationes atque cogitationes non nullae de monstris. Hu¨teri and Harmes, Cassellis, 1748. 87. Geoffroy Saint-Hilaire I: Historie des Anomalies. vols. 1–3. JB Baillie`re, Paris. 1832–1837. 88. Schenck J: Observationum Medicarum, Rararum, Novarum, Admirabilium, et Monstrosarum Volumen. N Hoffmannum, Frankfurt, 1609. 89. Aldrovandus U: Monstrorum Historia. N Tebaldinus, Bononiae, 1642. 90. Taruffi: Storia della teratologia, vols. l-VIII. Regia Tipografia, Bologna,1881–1894.
74
Overview
91. Lowne BT: Descriptive Catalogue of the Teratological Series in the Museum of the Royal College of Surgeons of England. Taylor and Francis, London, 1893. 92. Ballantyne JW: Manual of Antenatal Pathology and Hygiene. The Embryo. William Green and Sons, Edinburgh, 1904. 93. Warkany J: Congenital Malformations: Notes and Comments. Year Book, Chicago, 1971. 94. International Classification of Diseases, Rev 9, Clinical Modification (ICD.9.CM), ed 3. U .S. Department of Health and Human Services, Washington, DC, Publication 1:639, 1989. 95. British Paediatric Association: Classification of Diseases, ed 2. British Paediatric Association, London, 1987. 96. Centers for Disease Control: 6-Digit Code for Reportable Congenital Anomalies, Version 6/89. U.S. Department of Health and Human Services, Atlanta, 1989. 97. Cote R, Rothwell D, Palotay J, et al.: The Systematized Nomenclature of Human and Veterinary Medicine: SNOMED International College of American Pathologists, Northfield, IL, 1993. 98. Leichty E: The Omen Series Summa Izbu, JJ Augustin Publisher, Locust Valley, New York, 1970. 99. Billard CM: A Treatise on the Disease of Infants, ed 3. (translated by J Stewart) G Adlard, New York, 1839. 100. Forster A: Handbuch der Pathologischen Anatomie, vol II, Leipzig, 1862–1865. 101. McKusick VA: Mendelian Inheritance in Man. A Catalog of Human Genes and Genetic Disorders, ed 12. Johns Hopkins University Press, Baltimore, 1998. 102. Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). World Wide Web URL: http:// www.ncbi.nlm.nih.gov/omim, 2000. 103. Shepard TH: Catalog of Teratogenic Agents, ed 10. Johns Hopkins University Press, Baltimore, 2001. 104. Winter RM, Baraitser M: London Dysmorphology Database, version 3.0.3. Oxford University Press, Oxford, 2003. 105. Bankier A, Rose CM, Chemke J, et al.: ‘‘P.O.S.S.U.M.: Pictures of Standard Syndromes and Undiagnosed Malformations,’’ version 5.5. Computer Power Pty Ltd and Murdock Institute, Melbourne, 2004. 106. Flemming W: Beitrage zur Kenntniss der Zelle und ihrer Lebenserscheinungen. Arch Mikrosk Anat Entwickl 20:1, 1882. 107. Lejeune J: Le mongolisme. Premier example d’aberration autosomique humaine. Ann Genet Semaine Hop 1:41, 1959. 108. Waardenburg PJ: Das menschliche Auge und seine Erbanlagen. Martinus Nijhoff, Haag, 1932. 109. Bleyer A: Indications that mongoloid imbecility is a gametic mutation of degressive type. Am J Dis Child 47:342, 1934. 110. Tjio JH, Leyan A: The chromosome number of man. Hereditas 42:1, 1956. 111. Carr DH: Chromosome studies in abortuses and stillborn infants. Lancet 2:603, 1963. 112. Penrose LS, Delhanty JDA: Triploid cell cultures from a macerated fetus. Lancet 1:1261, 1961. 113. Hall B, Kallen B: Chromosome studies in abortuses and stillborn infants. Lancet 1:110, 1964. 114. Aula P, Hjeh L: A structural chromosome anomaly in a human fetus. Ann Paediatr Fenn 8:297, 1962. 115. Steele MW, Breg WR: Chromosome analysis of human amniotic fluid cells. Lancet 1:383, 1966. 116. Caspersson T, Lomakka G, Zech L: The 24 fluorescence patterns of human metaphase chromosomes—distinguishing characters and variability. Hereditas 67:89, 1971. 117. Sutherland GR: Heritable fragile sites on human chromosomes. I. Factors affecting expression in lymphocyte culture. Am J Hum Genet 31:125, 1979. 118. Yunis JJ: High resolution of human chromosomes. Science 191:1268, 1976.
119. Biesecker LG: The end of the beginning of chromosome ends. Am J Med Genet 107:263, 2002. 120. Pinkel D, Seagraves R, Sudar D, et al.: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20:207, 1998. 121. Hassold TJ: The origin of aneuploidy in humans. In: Aneuploidy, Etiology and Mechanisms. VL Dellarco, PE Voytek, A Hollaender, eds. Plenum Press, New York, 1985, p 103. 122. Therman E: Human Chromosomes, Structure, Behavior, Effects, ed 2. Springer-Verlag, New York, 1986. 123. Pai GS, Lewandowski RC, Borgaonkar DS: Handbook of Chromosomal Syndromes. John Wiley & Sons, Hoboken, 2003. 124. Plenge RM, Stevenson RE, Lubs HA, et al.: Skewed X-inactivation is a common feature of X-linked mental retardation disorders. Am J Hum Genet 71:168, 2002. 125. Rappold GA: The pseudoautosomal regions of the human sex chromosomes. Hum Genet 92:315, 1993. 126. Hall JG: Genomic imprinting: review and relevance to human diseases. Am J Hum Genet 46:857, 1990. 127. Lyon MF: Mechanisms and evolutionary origins of variable X-chromosome activity in mammals. Proc R Soc Lond [Biol] 187:243, 1974. 128. Nicholls RD, Knoll JHM, Butler MG, et al.: Genetic imprinting suggested by maternal heterodisomy in non-deletion Prader-Willi syndrome. Nature 342:281, 1989. 129. Hashimshony T, Zhang J, Keshet I, et al.: The role of DNA methylation in setting up chromatin structure during development. Nat Genet 34:187, 2003. 130. Pembrey ME: Time to take epigenetic inheritance seriously. Eur J Hum Genet 10:669, 2002. 131. Jiang Y-H, Bressler J, Beaudet AL: Epigenetics and human disease. Ann Rev Genomics Hum Genet 5:479, 2004. 132. Burmeister M, Monaco AP, Gillard EF, et al.: A 10-megabase physical map of human Xp21, including the Duchenne muscular dystrophy gene. Genomics 2:189, 1988. 133. Warburton D: Chromosomal causes of fetal death. Clin Obstet Gynecol 30:268, 1987. 134. Porter IH, Hook EB: Human Embryonic and Fetal Death. Academic Press, New York, 1980. 135. de Grouchy J, Turleau C: Clinical Atlas of Human Chromosomes, ed 2. John Wiley & Sons, New York, 1984. 136. Schinzel A: Catalogue of Unbalanced Chromosome Aberrations in Man, ed 2. Walter de Gruyter, Berlin, 2001. 137. Hsu LYF: Prenatal diagnosis of chromosomal abnormalities through amniocentesis. In: Genetic Disorders of the Fetus. Diagnosis, Prevention and Treatment, ed 4. Milunsky A, ed. John Hopkins Univ Press, Baltimore, 1998, p 179. 138. Alberman ED, Creasy MR: Frequency of chromosomal abnormalities in miscarriages and perinatal deaths. J Med Genet 14:313, 1977. 139. Hanna JS, Shires P, Matile G: Trisomy 1 in a clinically recognized pregnancy. Am J Med Genet 68:98, 1997. 140. Dunn TM, Grunfeld L, Kardon NB: Trisomy 1 in a clinically recognized IVF pregnancy. Am J Med Genet 99:152, 2001. 141. Rosenfeld RG, Grumbach MM: Turner Syndrome. Marcel Dekker, New York, 1990. 142. Stern C: Genetic mosaics in animals and man. In: Genetic Mosaics and Other Essays. C Stern, ed. Harvard University Press, Cambridge, 1968. 143. Happle R: Lyonization and the lines of Blaschko. Hum Genet 70:200, 1985. 144. Pagon RA, Hall JG, Davenport SLH, et al.: Abnormal skin fibroblast cytogenetics in four dysmorphic patients with normal lymphocyte chromosomes. Am J Hum Genet 31:54, 1979. 145. Donnai D, McKeown C, Andrews T, et al.: Diploid/triploid mixoploidy and hypomelanosis of Ito. Lancet 1:1443, 1986. 146. Thomas IT, Frias JL, Cantu ES, et al.: Association of pigmentary anomalies with chromosomal and genetic mosaicism and chimerism. Am J Hum Genet 45:193, 1989.
Human Malformations and Related Anomalies 147. Juberg RC, Holliday DJ, Hennesy VS: Familial sex chromosomal mosaicism. Pediatr Res 23:330A, 1988. 148. Kalousek DK, Barrett IJ, McGillivray BC: Placental mosaicism and intrauterine survival of trisomies 13 and 18. Am J Hum Genet 44:338, 1989. 149. Gartner AB, Barrett IJ, Kalousek DK: Confined placental mosaicism in spontaneous abortions. Am J Hum Genet 43:A130, 1988. 150. Kalousek DK, Dill FJ: Chromosomal mosaicism confined to the placenta in human conceptions. Science 221:665, 1983. 151. Lestou VS, Desilets V, Lomax BL, et al.: Comparative genomic hybridization: a new approach to screening for intrauterine complete or mosaic aneuploidy. Am J Med Genet 92:281, 2000. 152. Murachi S, Nogami H, Oki T, et al.: The tricho-rhino-phalangeal syndrome with exostoses: four additional patients without mental retardation, and review of the literature. Am J Med Genet 19:111, 1984. 153. Schmickel RD: Contiguous gene syndromes: a component of recognizable syndromes. J Pediatr 109:231, 1986. 154. Brewer C, Holloway S, Zawalnyski P, et al.: A chromosomal deletion map of human malformations. Am J Hum Genet 63:1153, 1998. 155. Koolen DA, Nillesen WM, Versteeg MHA, et al.: Screening for subtelomeric rearrangements in 210 patients with unexplained mental retardation using multiplex ligation dependent probe amplification (MLPA). J Med Genet 41:892, 2004. 156. Schwartz S, Graf MD: Microdeletion syndromes: characteristics and diagnosis. In: Molecular Cytogenetics. Protocols and Applications. Fan Y-S, ed. Humana Press, Totowa NJ, 2002, p 275. 157. Schinzel A: Microdeletion syndromes, balanced translocations, and gene mapping. J Med Genet 25:454, 1988. 158. Wyandt HE: Ring autosomes: identification, familial transmission, causes of phenotypic effects and in vitro mosaicism. In: The Cytogenetics of Mammalian Autosomal Rearrangements. A Daniel, ed. AR Liss, New York, 1988, p 667. 159. van Dyke DL: Isochromosomes and interstitial tandem direct and inverted duplications. In: The Cytogenetics of Mammalian Autosomal Rearrangements. A Daniel, ed. AR Liss, New York, 1988, p 635. 160. Schwartz S, Palmer CG, Yu P-L, et al.: Analysis of translocations observed in three different populations. II. Robertsonian translocations. Cytogenet Cell Genet 42:53, 1986. 161. Schwartz S, Palmer CG, Yu P-L, et al.: Analysis of translocations observed in three different populations. I. Reciprocal translocations. Cytogenet Cell Genet 42:42, 1986. 162. Abuelo DN, Barsel-Bowers G, Richardson A: Insertional translocations: report of two new families and review of the literature. Am J Med Genet 31:319, 1988. 163. Davis JR, Rogers BB, Hagaman RM, et al.: Balanced reciprocal translocations: risk factors for aneuploid segregant viability. Clin Genet 27:1, 1985. 164. Stene J, Stengel-Rutkowski S: Genetic risks of familial reciprocal and robertsonian translocation carriers. In: The Cytogenetics of Mammalian Autosomal Rearrangements. A Daniel, ed. AR Liss, New York, 1988, p 3. 165. Groupe de Cytoge´ne´ticiens Francais: Pericentric inversions in man: a French collaborative study. Am Genet 29:129, 1986. 166. Kleczkowska A, Fryns JP, Van den Berghe H: Pericentric inversions in man: personal experience and review of the literature. Hum Genet 75:333, 1987. 167. Groupe de Cytoge´ne´ticiens Francais: Paracentric inversions in man: a French collaborative study. Ann Genet 29:169, 1986. 168. Madan K, Seabright M, Lindenbaum RH, et al.: Paracentric inversions in man. J Med Genet 21:407, 1984. 169. Harbison M, Hassold T, Kobryn C, et al.: Molecular studies of the parental origin and nature of human X isochromosomes. Cytogenet Cell Genet 47:217, 1988. 170. Schmutz SM, Pinno E: Morphology alone does not make an isochromosome. Hum Genet 72:253, 1986. 171. Tedeschi B, Porfirio B, Vernole P, et al.: Common fragile sites: their prevalence in subjects with constitutional and acquired chromosomal instability. Am J Med Genet 27:471, 1987.
75
172. Sutherland GR, Baker E, Richards RI: Fragile sites still breaking. Trends Genet 14:501, 1998. 173. German J: Chromosome Mutations and Neoplasia. AR Liss, New York, 1983. 174. Auerbach AD, Alder B, Chaganti RSK: Prenatal and postnatal diagnosis and carrier detection of Fanconi anemia by a cytogenetic method. Pediatrics 67:128, 1981. 175. Parry DM, Mulvihill JJ, Tsai S, et al.: SC phocomelia syndrome, premature centromere separation, and congenital cranial nerve paralysis in two sisters, one with malignant melanoma. Am J Med Genet 24:653, 1986. 176. Kawame H, Sugio Y, Fuyama Y, et al.: Syndrome of microcephaly, Dandy-Walker malformation, and Wilms tumor caused by mosaic variegated aneuploidy with premature centromere division (PCD): report of a new case and review of the literature. J Hum Genet 44:219, 1999. 177. Gabriel JM, Higgins MJ, Gebuhr TC, et al.: A model system to study genomic imprinting of human genes. Proc Natl Acad Sci USA 95: 14857, 1998. 178. Fre´zal J, Schinzel A: Report of the committee on clinical disorders, chromosome aberrations and uniparental disomy. Cytogenet Cell Genet 58:986, 1991. 179. Reish O, Lerer I, Amiel A, et al.: Wiedemann-Beckwith syndrome: further prenatal characterization of the condition. Am J Med Genet 107:209, 2002. 180. Preece MA, Price SM, Davies V et al.: Maternal uniparental disomy 7 in Silver-Russell syndrome. J Med Genet 70:328, 1997. 181. Engel E, Antonarakis SE: Genomic Imprinting and Uniparental Disomy in Medicine: Clinical and Molecular Aspects. Wiley-Liss, New York, 2002. 182. Mendel G: Experiments in Plant Hybridisation. Translated by The Royal Horticultural Society of London. Harvard University Press, Cambridge, 1965. 183. Corcos AF, Monaghan FV: Role of DeVries in the recovery of Mendel’s work. J Hered 76:187, 1985; 78:275, 1987. 184. Corcos AF, Monaghan FV: Tschermak, a non-discoverer of mendelism. J Hered 77:468, 1986; 78:208, 1987. 185. Corcos AF, Monaghan FV: Correns, an independent discoverer of Mendelism? J Hered 78:330, 1987; 78:404, 1987. 186. Farabee WC: Inheritance of digital malformations in man. In: Papers of the Peabody Museum of American Archaeology and Ethnology, vol 3. Harvard University Press, Cambridge, 1905, p 69. 187. Garrod AE: Inborn errors of metabolism. Lancet 2:1, 73, 142, 214, 1908. 188. Garrod AE: The incidence of alkaptonuria: a study in chemical individuality. Lancet 2:1616, 1902. 189. Johannsen W: The genotype conception of heredity. Am Nat 45:129, 1911. 190. Strachan T, Read AP: Human Molecular Biology, ed 2. Wiley-Liss, New York, 1999. 191. Watson JD: Molecular Biology of the Gene, ed 5. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2004. 192. Padgett RA, Grabowski PJ, Konarska MM, et al.: Splicing of messenger RNA precursors. Annu Rev Biochem 55:1119, 1986. 193. Gilbert W: Genes-in-pieces revisited. Science 228:823, 1985. 194. Cao A, Moi P: Regulation of the globin genes. Ped Res 51:415, 2002. 195. Kornak U, Mundlos S: Genetic disorders of the skeleton: a developmental approach. Am J Hum Genet 73:447, 2003. 196. Epstein CJ, Erickson RP, Wynshaw-Brois A: Inborn Errors of Development. The Molecular Basis of Clinical Disorders of Morphogenesis. Oxford University Press, New York, 2004. 197. Watson JD, Jordan E: The human genome program at the National Institutes of Health. Genomics 5:654, 1989. 198. Barnhardt BJ: The Department of Energy (DOE) human genome initiative. Genomics 5:657, 1989. 199. International Human Genome Sequencing Consortium: Initial sequencing and analysis of the human genome. Nature 409:860, 2001. 200. Venter JC, Adams MD, Myers EW, et al.: The sequence of the human genome. Science 291:1304, 2001.
76
Overview
201. Cuticchia AJ: Human Gene Mapping: A Compendium. Johns Hopkins Univ Press, 1995. 202. Tsipouras P, Ramirez F: Genetic disorders of collagen. J Med Genet 24:2, 1987. 203. Knowlton RG, Weaver EJ, Struyk AF, et al.: Genetic linkage analysis of hereditary arthro-ophthalmopathy (Stickler syndrome) and the type II procollagen gene. Am J Hum Genet 45:681, 1989. 204. Hall JG: Review and hypothesis: somatic mosaicism: observations related to clinical genetics. Am J Hum Genet 43:355, 1988. 205. Cohn DH, Starman BJ, Blumberg B, et al.: Recurrence of lethal osteogenesis imperfecta due to parental mosaicism in a human type I collagen gene (Col 1Al). Am J Hum Genet 46:591, 1990. 206. Carter CO: Principles of polygenic inheritance. BDOAS XIII(3A):69, 1977. 207. Holt SB: Quantitative genetics of fingerprint patterns. Br Med Bull 17:247, 1961. 208. Carter CO: Genetics of common disorders. Br Med Bull 25:52, 1969. 209. Roberts JAF: Multifactorial inheritance in relation to normal and abnormal human traits. Br Med Bull 17:241, 1961. 210. Chinn S, Price CE, Rona RJ: Need for new reference curves for height. Arch Dis Child 64: 1545, 1989. 211. Edwards JG: The simulation of Mendelism. Acta Genet (Basel) 10:63, 1960. 212. Stevenson RE: The Fetus and Newly Born Infant, ed 2. CV Mosby, St. Louis, 1977. 213. Kalter H: Teratology in the 20th century. Environmental causes of congenital malformations in humans and how they were established. Neurotoxicol Teratol 25:131, 2003. 214. Kalter H, Warkany J: Congenital malformations: etiologic factors and their role in prevention. N Engl J Med 308:424, 491, 1983. 215. Brent R, Weitzman M, Balk S, et al.: The vulnerability, sensitivity and resiliency of the developing embryo, infant, child, and adolescent to the effects of environmental chemicals, drugs, and physical agents as compared to the adult. Pediatrics 113 (suppl):933, 2004. 216. Brent RL: Environmental causes of human congenital malformations: The pediatrician’s role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics 113(suppl):957, 2004. 217. Wilson JG: Current status of teratology: general principles and mechanisms derived from animal studies. In Handbook of Teratology, vol l. JG Wilson, FC Fraser, eds. Plenum, New York, 1977, p 47. 218. Trasler DG: Strain differences in susceptibility to teratogenesis: survey of spontaneously occurring malformations in mice. In: Teratology. JG Wilson, J Warkany, eds. University of Chicago Press, Chicago, 1965, p 38. 219. Fraser FC: The genetics of cleft lip and cleft palate. Am J Hum Genet 22:336, 1970. 220. Brent RL: Radiation teratogenesis. Teratology 21:281, 1980. 221. Penfil RL, Brown ML: Genetically significant dose to the United States population from diagnostic medical roentgenology, 1964. Radiology 90:209, 1968. 221a. Hujoel PP, Bollen AM, Noonan CJ, et al.: Antepartum dental radiography and infant low birth weight. JAMA. 291:1987, 2004. 222. Neel JV, Satoh C, Goriki K, et al.: Search for mutations altering protein charge and/or function in children of atomic bomb survivors: final report. Am J Hum Genet 42:663, 1988. 223. Mayer MD, Harris W, Wimpfheimer S: Therapeutic abortion by means of X-ray. Am J Obstet Gynecol 32:945, 1936. 224. Goldstein L, Murphy DP: Etiology of the ill-health in children born after maternal pelvic irradiation. Part II. Defective children born after postconception pelvic radiation. Am J Roentgenol 22:322, 1929. 225. Dekaban A: Abnormalities in children exposed to X-radiation injury to the human fetus. Part I. J Nucl Med 9:471, 1968. 226. Murphy DP: The outcome of 625 pregnancies in women subjected to pelvic radium or roentgen irradiation. Am J Obstet Gynecol 18:179, 1929. 227. Graham JM Jr, Jones KL, Brent RL: Contribution of clinical teratologists and geneticists to the evaluation of the etiology of congenital
228.
229. 230. 231.
232.
233.
234. 235.
236. 237.
238.
239.
240.
241.
242. 243. 244. 245. 246. 247. 248. 249.
250. 251.
252.
malformations alleged to be caused by environmental agents: ionizing radiation, electromagnetic fields, microwaves, radionuclides, and ultrasound. Teratology 59:307, 1999. Sankaranarayanan K: Ionizing radiation and genetic risks X. The potential ‘‘disease phenotypes’’ of radiation-induced genetic damage in humans: perspectives from human molecular biology and radiation genetics. Mutat Res 429:45, 1999. Russell KP, Rose H, Starr P: Maternal and fetal thyroid function during pregnancy. Surg Obstet Gynecol 104:560, 1957. Fisher WD, Voorhess ML, Gardner LI: Congenital hypothyroidism in infant following maternal I-131 therapy. J Pediatr 62:132, 1963. Brent RL: The effect of embryonic and fetal exposure to X-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Onco1 16:347, 1989. Brent RL: Radiations and other physical agents. In Handbook of Teratology, vol l. JG Wilson, FC Fraser, eds. Plenum Press, New York, 1977, p 153. Goldhaber MK, Polen MR, Hiatt RA: The risk of miscarriage and birth defects among women who use video display terminals during pregnancy. Am J Indust Med 13:695, 1988. Carstensen EL, Gates AH: The effects of pulsed ultrasound on the fetus. J Ultrasound Med 3:145, 1984. McLeod DR, Fowlow SB: Multiple malformations and exposure to therapeutic ultrasound during organogenesis. Am J Med Genet 34:317, 1989. Miller P, Smith DW, Shepard TH: Maternal hyperthermia as a possible cause of anencephaly. Lancet 1:519, 1978. Clarren SK, Smith DW, Harvey MAS, et al.: Hyperthermia— a prospective evaluation of a possible teratogenic agent in man. J Pediatr 95:81, 1979. Pleet H, Graham JMJ, Smith DW: Central nervous system and facial defects associated with maternal hyperthermia at four to 14 weeks’ gestation. Pediatrics 67:785, 1981. Edwards MJ: Congenital defects in guinea pigs: fetal resorptions, abortions, and malformations following induced hyperthermia during early gestation. Teratology 2:313, 1969. Supernau DW, Wertelecki W: Brief clinical report: similarity of effects—experimental hyperthermia as a teratogen and maternal febrile illness associated with oromandibular and limb defects. Am J Med Genet 21:575, 1985. Lipson AH, Webster WS, Brown-Woodman PDC, et al.: Mobius syndrome: animal model-human correlations and evidence for a brainstem vascular etiology. Teratology 40:339, 1989. Gibbs RS: The origins of stillbirth: infectious diseases. Semin Perinatol 26:75, 2002. Behrman RE, Kliegman RM, Jenson HB: Nelson Textbook of Pediatrics, ed 17. WB Saunders, Philadelphia, 2004. Gershon AA, Hotez PJ, Katz SL: Krugman’s Infectious Diseases of Children, ed 11. CV Mosby, Philadelphia, 2004. Monif GRG: Viral Infections of the Human Fetus. Macmillan, London, 1969. Hanshaw JB, Dudgeon JA, Marshall WC: Viral Diseases of the Fetus and Newborn, ed 2. WB Saunders, Philadelphia, 1985. Remington JS, Klein JO: Infectious Diseases of the Fetus and Newborn Infant, ed 5. WB Saunders, Philadelphia, 2001. Medearis DN: Observations concerning human cytomegalovirus infection and disease. Bull Johns Hopkins Hosp 114:181, 1964. Reynolds DW, Stagno S, Stubbs KG: Inapparent congenital cytomegalovirus infection with elevated cord IgM levels. N Engl J Med 290:291, 1974. Stern H, Tucker SM: Prospective study of cytomegalovirus infection in pregnancy. Br Med J 1:268, 1973. Enders G, Bader U, Lindemann L, et al.: Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. Prenat Diagn 21:362, 2001. Jarvis MA., Nelson JA: Mechanisms of human cytomegalovirus persistence and latency. Front in Biosci 7:d1575, 2002.
Human Malformations and Related Anomalies 253. Schaffer AJ: Diseases of the Newborn, ed 2. WB Saunders, Philadelphia, 1966. 254. South MA, Thompkins WAF, Morris CR, et al.: Congenital malformation of the central nervous system associated with genital type (type 2) herpes virus. J Pediatr 75:13, 1969. 255. Alkalay AL, Pomerance JJ, Rimoin DL: Fetal varicella syndrome. J Pediatr 111:320, 1987. 256. Paryani SG, Arvin AM: Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 314:1542, 1986. 257. Huang C-S, Lin S-P, Chiu N-C, et al.: Congenital varicella syndrome as an unusual cause of congenital malformation: report of one case. Acta Paediatr Tw 42:239, 2001. 258. Coffey VP, Jessop WJE: Maternal influenza and congenital deformities: a prospective study. Lancet 2:935, 1959. 259. Shone JD, Armas SM, Manning JA: The mumps antigen test in endocardial fibroelastosis. Pediatrics 37:423, 1966. 260. Gregg NM: Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 3:35, 1941. 261. Monif GRG, Hardy JB, Sever JL: Studies in congenital rubella, Baltimore 1964–65. Bull Johns Hopkins Hosp 118:85, 97, 1966. 262. Desmond MM, Wilson GS, Melnick JL, et al.: Congenital rubella encephalitis. J Pediatr 71:311, 1967. 263. Chiriboga-Klein S, Oberfield SE, Casullo AM, et al.: Growth in congenital rubella syndrome and correlation with chemical manifestations. J Pediatr 115:251, 1989. 264. Cooper LZ, Ziring PR, Ockerse AB, et al.: Rubella: clinical manifestations and management. Am J Dis Child 118:18, 1969. 265. Rodis JF, Hovick TJJ, Quinn DL, et al.: Human parvovirus infection in pregnancy. Obstet Gynecol 72:733, 1988. 266. Oleske J, Minnefor A, Cooper RJ, et al.: Immune deficiency syndrome in children. JAMA 249:2345, 1983. 267. Rubinstein A, Sicklick M, Gupta A, et al.: Acquired immunodeficiency with reversed T4-T8 ratios in infants born to promiscuous and drugaddicted mothers. JAMA 249:2350, 1983. 268. Scott GB, Buck BE, Leterman JG, et al.: Acquired immunodeficiency syndrome in infants. N Engl J Med 310:76, 1984. 269. Marion RW, Wiznia AA, Hutcheon RG, et al.: Human T-cell lymphotropic virus type III (HTLV-III) embryopathy. Am J Dis Child 140:638, 1986. 270. Iosub S, Bamji M, Stone RK, et al.: More on human immunodeficiency virus embryopathy. Pediatrics 80:512, 1987. 271. Brown GC, Evans TN: Serologic evidence of coxsackievirus etiology of congenital heart disease. JAMA 199:183, 1967. 272. Gauntt CG, Gudvangen RJ, Brans YW, et al.: Coxsackievirus group B antibodies in the ventricular fluid of infants with severe anatomic defects in the central nervous system. Pediatrics 76:64, 1985. 273. Gear J: Coxsackie virus infections in Southern Africa. Yale J Biol Med 34:289, 1961. 274. Manson MM, Logan WPD, Loy RM: Rubella and other virus infections during pregnancy. In Ministry of Health: Reports on Public Health and Medical Subjects. No.101. Her Majesty’s Stationery Office, London, 1960. 275. Green DM, Reid SM, Rhaney K: Generalized vaccinia in the human fetus. Lancet 1:1296, 1966. 276. Moss PD, Heffernan CK, Thurston JG: Enteroviruses and congenital abnormalities. Br Med J 1:110, 1967. 277. Siegel M, Greenberg M: Poliomyelitis in pregnancy. Effect on fetus and newborn infant. J Pediatr 49:280, 1956. 278. Lin HH, Lee TY, Chen DS, et al.: Transplacental leakage of HBeAgpositive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr 111:877, 1987. 279. Ryan GMJ, Abdella TN, McNeeley SG, et al.: Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. Am J Obstet Gyneco1 162:34, 1990. 280. Naessens A, Foulon W, Breynaert J, et al.: Postpartum bacteremia and placental colonization with genital mycoplasmas and pregnancy outcome. Am J Obstet Gynecol 160:647, 1989.
77
281. Braun P, Lee Y-H, Klein JO, et al.: Birth weight and genital mycoplasmas in pregnancy. N Engl J Med 284:167, 1971. 282. Monif GRG: Infectious Diseases in Obstetrics and Gynecology. Harper & Row, Hagerstown, MD, 1974. 283. Ewing CI, Roberts C, Davidson DC, et al.: Early congenital syphilis still occurs. Arch Dis Child 60:1128, 1985. 284. Groseclose SL, Brathwaite WS, Hall PA, et al.: Summary of notifiable diseases—United States, 2002. MMWR 51:1, 2004. 285. Harter CA, Benirschke K: Fetal syphilis in the first trimester. Am J Obstet Gynecol 124:705, 1976. 286. Putkonen T: Does early treatment prevent dental changes in congenital syphilis? Acta Derm Venereol (Stockh) 43:240, 1963. 287. Bulova SI, Schwartz E, Harrer WV: Hydrops fetalis and congenital syphilis. Pediatr 49:285, 1972. 288. Murphy FK, Patamasucon P: Congenital syphilis. In Sexually Transmitted Diseases. KK Holmes, P-A Mardh, PF Sparling, PJ Wiesner, eds. McGraw-Hill, New York, 1984, p 352. 289. Lindsay S, Luke IW: Fatal leptospirosis (Weil’s disease) in a newborn infant. J Pediatr 34:90, 1949. 290. MacDonald AB: Gestational Lyme borreliosis. Rheum Dis Clin North Am 15:657, 1989. 291. Bruner JP, Elliott JP, Kilbride HW, et al.: Candida chorioamnionitis diagnosed at amniocentesis with subsequent fetal infection. Am J Perinatol 3:213, 1986. 292. Sever JL, Ellenberg JH, Ley AC, et al.: Toxoplasmosis: maternal and pediatric findings in 23,000 pregnancies. Pediatrics 82:181, 1988. 293. Eichenwald HF: A study of congenital toxoplasmosis. In Human Toxoplasmosis. Ejnar Munksgaards Forlag, Copenhagen, 1960, p 41. 294. Saxon SA, Knight W, Reynolds DW, et al.: Intellectual deficits in children born with subclinical congenital toxoplasmosis: a preliminary report. J Pediatr 82:792, 1973. 295. Covell G: Congenital malaria. Trop Dis Bull 47:1147, 1950. 296. Jones KL, Smith DW, Ulleland CN, et al.: Pattern of malformation in offspring of chronic alcoholic mothers. Lancet 1:1267, 1973. 297. Warner RH, Rossett HL: The effects of drinking on offspring: an historical survey of the American and British literature. J Stud Alcohol 36:1395, 1975. 298. Lemoine P, Harousseau H, Borteyru J, et al.: Children of alcoholic parents: abnormalities observed in 127 cases. Quest Med 21:476, 1968. 299. Jones KL: The fetal alcohol syndrome. Growth Gen Horm 4:1, 1988. 300. Hadeed AJ, Siegel SR: Maternal cocaine use during pregnancy: effect on the newborn infant. Pediatrics 84:205, 1989. 301. Chasnoff IJ, Chisom GM, Kaplan WE: Maternal cocaine use and genitourinary tract malformations. Teratology 37:201, 1988. 302. Fulroth R, Phillips B, Durand DJ: Perinatal outcome of infants exposed to cocaine and/or heroin in utero. Am J Dis Child 143:905, 1989. 303. Bingol N, Fuchs M, Diaz V, et al.: Teratogenicity of cocaine in humans. J Pediatr 110:93, 1987. 304. Werler MM, Pober BR, Holmes LB: Smoking and pregnancy. In: Teratogen Update: Environmentally Induced Birth Defect Risks. JL Sever, RL Brent, eds. AR Liss, New York, 1986, p 131. 305. Naeye R, Harkness W, Utts J: The duration of maternal cigarette smoking, fetal and placental disorders. Early Hum Dev 3:229, 1979. 306. MacMahon B, Alpert M, Salber EJ: Infant weight and parental smoking habits. Am J Epidemiol 82:247, 1966. 307. Underwood P, Hester LL, Lafitte TJ, et al.: The relationship of smoking to the outcome of pregnancy. Am J Obstet Gynecol 91:270, 1965. 308. Hingson R, Alpert JJ, Day N, et al.: Effects of maternal drinking and marijuana use on fetal growth and development. Pediatrics 70:539, 1982. 309. Long SY: Does LSD induce chromosomal damage and malformations? A review of the literature. Teratology 6:75, 1972. 310. Meadow WR: Congenital abnormalities and anticonvulsant drugs. Proc R Soc Med 63:48, 1970. 311. Melchior JD, Svensmark O, Trolle D: Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. Lancet 2:860, 1967.
78
Overview
312. Kelly TE: Teratogenicity of anticonvulsant drugs. Am J Med Genet 19:413, 435, 445, 451, 1984. 313. Hill RM, Verniaud WM, Homing MG, et al.: Infants exposed in utero to antiepileptic drugs: a prospective study. Am J Dis Child 127:645, 1974. 314. Hanson JW, Smith DW: The fetal hydantoin syndrome. J Pediatr 87:285, 1975. 315. Hanson JW, Myrianthoupoulos NC, Harvey MAS, et al.: Risks to offspring of women treated with hydantoin anticonvulsants with emphasis on the fetal hydantoin syndrome. J Pediatr 89:662, 1976. 316. Zackai EH, Mellman WJ, Neiderer B, et al.: The fetal trimethadione syndrome. J Pediatr 87:280, 1975. 317. Robert E: Valproic acid and spina bifida: a preliminary report— France. MMWR 31:565, 1982. 318. DiLiberti JH, Farnon PA, Dennis NR, et al.: The fetal valproate syndrome. Am J Med Genet 19:473, 1984. 319. Hardinger HH, Atkin JF, Blackston RD, et al.: Verification of the fetal valproate syndrome phenotype. Am J Med Genet 29:171, 1988. 320. Jones KL, Lacro RV, Johnson KA, et al.: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320:1661, 1989. 321. Thiersch JB: Therapeutic abortions with a folic acid antagonist, 4-amino pteroylglutamic acid, administered by the oral route. Am J Obstet Gynecol 63:1298, 1952. 322. Shaw EB, Steinbach HL: Aminopterin-induced fetal malformation. Am J Dis Child 115:477, 1968. 323. Milunsky A, Fraef JW, Gaynor MF: Methotrexate-induced congenital malformations. J Pediatr 72:790, 1968. 324. Shaw EB, Rees EL: Fetal damage due to aminopterin ingestion: followup at 17½ years of age. Am J Dis Child 134:1172, 1980. 325. Coelho KE, Sarmento MF, Veiga CM, et al.: Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet 95:297, 2000. 326. Gonzalez CH, Marques-Dias MJ, Kim CE, et al.: Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 351:1624, 1998. 327. Pastuszak AL, Schu¨ler L, Speck-Martins CE, et al.: Use of misoprostol during pregnancy and Mo¨bius syndrome in infants. New Engl J Med 338:1881, 1998. 328. Schu¨ler L, Pastuszak A, Sanseverino MTV, et al.: Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 13:147, 1999. 329. Wheeler M, O’Meara P, Stanford M: Fetal methotrexate and misoprostol exposure: the past revisited. Teratology 66:73, 2002. 330. Lenz W: A short history of thalidomide embryopathy. Teratology 38:203, 1988. 331. Quibell EP: The thalidomide embryopathy: an analysis from the UK. Practitioner 225:721, 1981. 332. Taussig HB: A study of the German outbreak of phocomelia: the thalidomide syndrome. JAMA 180:1106, 1962. 333. Yang Q, Khoury MJ, James LV, et al.: The return of thalidomide: are birth defects surveillance systems ready? Am J Med Genet 73:251, 1997. 334. Rosa FW: Teratogenicity of isotretinoin. Lancet 2:513, 1983. 335. Rosa FW, Wilk AL, Kelsey FO: Teratogen update: vitamin A congeners. Teratology 33:355, 1986. 336. Fernhoff PM, Lammer EJ: Craniofacial features of isotretinoin embryopathy. J Pediatr 105:595, 1984. 337. Lammer EJ, Chen DT, Hoar RM, et al.: Retinoic acid embryopathy. N Engl J Med 313:837, 1985. 338. Lammer EJ, Schunior A, Holmes LB: Retinoic acid fetopathy. Proc Greenwood Genet Center 9:68, 1990. 339. Rothman KJ, Moore LL, Singer MR, et al.: Teratogenicity of high vitamin A intake. N Engl J Med 333:1369, 1995. 340. Mastroiacovo P, Mazzone T, Addis A, et al.: High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. Teratology 59:7, 1999.
341. Grote W, Harms D, Janig U, et al.: Malformation of a fetus conceived 4 months after termination of maternal etretinate treatment. Lancet 1:1276, 1985. 342. Grumbach MM, Ducharme JR: The effects of androgens on fetal sexual development: androgen-induced female pseudohermaph-rodism. Fertil Steril 11:157, 1960. 343. Wilkins L: Masculinization of female fetus due to the use of oral1y given progestins. JAMA 172:1028, 1960. 344. Burnstein R, Wasserman HC: The effect of Provera on the fetus. Obstet Gynecol 23:931, 1964. 345. Jewelewicz R, Perkins RP, Dyrenfurth I, et al.: Luteomas of pregnancy, a cause of maternal virilization. Am J Obstet Gynecol 109:24, 1971. 346. Verhoeven AT, Mastboom JL, van Levsden HA: Virilization in pregnancy coexisting with an (ovarian) mucinous cystadenoma-a case report and review of virilizing ovarian tumors in pregnancy. Obstet Gynecol Surv 28:597, 1973. 347. Bongiovanni AM, McPadden AJ: Steroids during pregnancy and possible fetal consequences. Fertil Steril 11:181, 1960. 348. Grajwer LA, Lilien LD, Pi1des RS: Neonatal subclinical adrenal insufficiency: result of maternal steroid therapy. JAMA 238:1279, 1977. 349. Janerich DT, Piper JM, Glebatis DM: Oral contraceptives and congenital limb-reduction defects. N Engl J Med 291:697, 1974. 350. Heinonen OP, Slone D, Monson RR, et al.: Cardiovascular birth defects and antenatal exposure to female sex hormones. N Engl J Med 296:67, 1977. 351. Kricker A, Elliott JW, Forrest JM, et al.: Congenital limb reduction deformities and use of oral contraceptives. Am J Obstet Gynecol 155: 1072, 1986. 352. Nora JJ, Nora AH, Wexler PL: Exogenous sex hormones and birth defects: continuing the dialogue. Am J Obstet Gynecol 144:860, 1982. 353. Nora JJ, Nora AH: Birth defects and oral contraceptives. Lancet 1:941, 1973. 354. Lammer EJ, Cordero JF: Exogenous sex hormone exposure and the risk for major malformations. JAMA 255:3128, 1986. 355. Gal I, Kirman B, Stern J: Hormonal pregnancy tests and congenital malformation. Nature 216:83, 1967. 356. Czeizel A, Keller S, Bod M: An etiological evaluation of increased occurrence of congenital limb reduction abnormalities in Hungary, 1975–1978. Int J Epidemiol 12:445, 1983. 357. Oakley GP, F1ynt JW, Falek A: Hormonal pregnancy tests and congenital malformations. Lancet 2:256, 1973. 358. Mulvihill JJ, Mulvihill CG, Neill CA: Congenital heart defects and prenatal sex hormones. Lancet 1:1168, 1974. 359. Harlap S, Prywes R, Davies AM: Birth defects and oestrogens and progesterones in pregnancy. Lancet 1:682, 1975. 360. Stillman RJ: In utero exposure to diethylstilbestrol: adverse effects on the reproductive tract and reproductive performance in male and female offspring. Am J Obstet Gynecol 142:905, 1982. 361. Herbst AL, Scully RE: Adenocarcinoma of the vagina in adolescence: a report of seven cases including clear cell carcinomas (so-called mesonephromas). Ca 25:745, 1970. 362. Mills JL, Bongiovanni AM: Effect of prenatal estrogen exposure on male genitalia. Pediatrics 62(Suppl):1160, 1978. 363. Burrows RF, Burrows EA: Assessing the teratogenic potential of antiotensin-converting enzyme inhibitors in pregnancy. Aust NZ J Obstet Gynaecol 38:306, 1998. 364. Barr M, Cohen MM: Ace inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Teratology 44:485, 1991. 365. Niswander KR, Gordon M: The Women and Their Pregnancies. WB Saunders, Philadelphia, 1972, p 246. 366. Refetoff S, Ochi Y, Selenkow HA, et al.: Neonatal hypothyroidism and goiter in one infant of each of two sets of twins due to maternal therapy with antithyroid drugs. J Pediatr 85:240, 1974. 367. Burrow GN, Bartsocas C, Klatskin EH, et al.: Children exposed in utero to propylthiouracil: subsequent intellectual and physical development. Am J Dis Child 116:161, 1968.
Human Malformations and Related Anomalies 368. Foulds N, Walpole I, Elmslie F, et al.: Carbimazole embryopathy: an emerging phenotype. Am J Med Genet 132A:130, 2005. 369. Wilson LC, Kerr BA, Wilkinson R, et al.: Choanal atresia and hypothelia following methimazole exposure in utero: a second report. Am J Med Genet 75:220, 1998. 370. Diav-Citrin O, Ornoy A: Teratogen update: antithyroid drugsmethimazole, carbimazole, and propylthiouracil. Teratology 65:38, 2002. 371. Senior B, Chernoff HL: Iodide goiter in the newborn. Pediatrics 47:510, 1971. 372. Weinstein MR: The international registry of lithium babies. Drug Infect J 10:94, 1976. 373. Cohen LS, Friedman JM, Jefferson JW: A reevaluation of risk of in utero exposure to lithium. JAMA 271:146, 1994. 374. Murakami U: The effect of organic mercury on intrauterine life. Adv Exp Med Biol 27:301, 1971. 375. Amin-zaki L, Majeed MA, Elhassani SB, et al.: Prenatal methylmercury poisoning: clinical observations over five years. Am J Dis Child 133:172, 1979. 376. Hall JG: Embryopathy associated with oral anticoagulant therapy. BDOAS XII(5):33, 1976. 377. Stevenson RE, Burton M, Ferlauto GJ, et al.: Hazards of oral anticoagulants during pregnancy. JAMA 243:1549, 1980. 378. Hall JG, Pauli RM, Wilson KM: Maternal and fetal sequelae of anticoagulants during pregnancy. Am J Med 68:122, 1980. 379. Rogan WJ, Gladen BC, Hung K-L, et al.: Congenital poisoning by polychlorinated biphenyls and their contaminants in Taiwan. Science 241:334, 1988. 380. Miller RW: Cola-colored babies: chlorobiphenyl poisoning in Japan. Teratology 4:211, 1971. 381. Lee BE, Feinberg M, Abraham JJ, et al.: Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J 11:1062, 1992. 382. Mastroiacovo P, Mazzone T, Botto LD, et al.: Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 175:1645, 1996. 383. Pursley TJ, Blomquist IK, Abraham J, et al.: Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 22:336, 1996. 384. Aleck KA: Long-term follow-up of fluconazole embryopathy—a disorder caused by inhibition of normal sterol metabolism. Proc Greenwood Genet Center 22:60, 2003. 385. Friedman JM, Little BB, Brent RL, et al.: Potential human teratogenicity of frequently prescribed drugs. Obstet Gynecol 75:594, 990. 386. Wilson JG; Embryotoxicity of drugs in man. In: Handbook or Teratology, vol 1. JG Wilson, FC Fraser, eds. Plenum Press, New York, 1977, p 309. 387. Holmes LB: Teratogen update: bendectin. Teratology 27:277, 1983. 388. Carter MP, Wilson F: Antibiotics in early pregnancy and congenital malformations. Dev Med Child Neurol 7:353, 1965. 389. Mjolnerod OK, Rasmussen K, Dommerud SA, et al.: Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1:673, 1971. 390. Doll DC, Ringerberg S, Yarbro JW: Antineoplastic agents and pregnancy. Semin Oncol 16:337, 1989. 391. Farquhar JW: The child of the diabetic woman. Arch Dis Child 34:76, 1959. 392. North AFJ, Mazumdar S, Logrillo VM: Birthweight, gestational age, and perinatal deaths in 5,471 infants of diabetic mothers. J Pediatr 90:444, 1977. 393. Naeye RL: Infants of diabetic mothers: a quantitative, morphologic study. Pediatrics 35:1980, 1965. 394. Farquhar JW: Prognosis for babies born to diabetic mothers in Edinburgh. Arch Dis Child 44:36, 1969. 395. Pedersen LM, Tygstrup I, Pederson J: Congenital malformations in newborn infants of diabetic women: correlation with maternal diabetic vascular complications. Lancet 1:1124, 1964. 396. Lucas MJ, Leveno KJ, Williams ML: Early pregnancy glycosylated hemoglobin, severity of diabetes, and fetal malformations. Am J Obstet Gynecol 161:426, 1989.
79
397. Mills JL: Malformations in infants of diabetic mothers. In: Teratogen Update: Environmentally Induced Birth Defect Risks. JL Sever, RL Brent, eds. AR Liss, New York, 1986, p 165. 398. Janssen PA, Rothman I, Schwartz SM: Congenital malformations in newborns of women with established and gestational diabetes in Washington State, 1984–91. Pediatr Perinat Epidemiol 10:52, 1996. 399. Becerra JE, Khoury MJ, Cordero JF, et al.: Diabetes mellitus during pregnancy and the risks for specific birth defects: a population based case-control study. Pediatrics 85:1, 1990. 400. Reece EA, Quintela PA, Homko CJ, Sivan E: Early fetal growth delay: is it really predictive of congenital anomalies in infants of diabetic women? J Mat-Fet Med 6:168, 1997. 401. Roberts AB, Pattison NS: Pregnancy in women with diabetes mellitus, twenty years experience: 1968–1987. New Zealand Med J 103:211, 1990. 402. Siegler AM: Pregnancy and cretinism: report of a case and review of the literature. Obstet Gynecol 8:639, 1956. 403. Jones WS, Man EB: Thyroid function in human pregnancy. VI. Premature deliveries and reproductive failures of pregnant women with low serum butanol-extractable iodines. Maternal serum TBG and TBPA capacities. Am J Obstet Gynecol 104:909, 1969. 404. Sutherland JM, Esselborn VM, Burket RL, et al.: Familial non-goitrous cretinism apparently due to maternal antithyroid antibody. N Engl J Med 263:336, 1960. 405. Green WL: Humoral and genetic factors in thyrotoxic Graves disease and neonatal thyrotoxicosis. JAMA 235:1449, 1976. 406. Burrow GN: The management of thyrotoxicosis in pregnancy. N Engl J Med 313:562, 1985. 407. Davis LE, Lucas MJ, Hankins GDV, et al.: Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 160:63, 1989. 408. Sunshine P, Kusumoto H, Kriss JP: Survival time of circulating longacting thyroid stimulator in neonatal thyrotoxicosis: implications for diagnosis and therapy of the disorder. Pediatrics 36:869, 1965. 409. Nutt J, Clark F, Welch RG, et al.: Neonatal hyperthyroidism and longacting thyroid stimulator protector. Br Med J 2:695, 1974. 410. Stevenson RE, Trent HW III: Maternal hyperthyroidism and congenital craniosynostosis. Proc Greenwood Genet Center 9:3, 1990. 411. Hollingsworth DR, Mabry CC, Eckerd JM: Hereditary aspects of Graves’ disease in infancy and childhood. J Pediatr 81:446, 1972. 412. Landing BH, Kamoshita S: Congenital hyperparathyroidism secondary to maternal hypoparathyroidism. J Pediatr 77:842, 1970. 413. Jacobson BB, Terslev E, Lund B, et al.: Neonatal hypocalcemia associated with maternal hyperparathyroidism. Arch Dis Child 53:308, 1978. 414. Koerten JM, Morales WJ, Washington SR III, et al.: Cushing’s syndrome in pregnancy: a case report and literature review. Am J Obstet Gynecol 154:626, 1986. 415. Kolodny RC: Herpes gestationis. Am J Obstet Gynecol 104:39, 1969. 415a. Nelson JL: Microchimerism in human health and disease. Autoimmun 36:5, 2003. 416. Mabry CC, Denniston JC, Coldwell JG: Mental retardation in children of phenylketonuric mothers. N Engl J Med 275:1331, 1966. 417. Stevenson RE, Huntley CC: Congenital malformations in off-spring of phenylketonuric mothers. Pediatr 40:33, 1967. 418. Lenke RR, Levy HL: Maternal phenylketonuria and hyperphenylalaninemia. N Engl J Med 303:1202, 1980. 419. Platt LD, Koch R, Hanley WB, et al.: The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. Am J Obstet Gynecol 182:326, 2000. 420. Mahon BE, Levy HL: Maternal Hartnup disorder. Am J Med Genet 24:513, 1986. 421. Stevenson RE, Taylor HA: Pregnancy and pyridoxine-responsive homocystinuria. Proc Greenwood Genet Center 3:47, 1984. 422. Scriver CR, Beaudet AL, Sly WS, et al.: The Metabolic & Molecular Bases of Inherited Disease, 8 ed. McGraw-Hill, New York, 2001. 423. Smithells RW, Sheppard S, Schorah CJ: Vitamin levels and neural tube defects. Arch Dis Child 51:944, 1959.
80
Overview
424. Smithells RW, Nevin NC, Seller MJ, et al.: Further experience of vitamin supplementation for prevention of NTD recurrences. Lancet 1:1027, 1983. 425. Smithells RW, Sheppard S, Wild J, et al.: Prevention of neural tube defect recurrence in Yorkshire: Final report. Lancet 2:498, 1989. 426. Laurence KM, James N, Miller MH, et al.: Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural tube defects. Br Med J 282:1509, 1981. 427. Mulinare J, Cordero JF, Erickson JD, et al.: Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 260:3141, 1988. 428. Milunsky A, Jick H, Jick SS, et al.: Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 262:2847, 1989. 429. Mills JL, Rhoads GG, Simpson JL, et al.: The absence of a relation between the periconceptional use of vitamins and neural-tube defects. N Engl J Med 321:430, 1989. 430. MRC Vitamin Study Research Group: Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338:131, 1991. 431. Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by preconceptional vitamin supplementation. N Engl J Med 327:1832, 1992. 432. Berry RJ, Li Z, Erickson JD, et al.: Prevention of neural tube defects with folic acid in China. N Engl J Med 341:1485, 1999. 433. Stevenson RE, Allen WP, Pai GS, et al.: Decline in prevalence of neural tube defects in a high-risk region of the United States. Pediatrics 106:677, 2000. 434. Chan A, Pickering J, Haan EA, et al.: ‘‘Folate before pregnancy’’: the impact on women and health professionals of a population-based health promotion campaign in South Australia. Med J Aust 174:631, 2001. 435. Martı´nez de Villarreal L, Pe´rez JZV, Va´zquez PA, et al.: Decline of neural tube defects cases after a folic acid campaign in Neuvo Leo´n, Me´xico. Teratology 66:249, 2002. 436. US Department of Health and Human Services, Food and Drug Administration: Food standards: amendment to the standards of identity for enriched grain products to require addition of folic acid. Federal Register 61:8781, 1996. 437. Jacques PF, Selhub J, Bostom AG, et al.: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340:1449, 1999. 438. Honein MA, Paulozzi LJ, Mathews TJ, et al.: Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285:2981, 2001. 439. Botto LD, Olney RS, Erickson JD: Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet Part C (Semin Med Genet) 125C:12, 2004. 440. Scanlon KS, Ferencz C, Loffredo CA, et al.: Preconceptional folate intake and malformations of the cardiac outflow tract. BaltimoreWashington Infant Study Group. Epidemiology 9:95, 1998. 441. Shaw GM, O’Malley CD, Wasserman CR, et al.: Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 59: 536, 1995. 442. Tolarova M, Harris J: Reduced recurrence of orofacial clefts after periconceptional supplementation with high-dose folic acid and multivitamins. Teratology 51:71, 1995. 443. Pritchard JA, Scott DE, Whalley PJ, et al.: Infants of mothers with megaloblastic anemia due to folate deficiency. JAMA 211:1982, 1970. 444. Bureau MA, Shapcott D, Berthiaume Y, et al.: Maternal cigarette smoking and fetal oxygen transport: a study of P50, 2,3-diphosphoglycerate, total hemoglobin, hematocrit and type F hemoglobin in fetal blood. Pediatrics 72:22, 1983. 445. Gordon M, Niswander KR, Berendes H, et al.: Fetal morbidity following potentially anoxigenic obstetric conditions. VII. Bronchial asthma. Am J Obstet Gynecol 106:421, 1970.
446. Neill CA, Swanson S, Hellegers AE: Cyanotic congenital heart disease in pregnancy. In: Intrauterine Development. AC Barnes, ed. Lea & Febiger, Philadelphia, 1968. 447. Anderson M, Went LN, MacIver JE, et al.: Sickle-cell disease in pregnancy. Lancet 2:516, 1960. 448. Ballew C, Haas JD: Hematologic evidence of fetal hypoxia among newborn infants at high altitude in Bolivia. Am J Obstet Gynecol 155:166, 1986. 449. Yip R: Altitude and birth weight. J Pediatr 111:869, 1987. 450. Alzamora V, Rotta A, Battilana G, et al.: On the possible influence of great altitudes on the determination of certain cardiovascular anomalies. Pediatr 12:259, 1953. 451. Johnson GT: Comments in Non-toxaemic Hypertension in Pregnancy. NF Morris, JCM Browne, eds. Churchill, London, 1958, p 60. 452. Maxwell JP: Further studies in adult rickets (osteomalacia) and foetal rickets. Proc R Soc Med 28:265, 1934. 453. Pitkin RM: Calcium metabolism in pregnancy and the perinatal period: a review. Am J Obstet Gynecol 151:99, 1985. 453a. Larkin EC, Rao GA: Importance of fetal and neonatal iron: adequacy for normal development of central nervous system. In: Brain, Behavior, and Iron in the Infant Diet. Dobbing J, ed. Springer-Verlag, London, 1990, p 43. 454. Held KR, Cruz ME, Moncayo F: Clinical pattern and genetics of the fetal iodine deficiency disorder (endemic cretinism): results of a field study in highland Ecuador. Am J Med Genet 35:85, 1990. 455. Stafford PA, Biddinger PW, Zumwalt RE: Lethal intrauterine fetal trauma. Am J Obstet Gynecol 159:485, 1988. 456. Franger AL, Buchsbaum HJ, Peaceman AM: Abdominal gunshot wounds in pregnancy. Am J Obstet Gynecol 160:1125, 1989. 456a. Hall JG: Arthrogryposis associated with unsuccessful attempts at termination of pregnancy. Am J Med Genet 63:293, 1996. 457. Miller ME, Dunn PM, Smith DW: Uterine malformation and fetal deformation. J Pediatr 94:387, 1979. 458. Graham JMJ, Miller ME, Stephen MJ, et al.: Limb reduction anomalies and early in utero limb compression. J Pediatr 96:1052, 1980. 459. Bryan EM: The intrauterine hazards of twins. Arch Dis Child 61:1044, 1986. 460. Phelan MC, Stevenson RE: Adverse outcomes of twin pregnancies. Proc Greenwood Genet Center 8:3, 1989. 461. McKeown T, Record RG: Observations and fetal growth in multiple pregnancies in man. J Endocrinol 8:386, 1952. 461a. Hunter AG: A pilot study of the possible role of familial defects in anticoagulation as a cause for terminal limb reduction malformations. Clin Genet 57:197, 2000. 461b. Shalev SA, Hall JG: Poland anomaly—report of an unusual family. Am J Med Genet 118A:180, 2003. 462. Thomas IT, Smith DW: Oligohydramnios, cause of the non-renal features of Potter’s syndrome, including pulmonary hypoplasia. J Pediatr 84:811, 1974. 463. Torpin R: Fetal Malformations Caused by Amnion Rupture During Gestation. Charles C Thomas, Springfield, IL, 1968. 464. Higginbottom MC, Jones KL, Hall BD, et al.: The amniotic band disruption complex: timing of amnion rupture and variable spectra of consequent defects. J Pediatr 95:544, 1979. 465. Miller ME, Graham JMJ, Higginbottom MC, et al.: Compressionrelated defects from early amnion rupture: evidence for mechanical teratogenesis. J Pediatr 98:292, 1982. 466. Gleicher N, El-Roeiy A: The reproductive autoimmune failure syndrome. Am J Obstet Gynecol 159:223, 1988. 467. Sargent IL, Wilkins T, Redman CWG: Maternal immune responses to the fetus in early pregnancy and recurrent miscarriage. Lancet 2:1099, 1988. 468. McIntyre JA, Faulk WP: Recurrent spontaneous abortion in human pregnancy: results of immunogenetical, cellular, and humoral studies. Am J Reprod Immunol 4:165, 1983. 469. Cohen F, Zuelzer WW, Gustafson DC, et al.: Mechanisms of isoimmunization. I. The transplacental passage of fetal erythrocytes in homospecific pregnancies. Blood 23:621, 1964.
Human Malformations and Related Anomalies 470. Scanlon JW, Muirhead DM: Hydrops fetalis due to anti-Kell isoimmune disease: survival with optimal long-term outcome. J Pediatr 88:484, 1976. 471. Palchak AE, Aster RH, Gottschall J, et al.: Effect of maternal-fetal platelet incompatibility on fetal development. Pediatr 74:570, 1984. 472. Matsuda T, Momoi T, Akaishi K, et al.: Transient neonatal hyperthyroidism and maternal thyroid stimulating immunoglobulins. Arch Dis Child 63:205, 1988. 473. Connors MH, Styne DM: Transient neonatal ‘‘athyreosis’’ resulting from thyrotropin-binding inhibitory immunoglobulins. Pediatrics 78:287, 1986. 474. Doshi N, Smith B, Klionsky B: Congenital pericarditis due to maternal lupus erythematosus. J Pediatr 96:699, 1980. 475. Olson NY, Lindsley CB: Neonatal lupus syndrome. Am J Dis Child 141:908, 1987. 476. Merlob P, Metzker A, Hazaz B, et al.: Neonatal pemphigus vulgaris. Pediatrics 78:1102, 1986. 477. Oosterhuis HJGH, Feltkamp TEW, van der Geld HRW: Muscle antibodies in myasthenic mothers and their babies. Lancet 2:1225, 1966. 478. Borzy MS, Magenis E, Tomar D: Bone marrow transplantation for severe combined immune deficiency in an infant with chimerism due to intrauterine-derived maternal lymphocytes: donor engraftment documented by chromosomal marker studies. Am J Med Genet 18:527, 1984. 479. Stevenson RE, Sorell M, Kapoor N, et al.: Chimerism in an infant with severe combined immunodeficiency. Proc Greenwood Genet Center 3:30, 1984. 480. Bastian JF, Williams RA, Ornelas W, et al.: Maternal isoimmunization resulting in combined immunodeficiency and fatal graft-versus-host disease in an infant. Lancet 1:1435, 1984. 481. Turner JH, Hutchinson DL, Petricciani JC: Chimerism following fetal transfusion. Scand J Haematol 10:358, 1973. 482. Parkman R, Mosier D, Umansky I, et al.: Graft-versus-host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Engl J Med 290:359, 1974. 483. Elias S, Simpson JL: Prospects for prenatal diagnosis by isolating fetal cells from maternal blood. Centemp Rev Obstet Gynecol 7:135, 1995. 484. Bianchi DW: Fetal cells in the maternal circulation: feasibility for prenatal diagnosis. Fr J Haemotol 105:574, 1999. 485. Hall JM, Williams SJ: Isolation and purification of CD34þ fetal cells from maternal blood. Am J Hum Genet 51:A257, 1992. 486. Hafner E, Schucher K, Liebhart E, et al.: Results of routine fetal nuchal translucency measurement at weeks 10-13 in 4,233 unselected pregnanct women. Prenat Diagn 18:29, 1998. 487. Hata T, Manabe A, Aoki SW, et al.: Three-dimensional intrauterine sonography in the early first-trimester of pregnancy: preliminary study. Hum Reprod 13:740, 1998. 488. Platt LD, Feuchtbaum L, Filly R, et al.: The California maternal serum alpha-fetoprotein program: the role of ultrasonography in the detection of spina bifida. Am J Obstet Gynecol 166:1328, 1992. 489. Canick JA, Kellner LH: First trimester screening for aneuploidy: serum biochemical markers. Semin Perinatol 23:359, 1999. 490. CEMAT Group: Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. The Canadian early and midtrimester amniocentesis trial (CEMAT) Group. Lancet 351:242, 1998. 491. Nicolaides K, Brizot ML, Patel F, et al.: Comparison of chorionic villus sampling and early amniocentesis for karyotyping in 1,492 singleton pregnancies. Fetal Diagn Ther 11:9, 1996. 492. Olney RS, Khoury MJ, Alo CJ, et al.: Increased risk transverse digital deficiency after chorionic villus sampling: results of the United States multistate case-control study, 1988-1992. Teratology 51:20, 1995. 493. Dolk H, Beatrand F, Lechat MF (Eurocat): Chorionic villus sampling and limb abnormalities. Lancet 339:876, 1992. 494. Evans MI, Hoffman EP, Cadrin C, et al.: Fetal muscle biopsy: Collaborative experience with varied indications. Obstet Gynecol 84:913, 1994.
81
495. O’Rahilly R, Muller F: Developmental Stages in Human Embryos. Carnegie Institution of Washington, Washington, DC, 1987, Publication 637. 496. Saul RA, Geer JS, Seaver LH, et al.: Growth References: Third Trimester to Adulthood. Greenwood Genetic Center, Greenwood, SC, 1998. 497. Scammon RE, Calkins LA: The Development and Growth of the External Dimensions of the Human Body in the Fetal Period. University of Minnesota Press, Minneapolis, 1929. 498. Elejalde BR, de Elejalde MM: The prenatal growth of the human body determined by the measurement of bones and organs by ultrasonography. Am J Med Genet 24:575, 1986. 499. Morris CA, Demsey SA, Leonard CO, et al.: Natural history of Williams syndrome, physical characteristics. J. Pediatr 113:318, 1988. 500. Allanson JE, Hall JG, Hughes HE, et al.: Noonan syndrome: the changing phenotype. Am J Med Genet 21:507, 1985. 501. Butler MG, Meaney FJ, Palmer CG: Clinical and cytogenetic survey of 39 individuals with Prader-Labhart-Willi syndrome. Am J Med Genet 23:793, 1986. 502. DeBusk FL: The Hutchinson-Gilford progeria syndrome: review of 4 cases and review of the literature. J Pediatr 80:697, 1972. 503. Stevenson RE, Prouty LA: Fragile X syndrome. VI. A subjective assessment of the facial features in blacks and whites. Proc Greenwood Genet Center 7:103, 1988. 504. Simpson JL: Disorders of Sexual Differentiation: Etiology and Clinical Delineation. Academic Press, New York, 1976, p 260. 505. Aase JM: Diagnostic Dysmorphology. Plenum Medical Book Co, New York, 1990. 506. Jones KL: Morphogenesis and dysmorphogenesis. In: Smith’s Recognizable Patters of Human Malformations, ed 5. WB Saunders, Philadelphia, 1997, p 695. 507. Wilson GN: Pediatric genetics, birth defects and syndromology. In: Clinical Genetics. A Short Course. Wiley-Liss, New York, 2000, p 251. 508. Snedecor GW, Cochran WG: Statistical Methods, ed 6. Iowa State University Press, Ames, 1967. 509. Hall JG, Froster-Iskenius UG, Allanson JE: Handbook of Normal Physical Measurements. Oxford University Press, Oxford, 1989. 510. Brandt JM, Allen GA, Haynes JL, et al.: Normative standards and comparison of arthropometric data of white and black newborn infants. Dysmorph Clin Genet 4:121, 1990. 511. Gordon CC, Churchill T, Clauser CE: 1988 Anthropometric Survey of U.S. Army Personnel: Summary Statistics Interim Report. U.S. Army Natick Research, Development and Engineering Center, Natick, MA, 1989. 512. Horton WA, Rotter JI, Rimoin DL, et al.: Standard growth curves for achondroplasia. J Pediatr 93:435, 1978. 513. Meaney FJ, Farrer LA: Clinical anthropometry and medical genetics: a compilation of body measurements in genetic and congenital disorders. Am J Med Genet 25:343, 1986. 514. Broadbent BH:A new x-ray technique and its application to orthodontia. Angle Orthod 1:45, 1931. 515. Knott VB: Change in cranial base measures of human males and females from age 6 years to early adulthood. Growth 35:145, 1971. 516. Frias JL, King GJ, Williams CA: Cephalometric assessment of selected malformation syndromes. BDOAS XVIII(1):139, 1982. 517. Poznanski AK: The Hand in Radiological Diagnosis. WB Saunders, Philadelphia, 1984, p 31. 518. Vannier MW, Marsh JL, Warren JO: Three-dimensional CT reconstruction images for craniofacial surgical planning and evaluation. Radiology 150:179, 1984. 519. Vannier MW, Gutierrez FR, Laschinger JC, et al.: Three-dimensional magnetic resonance imaging of congenital heart disease. Radio Graphics 8:857, 1988. 520. Geist D, Vannier MW: PC-based 3-D reconstruction of medical images. Comput Graphics 13:135, 1989. 521. Vannier MW, Knapp RH, Offutt CJ, et al.: Computers in radiology. Curr Imaging 1:128, 1989.
82
Overview
522. Vannier MW, Marsh JL: Three-dimensional reconstruction. In: Otolaryngology-Head and Neck Surgery: Update I. CW Cummings, et al., eds. CV Mosby, St. Louis, 1989, p 28. 523. Johnson JP: Acquired dysmorphic craniofacial features associated with chronic phenytoin therapy. Proc Greenwood Genet Center 3:114, 1984. 524. Lubchenco LO, Hansman C, Boyd E: Intrauterine growth in length and head circumference as estimated from live births at gestational ages from 26 to 44 weeks. Pediatrics 37:403, 1966. 525. Usher R, McLean F: Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 74:901, 1969. 526. Merlob P, Sivan Y, Reisner SH: Anthropometric measurements of the newborn infant (27 to 41 gestational weeks). BDOAS XX(7):1, 1984. 527. Hamill PVV, Drizd TA, Johnson CL, et al.: Physical growth: National Center for Health Statistics Percentiles. Am J Clin Nutr 32:607, 1979. 528. Tanner JM, Davies PSW: Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 107:317, 1985. 529. Ogden CL, Kuczmarski RJ, Flegal KM, et al.: Centers for Disease Control and Prevention 2000 growth charts for the United States: Improvements to the 1977 National Center for Health Statistics Version. Pediatrics 109:45, 2002. 530. Nellhaus G: Head circumference from birth to eighteen years: practical composite international and interracial graph. Pediatrics 41:106, 1968. 531. Roche AF, Mukherjee D, Guo S, et al.: Head circumference reference data: birth to 18 years. Pediatrics 79:706, 1987. 532. Feingold M, Bossert WH: Normal values for selected physical parameters: an aid to syndrome delineation. BDOAS X(13):135, 141, 153, 1974. 533. Burin MG, Scholz AP, Gus R, et al.: Investigation of lysosomal storage diseases in nonimmune hydrops fetalis. Prenatal Diagn 24:653, 2004. 534. Leroy JG, Demars RI, Opitz JM: I-cell disease. BDOAS V(4):174, 1969. 535. Singh I, Johnson GH, Brown FR III: Peroxisomal disorders: biochemical and clinical diagnostic considerations. Am J Dis Child 142:1297, 1988. 536. Mitchell G, Saudubray JM, Gubler MC, et al.: Congenital anomalies in glutaric aciduria type 2. J Pediatr 104:961, 1984. 537. Marquardt T, Denecke J: Congenital disorders of glycosylation: review of their molecular bases, clinical presentations, and specific therapies. Eur J Pediatr 162:359, 2003. 538. Nissenkorn A, Michelson M, Ben-Zeev B, et al.: Inborn errors of metabolism: a cause of abnormal brain development. Neurology 56: 1265, 2001.
539. Kelley RI, Herman GE: Inborn errors of sterol biosynthesis. Ann Rev Genomics Hum Genet 2:299, 2001. 540. Spranger JW, Brill PW, Poznanski A: Bone Dysplasias: An Atlas of Genetic Disorders of Skeletal Development, ed 2. Oxford University Press, Oxford, 2002. 541. Loeys BL, Metthys DM, de Paepe AM: Genetic fibrillinopathies: new insights in molecular diagnosis and clinical management. Acta Clin Belg 58:3, 2003. 542. Biggin A, Holman K, Brett M, et al.: Detection of thirty novel FBN1 mutations in patients with Marfan syndrome or a related fibrillinopathy. Hum Mutat 23:99, 2004. 543. Ades LC, Holman KJ, Brett MS, et al.: Ectopia lentis phenotypes and the FBN1 gene. Am J Med Genet 126A:284, 2004. 544. Donnai D, Karmiloff-Smith A: Williams syndrome: from genotype through to the cognitive phenotype. Am J Med Genet 97:164, 2000. 545. Metcalfe K, Rucka AK, Smoot L, et al.: Elastin: mutational spectrum in supravalvular aortic stenosis. Eur J Hum Genet 8:955, 2000. 546. Hakamori S, Fukuda M, Sekiguchi K, et al.: Fibronectin, laminin, and other extracellular glycoproteins. In: Extracellular Matrix Biochemistry. Picz KA, Reddi AH, eds. Elsevier, New York, pp 229–276. 547. Thomas GH, Howell RR: Selected Screening Tests for Genetic Metabolic Diseases. Year Book Medical Publishers, Chicago, 1973. 548. Sewell AC: Urinary oligosaccharides. In: Techniques in Diagnostic Human Biochemical Genetics. FA Hommes, ed. Wiley-Liss, New York, 1991, p 219. 549. De Vries BB, Winter R, Schinzel A, van Ravenswaaij-Arts C: Telomeres: a diagnosis at the end of the chromosomes. J Med Genet 40:385, 2003. 550. Vissers LELM, de Vries BBA, Osoegawa K, et al.: Array-based comparative genomic hybridization for the genomewide detection of submicrocopic chromosomal abnormalities. Am J Hum Genet 73: 1261, 2003. 551. Mantripragada KK, Buckley PG, de Stahl TD, Dumanski JP: Genomic microarrays in the spotlight. Trends Genet 20:87, 2004. 552. Thompson GH, Bilenker RM: Comprehensive management of arthrogryposis multiplex congenita. Clin Orthop Rel Res 194:6, 1985. 553. Salyer KE, Munro IR, Whitaker LA, et al.: Difficulties and problems to be solved in the approach to craniofacial malformations. BDOAS XI(7):315, 1975. 554. Lee PA, Mazur T, Danish R, et al.: Micropenis. I. Criteria, etiologies and classification. Johns Hopkins Med J 146:156, 1980.
Part II Cardiorespiratory Organs
This page intentionally left blank
2 Heart Angela E. Lin, John Belmont, and Sadia Malik
I
n common practice, malformation of the heart refers to a defect of the intracardiac structures, that is, the atrial and ventricular chambers and septa, and the atrioventricular and semilunar valves. Beyond the heart itself are the great arteries which are frequently associated with abnormalities of outflow tract septation (conotruncal defects), and the systemic and pulmonary veins. Because intra-cardiac and extra-cardiac malformations cannot be easily separated, this chapter uses the broader term cardiovascular malformation (CVM), also known as a congenital heart defect. The term congenital heart disease is not employed since it connotes an active pathologic process. Caring for an individual with a CVM of any age can be a challenge even to an astute cardiac specialist. The number of individual CVMs is vast, the anatomy often complex, and the terminology likewise complex.1 An approach to the heart by sequential segmental analysis has had widespread appeal (Table 2-1).2 Naming complex CVMs has prompted vigorous discussion. Two recent systems of nomenclature are marvels of scope, but somewhat unwieldy in length.3,4 This chapter has been guided by the practical approach to classify CVMs based on mechanistic ‘‘families.’’5–7 Much has been learned about CVMs in the decade since the first edition of this book was published.8 This chapter has been substantially revised. Notably, the introduction now includes reviews of the embryology, epidemiology and molecular basis of CVMs. For selected defects, additional sub-sections have been added. As in the previous edition, several CVMs mentioned in this chapter are discussed elsewhere in the book. For example, patients with CVMs may have thoraco-abdominal malformations, including abnormal situs. Thus, laterality defects (also known as heterotaxy) span the content of the chapters on the Heart, the Spleen (Chapter 5), and Asymmetry and Hypertrophy (Chapter 33). Likewise, several CVMs involving the outflow tract, descending aorta, and great veins are also discussed in the chapter on Systemic Vasculature (Chapter 3). For additional information about the anatomy, diagnosis, and treatment of CVMs, the reader is referred to two excellent pediatric cardiology textbooks which themselves have been revised since the previous edition of this book.9,10 Chapters from these texts formed the core of the cardiology references. Rather than endorse a single
The authors acknowledge the contributions of Donald A. Riopel, author of this chapter in the first edition of Human Malformations and Related Anomalies.
system of cardiac nomenclature, we cited multiple sources and used cardiac terminology accordingly. The vast number of chromosome disorders, Mendelian gene mutations, and teratogens associated with CVMs have been listed elsewhere.11,12 We have added new tables listing many syndromes and conditions. These tables are not meant to be exhaustive compendia of the occurrence of a CVM in every possible syndrome. Instead, we emphasize CVMs with very frequent or very distinctive associations, omitting limited associations or private syndromes. A recurring dilemma in any review of the heart is narrowing the scope of the discussion. The spectrum of cardiac abnormalities extends from congenital malformations to complex acquired disorders. To maintain the focus on malformations and structural birth defects, we alert readers that this edition does not include sections on primary pulmonary hypertension, cardiomyopathy, and rhythm disturbances. Embryology
Cardiac development is among the most studied processes in vertebrate embryology, accompanied by a wealth of information from animal models. Yet there are considerable uncertainties with regard to the details of human heart development because of the difficulties inherent in studying early human embryos. The most extensively studied mammalian model of embryonic development is the mouse. However, the topology of the gastrulation and early somite stage embryos of this species compared to primates is somewhat different.13 The identity of morphogens, signaling cascades, and controlling transcriptional factors cannot be assumed to be identical when comparing species.14 In general, one could view abnormal cardiac development as a cascade of linked events in which there is an initial inciting event in a specific region or process (Fig. 2-1). This may be strongly suggested by some specific CVMs (e.g., dextrocardia and atrial isomerism) in which abnormalities in left–right axis patterning affect orientation of the inflow structures with respect to the midline or directionality of looping. But, for many CVMs the situation is ambiguous and they may be interpreted as arising from either an early event or a later and more specific process. This is particularly true of ventricular septal defects that may accompany either an early event (e.g., malalignment of the conal septum) or late disturbance (e.g., failure to close the muscular ventricular septum) in 85
86
Cardiorespiratory Organs Table 2-1. Segmental analysis of the heart Anatomic Feature
Thoracoabdominal situs Cardiac position Atrial arrangement (atrial appendage) Atrioventricular connection Ventricular topology Conus Ventriculoarterial connection Great vessels From Anderson and Ho.2
cardiac morphogenesis. Given the large body of animal data that support mechanistic inferences about aberrant development in CVMs, there is a distinct lack of data from abnormal human embryos, particularly data reflecting on molecular mechanisms.
Commitment of Precardiac Mesoderm
Cells that will contribute to the heart arise from the anterior embryonic mesoderm. Their commitment to the cardiac lineage is established in the process of migration through the primitive streak.15,16 The activity of the transcription factor MesP1 is required for mesodermal cells to migrate out of the primitive streak.17 Anterior mesoderm cells are fated to contribute to the myocardium with the posterior boundary controlled by the Wnt family of growth factors.18 The precardiac mesoderm forms two lineages, myocardial and subjacent endocardial cells.19 Wnt inhibitory molecules, crescent and dickkoph, are expressed by the cardiac mesoderm; ectopic expression of these in posterior mesoderm is sufficient to induce heart formation.20 Wnt inhibi tion and BMP-type growth factors15,16 produced by adjacent neuroectoderm and foregut endoderm together induce cardiac mesoderm committment. In mice, the cardiogenic mesoderm expresses the transcription factor Nkx2.5, an NK homeobox family member with specific functions in both early and late cardiac development.21,22 Nkx2.5 is
Fig. 2-1. Schematic of heart development showing some key processes and mechanisms. The listed genes have been shown to play required roles in these processes (not exhaustive) or have been associated with syndromic or nonsyndromic cardiovascular malformations. See text for specific disease associations and gestational timing.
Heart
the vertebrate homologue of Drosophila tinman, which is required for the formation of the heart-like vessel in flies.23,24 The early cardiomyocytes express heart-specific differentiation markers including Mef-2C, cardiac actin, desmin, eHand, and cardiac-specific ankyrin protein (CARP), which probably act downstream of Nkx2.5.25,26 A second heart-forming field has recently been defined.27–29 This field arises from a more medial population of mesoderm cells just anterior to the cardiac crescent. Descendants of the precursors in the anterior heart-forming field will give rise to the common outflow tract or more cranially derived structures of the more mature heart. Cardiac organogenesis begins at day 18 as the cardiogenic mesoderm coalesces toward the midline. A pair of elongated mesenchymal strands canalize to form paired endothelial tubes which then fuse in the midline. The future cardiac myocytes are separated from the endothelial lining of the heart tube by cardiac jelly,30 a gelatinous connective tissue matrix which forms a subendocardial zone. GATA family transcription factors are necessary for the movements of cardiac mesoderm in forming the linear heart tube.31 GATA4 functions in endoderm underlying the myocardial precursors. OEP/cryptic32 and casanova33 mutations, which also affect endoderm development, lead to cardia bifida and, thus, demonstrate the importance of endoderm–mesoderm interaction. Heart Tube
By day 22, the single heart tube elongates, and segmentations define the truncus arteriosus, bulbus cordis, primitive ventricles, atrium, and sinus venosus. These structures indicate the cranialto-caudal patterning in the otherwise symmetric heart tube.34 At the cranial end, the truncus arteriosus is continuous with the aortic sac and aortic arch arteries. At the caudal end of the heart tube, the sinus venosus receives respectively the umbilical, vitelline, and common cardinal veins from the chorion (primitive placenta), yolk sac, and embryo proper.35 Shortly after coalescing into this heart tube, rhythmic contractions result from the intrinsic contractile and rhythmic properties of the myocardial cells. In the absence of valves, the flow of blood is directed from the inflow to the outflow by a kind of peristaltic action beginning in the sinus venosus. Normal flow is required for proper growth and remodeling of the heart such that obstruction leads to morphological abnormalities that are suggestive of human malformations like hypoplastic left-heart syndrome.36 Concomitant processes specify chamber identity. The transcription factors Mesp1 and Mesp217 also play a cell autonomous role in ventricular but not atrial chamber formation. Irx4 is also involved in ventricular specification.37,38 Irx4 seems to be regulated by Nkx2.5 and another transcription factor, dHand.39 dHand and eHand are both required for normal ventrical growth, although they exhibit generally complementary patterns of expression. eHand is predominantly expressed in the left ventricle and outflow tract. Right ventricle (RV) growth is specifically impaired in dHand mutant embryos leading to defective looping stage development.40 Another transcription factor, Mef2c, is also required for both left ventricle (LV) and RV growth,41 whereas COUP-TFII is required for atrial and sinus venosus precursor development.42 Looping
By day 23, a slight asymmetric growth of the left sino-atrial areas produces a ‘‘leftward jog’’ that is the first manifestation of the future left–right (LR) asymmetry of the mature heart.43 Because the bulbus cordis and the outer curvature of the RV grow faster than the other segments, the heart tube bends ventrally. This bending proceeds to a rightward folding of the ventricular seg-
87
ment forming the C-looped heart. As growth continues, an Sshaped heart forms as the atrium and sinus venosus are pushed behind the future ventricles. The relative positions of the future LV and RV are also established at this stage. There is an extensive literature on the establishment of the left–right axis in the various animal model systems.44–46 There are several linked processes that mediate this cascade: (1) symmetry breaking; (2) formation of the node that will relay LR positional information from the organizer to the lateral plate mesoderm (LPM); (3) expression of the nodal-dependent signal transduction pathway in the left LPM; and (4) transfer of positional information to organ primordia. The node is a critical organizer that forms at the anterior most portion of the primitive streak.47,48 The node is composed of specialized epithelial cells with ventral monocilia. The monocilia exhibit a gyrorotatory motion leading to the ‘‘nodal flow hypothesis’’ in which the motion of the monocilia generates a morphogen gradient necessary to induce left side identity.49 Nodal, a growth regulator produced by the node, is a TGFb family signaling molecule that plays a variety of roles in the early embryo.50 Nodal expression in the node is required for proper left– right patterning. LeftyA is a nodal antagonist that is expressed in medial left LPM that is required to delimit the area of nodal activity and mutations that lead to left isomerism.51,52 Transfer of positional information to organ primordia is mediated in part by PitX2, a homeobox transcription factor that plays a central role in cardiac growth and development of the common outflow tract.53 PitX2 is directly regulated by nodal to mediate the left–right patterning inherent in the looping process. PitX2 is also directly regulated by the Wnt/b-catenin pathway to control development of the outflow tract via interaction with neural crest cells.54 Atrioventricular Canal and Atrial Septation
Blood flows from the sinus venosus to the common atrium and passes through the atrioventricular (AV) canal into the future ventricles. Partition of the AV canal at the common atrium and the ventricles begins about the middle of the 4th week. The endocardial cushions emerge from the subendocardial dorsal and ventral walls of the AV canal. By the 5th week the endocardial cushions fuse in the dorsal ventral midline to divide the AV canal into the right and left canals, preceding formation of the mature AV valves. The transcription factors, PitX2 and FOG-2,55,56 also are involved in the formation of the AV canal, and their mutation may lead to abnormal atrial septation. FOG2 specifically interacts with GATA4, and its deficiency leads to defects that resemble tetralogy of Fallot.57 AV canal defects are also observed in Tolloid-1 mutants.58 At the level of the common atrium, the septum primum grows from the wall of the atrial chamber. Before foramen primum (the gap in the incomplete septum) is completely closed, it becomes perforated to form another gap called the foramen secundum. Late in the 5th week, the septum secundum emerges to the right of the septum primum. The septum secundum grows toward the endocardial cushions and covers the foramen secundum. The septum secundum is incomplete, and its opening is called the foramen ovale. The septum primum forms a flap valve for the foramen ovale. Before birth, the foramen ovale lets most of the blood entering the right atrium from the inferior vena cava cross to the left atrium. After birth, the foramen ovale closes as a result of fusion of the septum primum and secundum. Much of the molecular information about these processes comes from the observation of mutations in families with dominant forms of atrial septal defects. Two genes, NKX2.559,60 and TBX5, have been implicated.61,62
88
Cardiorespiratory Organs
Left Atrium and Pulmonary Veins
The primitive pulmonary venous plexus coalesces into the pulmonary veins, which in turn merge into the common pulmonary vein. This vein grows toward the primitive left atrium in a process of targeted growth. The venous wall is gradually incorporated into the wall of the left atrium. Later, the proximal branches of the pulmonary veins are incorporated into the dorsal wall of the chamber, resulting in four pulmonary veins with separate openings into the atrium. The left atrial appendage, which is a remnant derived from the primitive atrium, develops trabeculations reflecting its distinct embryonic origin compared to the remainder of the smooth-walled left atrium. At present, there are almost no molecular data from any of the animal model systems that reflect on these interesting processes despite their importance in human CVM. AV Canal–Ventricular Septation
Partitioning of the right and left ventricles begins with a muscular fold in the constriction (interventricular groove) between the primitive ventricles. The fold increases in prominence as a result of the differential growth of the ventricles on each side, as well as active upward growth of myocardium, forming the muscular interventricular septum. The wall between the ventricles remains incomplete through the 7th week. The final closure of the interventricular septum is coupled with the partitioning of the common outflow tract. Ridges from both the right and left side of bulbus cordis emerge, and these in turn fuse with the ridge produced by the endocardial cushions of the AV canal. The membranous interventricular septum derives from the right side of the endocardial cushions joining the aorticopulmonary septum and the muscular part of the interventricular septum. At closure of the interventricular septum, the pulmonary trunk connects with the right ventricle and the aorta with the left ventricle. Several transcription factors have been shown to play a role in ventricular septation,38,63 including a retinoic acid coreceptor (RXRa), TEF1, N-myc, and Sox4. Valvulogenesis
The semilunar (aortic and pulmonary) valves develop from three ridges of the endocardial tissue at the orifices of the aorta and pulmonary trunk. These swellings become hollowed out and reshaped to form the three thin-walled